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II. Abbreviations	
aGvHD	 	 	 Acute	Graft-versus-Host	Disease	
AIRE	 	 	 	 Autoimmune	regulator	
ANA	 	 	 	 Anti-nuclear	antibody	
anti-RBC	 	 	 Isologous	IgG	anti-erythrocyte	antibody	
APC	 	 	 	 Antigen	presenting	cell	
APS-1	 	 	 	 Autoimmune	polyendocrinopathy	syndrome	type	1	
B6	 	 	 	 C57BL/6	
BAFF	 	 	 	 B	cell	activating	factor	
Bcl-6	 	 	 	 B	cell	lymphoma	protein	6	
BCR	 	 	 	 B	cell	receptor	
BDF1	 	 	 	 F1	generation	of	C57BL/6	and	DBA/2	mice	
BTK	 	 	 	 Bruton’s	tyrosine	kinase	
CD	 	 	 	 Cluster	of	differentiation	
cGvHD	 	 	 Chronic	Graft-versus-Host	Disease	
cTEC	 	 	 	 Cortical	thymic	epithelial	cell	
CTL	 	 	 	 Cytotoxic	T	lymphocytes	
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CTLA-4	 	 	 Cytotoxic	T-lymphocyte-associated	protein	4	
Dbl-tg	 	 	 	 Double-transgenic	
DC	 	 	 	 Dendritic	cell	
DMEM		 	 	 Dulbecco’s	modified	Eagle	Medium		
DP	 	 	 	 Double-positive	for	CD4	and	CD8	expression	
dsDNA	 	 	 Double-stranded	deoxyribonucleic	acid		
EAE	 	 	 	 Experimental	autoimmune	encephalomyelitis	
FCGR2	 	 	 Fc-γ	receptor	2	
FCS	 	 	 	 Fetal	calf	serum	
FITC	 	 	 	 Fluorescein	isothiocyanate	
FoxP3		 	 	 Forkhead-box-protein	P3	
FTOC	 	 	 	 Fetal	thymus	organ	culture	
GITR	 	 	 	 Glucocorticoid-induced	TNFR-related	protein	
GvHD	 	 	 	 Graft-versus-Host	Disease	
GWAS		 	 	 Genome	wide	association	study	
H-2	 	 	 	 Murine	major	histocompatibility	complex	
HEL	 	 	 	 Hen	egg	lysozyme	
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HLA	 	 	 	 Human	major	histocompatibility	complex	
i.p.	 	 	 	 Intraperitoneal		
i.v.	 	 	 	 Intravenous	
ICGN	 	 	 	 Immune	complex	glomerulonephritis	
ICOS	 	 	 	 Inducible	T	cell	co-stimulator	
IFN	 	 	 	 Interferon	
Ig	 	 	 	 Immunoglobulin	
IgH	 	 	 	 Immunoglobulin	heavy	chain	
IgL	 	 	 	 Immunoglobulin	light	chain	
IL	 	 	 	 Interleukin	
IL-2R	 	 	 	 Interleukin-2	receptor	
IMDM	 	 	 	 Iscove’s	modified	Dulbecco’s	Medium	
IPEX	 Immune	 dysregulation,	 polyendocrinopathy,	 enteropathy,	and	X-linked	inheritance	syndrome	
IRAK	 	 	 	 Interleukin-1	receptor	associated	kinase	
IRF	 	 	 	 Interferon	response	factor	
iTreg	 	 	 	 Induced	regulatory	T	cell	
JAK	 	 	 	 Janus	kinase	
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JES6/IL-2	 	 	 IL-2	bound	to	JES6.1	mAb	
LN	 	 	 	 Lymph	node	
LPS	 	 	 	 Lipopolysaccharide	
mAb	 	 	 	 Monoclonal	antibody	
MAPK		 	 	 Mitogen-activated	protein	kinase	
MHC	 	 	 	 Major	histocompatibility	complex		
mTEC	 	 	 	 Medullary	thymic	epithelial	cell	
mTOR		 	 	 Mammalian	target	of	rapamycin	
NFAT	 	 	 	 Nuclear	factor	of	activated	T	cells	
NFκB	 Nuclear	 factor	 kappa-light-chain-enhancer	 of	 activated	 B	cells	
NK	 	 	 	 Natural	killer	cell	
NZB	 	 	 	 New	Zealand	Black	
NZW	 	 	 	 New	Zealand	White	
NZW/B	F1	 	 	 F1	generation	of	NZW	and	NZB	
OT1-BDF1	 F1	 generation	 of	 C57BL/6-Tg(TcraTcrb)1100Mjb	 and	DBA/2	mice	
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OT2-BDF1	 F1	generation	of	C57BL/6-Tg(TcraTcrb)425Cbn	and	DBA/2	mice	
OVAp	 	 	 	 Ovalbumin	peptide	
PALS	 	 	 	 Periarteriolar	lymphoid	sheath	
PBS	 	 	 	 Phosphate	buffered	saline	
PI3K	 	 	 	 Phosphatidylinositol-4,5-bisphosphate	3-kinase	
PMA	 	 	 	 Phorbol-12-myristat-13-acetat	
PTPN22	 	 	 Protein	tyrosine	phosphatase,	non-receptor	type	22	
RAG	 	 	 	 Recombination-activating	genes	
RT	 	 	 	 Room	temperature	
S4B6/IL-2	 	 	 IL-2	bound	to	monoclonal	antibody	S4B6	
SCID	 	 	 	 Severe	combined	immunodeficiency	
SLAM	 	 	 	 Signaling	lymphocyte	activation	molecule	
SLE	 	 	 	 Systemic	Lupus	Erythematous		
SP	 	 	 	 Single-positive	for	CD4	or	CD8	
ssDNA		 	 	 Single-stranded	deoxyribonucleic	acid	
STAT	 	 	 	 Signal	transducer	and	activator	of	transcription	
TACI	 	 	 	 Transmembrane	activator	and	CAML	interactor	
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Tcm	 	 	 	 Central	memory	T	cell	
TCR	 	 	 	 T	cell	receptor	
Tfh	 	 	 	 Follicular	helper	T	cell	
TGF	 	 	 	 Transforming	growth	factor	
TLR	 	 	 	 Toll-like	receptor	
TNFR	 	 	 	 Tumor	necrosis	factor	receptor	
TRA	 	 	 	 Tissue-restricted	antigen	
Treg	 	 	 	 Regulatory	T	cell	
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III. Aim	of	the	Thesis	
This	thesis	tries	to	answer	the	following	questions	surrounding	cGvHD:	
- Is	 there	 a	 prophylactic	 or	 therapeutic	 potential	 of	 IL-2	 complexes	 in	 SLE-like	murine	cGvHD	induced	by	DBA/2	lymphocytes	in	BDF1	mice?	- Do	donor	CD8+	T	cells	contribute	 to	 the	pathogenesis	 in	 this	cGvHD	induced	by	DBA/2	lymphocytes?	- What	 is	 the	 influence	 of	 host	 T	 cells	 on	 graft-versus-host	 reactions	 induced	 by	DBA/2	lymphocytes?	- What	 is	 the	 effect	 of	 a	 restricted	 host	 TCR	 repertoire	 on	 graft-versus-host	reactions	induced	by	the	transfer	of	DBA/2	lymphocytes	into	BDF1	mice?	
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IV. Summary	
It	has	been	shown	previously	that	administration	of	Interleukin-2	(IL-2)	bound	to	anti-IL-2	monoclonal	 antibodies	 (IL-2	 complexes)	 leads	 to	 a	 selective	 stimulation	 of	 T	 cell	subsets	based	on	the	antibody	used	 for	 the	 formation	of	 the	complexes.	Moreover,	 the	increased	 selectivity	 of	 IL-2	 complexes	 prevents	 adverse	 side	 effects	 observed	 from	administration	of	plain	IL-2	and	at	the	same	time	leads	to	an	enhanced	biological	activity	of	this	cytokine.	
In	 this	 study	 we	 investigated	 the	 prophylactic	 and	 therapeutic	 effects	 of	 two	 IL-2	complexes,	 JES6/IL-2	 and	 S4B6/IL-2,	 on	 murine	 chronic	 Graft-versus-Host	 Disease	(cGvHD).	 Therefore,	 we	 used	 the	 p!F1	model	 of	 cGvHD	 and	 induced	 the	 disease	 by	transfer	 of	 DBA/2	 lymphocytes	 into	 BDF1	 mice.	 The	 IL-2	 complexes	 were	 either	administrated	 prophylactically,	 before	 disease	 induction,	 or	 therapeutically,	 4	 weeks	after	disease	induction.	
We	found	that	the	JES6/IL-2	and	S4B6/IL-2	have	opposing	effects	on	SLE-like	symptoms	in	 murine	 cGvHD.	 Whereas	 the	 prophylactic	 treatment	 with	 JES6/IL-2	 had	 an	ameliorating	 effect	 on	disease	 symptoms	accompanied	by	generally	 suppressed	donor	lymphocytes,	 prophylactic	 S4B6/IL-2	 treatment	 resulted	 in	 a	 more	 severe	 cGvHD	accompanied	 by	 a	 more	 activated	 donor	 compartment.	 When	 IL-2	 complexes	 were	administrated	 therapeutically	 (following	 the	 initiation	 of	 the	 disease),	 only	 S4B6/IL-2	complexes	 exhibited	 an	 effect	 and	 efficiently	 reduced	 disease	 symptoms.	 Our	 findings	further	 suggest	 an	 important	 suppressive	 role	 of	 donor	 CD8+	 T	 cells	 in	 this	model	 of	cGvHD	 because	 (i)	 the	 beneficial	 effect	 of	 therapeutic	 treatment	 with	 S4B6/IL-2	
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complexes	 depended	 on	 the	 presence	 of	 this	 population	 and	 (ii)	 a	 more	 aggressive	cGvHD	develops	in	the	absence	of	these	cells.	
Host	 T	 cells,	 especially	 CD4+	 FoxP3+	 regulatory	 T	 cells	 (Tregs),	 are	 thought	 to	 be	critically	involved	in	the	control	and	regulation	of	disease	driving	mechanisms	resulting	in	GvHD.	To	investigate	the	role	of	host	T	cells	in	graft-versus	host	reactions	in	the	p!F1	model,	 we	 transferred	 DBA/2	 lymphocytes	 into	 BDF1	 mice	 with	 a	 restricted	 TCR	repertoire	 (OT1-BDF1	 and	 OT2-BDF1).	 Our	 findings	 that	 the	 transfer	 of	 DBA/2	lymphocytes	(containing	CD8+	T	cells)	leads	to	an	acute	GvHD	(aGvHD)	in	TCR	restricted	(TCR	oligoclonal)	BDF1	mice	but	cGvHD	in	normal	BDF1	mice	provides	further	evidence	for	 an	 important	 influence	 of	 host	 T	 cells	 on	 graft-versus-host	 reactions.	 Likely	 as	 a	consequence	of	 the	 greatly	 reduced	Treg	 compartment	 in	OT1-BDF1	mice,	 these	mice	develop	 stronger	 aGvHD	compared	 to	OT2-BDF1	mice.	Moreover,	 these	 findings	 show	that	donor	CD8+	T	cells	are	central	for	the	induction	of	acute	GvHD	and	suggest	that	an	insufficient	control	of	donor	CD8+	T	cells	by	a	TCR	restricted	host	might	result	in	aGvHD	in	 OT1-	 and	 OT2-BDF1	mice.	When	 DBA/2	 lymphocytes	 depleted	 of	 CD8+	 T	 cells	 are	used	 to	 induce	 GvHD	 in	 TCR	 transgenic	 BDF1	mice,	 cGvHD	 developed,	 showing	 again	more	 severe	 symptoms	 in	 OT1-BDF1	 mice	 and	 milder	 symptoms	 in	 OT2-BDF1	 mice.	These	 results	 establish	 an	 important	 role	 of	 a	 diverse	 host	 T	 cell	 repertoire	 in	 the	regulation	of	graft-versus-host	reactions	and	the	resulting	GvHD.	
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Introduction	
1. Immunological	tolerance	
Tolerance	can	be	described	as	induced	state	of	non-responsiveness	to	a	specific	antigen.	The	immune	system	has	to	discriminate	between	self	and	foreign	in	order	to	mount	an	immune	 response	 only	 against	 potentially	 harmful	 non-self	 antigens.	 Self-tolerance	 is	established	during	 lymphocyte	 development	 and	 constantly	maintained	 in	 the	mature	compartment	through	antigen	dependent	mechanisms.	Whether	an	antigen	 induces	an	immune	response	or	tolerance	(tolerogen)	depends	on	many	factors	(e.g.	chemical	form,	route	of	entry	into	the	body,	dose,	tissue	localization).	If	self-tolerance	is	broken	by	any	means,	immune	responses	against	self-antigens	may	lead	to	autoimmune	disease.	
a) B	cell	tolerance	
Tolerance	in	the	B	cell	compartment	is	established	by	several	mechanisms	depending	on	the	interaction	of	the	B	cell	receptor	(BCR)	with	the	antigen,	the	developmental	stage	of	the	B	cell,	the	anatomical	location	where	the	antigen	is	encountered	and	the	presence	of	co-stimulatory	signals	[1].	
i) Clonal	deletion	The	concept	of	clonal	deletion	has	been	introduced	by	Frank	Macfarlane	Burnet	as	part	of	his	clonal	selection	theory	on	acquired	immunity	for	which	he	was	awarded	the	Nobel	Prize	 in	 Medicine	 and	 Physiology	 in	 1960	 jointly	 with	 Peter	 Brian	 Medawar.	 Clonal	deletion	 describes	 a	 process	 by	 which	 autoreactive	 B	 cells	 are	 physically	 eliminated	upon	engagement	of	their	antigen	receptor	during	development.	At	the	IgM+	immature	B	cell	stage	when	developing	B	cells	first	express	a	functionally	rearranged	BCR,	they	are	
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tested	for	receptor	fitness	and	self-reactivity.	If	the	receptor	binds	self-antigens	with	too	strong	affinity,	the	B	cell	is	induced	to	undergo	apoptotic	cell	death.	
Namazee	 and	 Bürki	 provided	 the	 experimental	 evidence	 for	 clonal	 deletion	 by	 using	BALB/c	 (H-2Kd)	mice	 expressing	 a	 transgenic	BCR	 (3-83tg)	 that	 recognizes	 the	major	histocompatibility	complex	class-I	(MHC-I)	molecule	H-2Kk	[2].	The	3-83	antibody	binds	MHC-I	 from	 the	H-2k	haplotype	with	high	 affinity	 and	MHC-I	 from	 the	H-2b	haplotype	with	much	 lower	affinity.	Crossing	 these	3-83tg	mice	 to	H-2k	expressing	mice	 leads	 to	deletion	 of	 developing	 B	 cells	 expressing	 the	 3-83	 BCR	 in	 the	 bone	 marrow	 (central	deletion).	Thus,	no	IgM+	B	cells	carrying	the	3-83	idiotype	are	detected	in	the	spleen	and	lymph	node	(LN)	of	H-2d/k	3-83tg	mice;	furthermore,	3-83	specific	IgM	is	not	detectable	in	the	sera	of	such	mice.	In	contrast,	3-83tg	mice	on	the	H-2d/d	background	show	no	such	deletion.	These	experiments	provide	evidence,	for	deletion	of	immature	B	cells	bearing	a	self-reactive	BCR	in	the	bone	marrow	upon	encounter	of	membrane-bound,	multivalent,	highly	BCR	crosslinking	self-antigens.	Additionally,	also	 low-affinity	B	cells	can	bind	to	multivalent	self-antigens	with	high	avidity.	However,	B	cells	of	non-transgenic	mice	are	capable	of	modifying	their	antigen	receptor	away	from	self-reactivity	to	escape	the	fate	of	clonal	deletion.	
ii) Receptor	editing	The	fate	of	B	cells	expressing	a	self-reactive	antigen	receptor	does	not	ultimately	result	in	 clonal	 deletion.	 It	 was	 shown	 independently	 by	 several	 groups	 that	 tolerance	mechanisms	 exist	 which	 rescue	 autoreactive	 B	 cells	 from	 clonal	 deletion	 [3,	 4].	Developing	 B	 cells	 that	 receive	 signals	 through	 a	 self-reactive	 receptor	 upon	 antigen	encounter	 are	 arrested	 in	 their	 developmental	 progression	 and	 reactivate	 the	recombination-activating	 gene	 (RAG)	 protein	 machinery.	 Ongoing	 VJ	 recombination	
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within	the	Ig	 light	chain	(IgL)	 loci	and	successful	pairing	with	the	Ig	heavy	chain	(IgH)	can	lead	to	a	new	receptor	with	non-self	specificity;	this	allows	the	developing	B	cell	to	escape	deletion	and	resume	its’	developmental	progression.	In	the	periphery,	however,	receptor	 editing	 does	 not	 occur	 upon	 auto-antigen	 encounter	 and	 self-reactive	B	 cells	are	regulated	by	other	mechanisms.	
Receptor	editing	was	demonstrated	in	mice	expressing	the	transgene	for	the	IgH	derived	from	 the	 3H9	 antibody	 specific	 for	 double-stranded	 (ds)	 DNA	 [5].	 Most	 IgH	 and	 IgL	combinations	containing	the	VH3H9	transgene	are	specific	for	ds	or	single-stranded	(ss)	DNA.	 However,	 only	 few	 hybridomas	 prepared	 from	 the	 spleen	 of	 those	 VH3H9-only	mice	 generated	 antibodies	 that	 bind	 ssDNA	 and	 not	 dsDNA.	 By	 analyzing	 the	 IgL	repertoire	of	such	hybridomas,	 it	was	found	that	some	Vk	genes	were	overrepresented	and	 IgL	containing	 Jk5	were	 frequent.	Together	 this	 reflects	 the	many	combinations	of	VH3H9	together	with	endogenous	IgL	chains	to	generate	anti-DNA	specific	receptors	and	allows	 efficient	 editing	 or	 elimination	 of	 those	 anti-self	 specificities	 upon	 antigen	encounter.	The	frequent	use	of	Jk5	indicates	several	rounds	of	IgL	editing	in	order	to	find	an	appropriate	combination	of	 IgH	and	IgL	genes	that	do	not	generate	an	autoreactive	specificity.	
Another	 approach	 to	 demonstrate	 receptor	 editing	 of	 immature	 B	 cells	 compared	centrally	 deleting	 3-83tg	 x	 H-2b	 mice	 to	 peripheral	 deleting	 3-83tg	 x	 MT-Kb	 mice,	expressing	the	Kb	antigen	only	 in	 liver,	pancreatic	 islets	and	kidney.	 It	was	shown	that	immature	 anti-idiotype	 (54.1)	 specific	 B	 cells	 exhibited	 elevated	 RAG2	 expression	 in	contrast	 to	 non-self	 reactive	 B	 cells.	 Further,	 bone	marrow	 cells	 of	 centrally	 deleting	mice	 showed	 elevated	 IgL	 gene	 recombination,	 detected	 by	 excision	 products,	 and	 a	higher	 frequency	 of	 lambda	 light	 chain	 rearrangements.	 Taken	 together,	 these	
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experiments	support	 the	 idea	 that	signaling	 through	autoreactive	BCRs	 in	 immature	B	cells	induces	further	VJ	recombination	leading	to	secondary	rearrangement	of	IgL	genes	and	 possibly	 a	 change	 in	 specificity	 away	 from	 self-reactivity,	 thereby	 rescuing	 cells	from	clonal	deletion.	
In	hybridomas	generated	from	3H9	(IgH	+	IgL)	transgenic	B	cells	of	adult	mice,	the	B	cell	repertoire	comprises	receptors	composed	of	 transgenic	 IgH	together	with	endogenous	IgL	 [3].	 Although	 mRNA	 of	 both,	 the	 transgenic	 IgL	 and	 the	 endogenous	 IgL	 are	transcribed,	endogenous	IgL	preferentially	pair	with	the	3H9	IgH.	The	restricted	usage	of	endogenous	Igκ	V	genes	reflects	a	selection	of	many	IgL	chains	that	pair	with	IgH	from	the	3H9	antibody.	This	 form	of	receptor	editing	 is	 the	dominant	 tolerance	mechanism,	which	 is	 actively	driven	by	antigen	 that	 acts	on	 immature	B	 cells	 in	 the	bone	marrow	leading	to	a	change	in	specificity	at	the	genetic	level.	
iii) Anergy	Another	 mechanism	 for	 tolerance	 induction	 in	 B	 cells	 is	 functional	 inactivation,	 also	known	as	clonal	anergy.	Tolerance	by	anergy	was	first	demonstrated	in	mice	transgenic	for	a	soluble	form	of	hen	egg	lysozyme	(HEL),	which	were	crossed	to	mice	transgenic	for	a	BCR	specific	for	HEL.	This	HEL/anti-HEL	double-transgenic	(HEL-Dbl-tg)	mouse	model	(MD4xML5)	 was	 developed	 by	 Goodnow	 [6].	 In	 these	 mice,	 antigen	 specific	 B	 cells	expressing	a	transgene-encoded	BCR	are	not	deleted	in	the	bone	marrow	and	found	in	normal	 numbers	 in	 the	 periphery.	 However,	 lysozyme	 specific	 antibodies	 are	 not	detectable	 in	 the	 serum.	 Anergy	 induction	 in	 HEL-Dbl-tg	 B	 cells	 is	 accompanied	 by	down-regulation	 of	 surface	 IgM	 levels	 whereas	 expression	 of	 IgD	 is	 maintained.	Additionally,	such	B	cells	are	unable	to	upregulate	CD86	co-stimulatory	molecules.	
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When	 anergic	 B	 cells	 are	 removed	 from	 their	 tolerogenic	 environment	 in	 HEL-Dbl-tg	mice	and	“parked”	in	non-transgenic	hosts	(HEL-free),	they	progressively	regain	surface	IgM	levels	comparable	to	those	of	transferred	non-tolerant	anti-HEL	transgenic	B	cells.	Moreover,	 functional	 recovery	 of	 anergic	 B	 cells	was	 achieved	 by	 several	 days	 of	 LPS	stimulation	 in	 vitro	 [7].	 Thus,	 anergy	 is	 a	 reversible,	 intrinsically	 regulated	 state	 of	induced	unresponsiveness.	
Induction	of	anergy	requires	a	certain	threshold	concentration	of	antigen.	This	could	be	demonstrated	in	HEL-Dbl-tg	mice	by	manipulation	of	the	serum	concentration	of	soluble	lysozyme	 via	 an	 inducible	metallothionein	 promoter	 in	 the	 HEL	 transgene	 [8].	 It	was	calculated	that	concentrations	at	which	only	4.5%	of	BCRs	are	occupied	by	lysozyme	in	HEL-Dbl-tg	mice	failed	to	induce	tolerance	whereas	receptor	occupancy	of	45%	resulted	in	anergic	tolerance	to	HEL.	
Anergic	B	cells	have	a	reduced	lifespan	(only	2	to	3	days)	and	are	excluded	from	splenic	follicular	 and	 marginal	 zones	 through	 competition	 with	 non-self-reactive	 B	 cells	 [9].	Anergy	represents	an	important	mechanism	by	which	autoreactive	B	cells	are	rendered	tolerant	and	the	reactivation	of	anergic	B	cell	can	lead	to	severe	autoimmune	responses.	
A	limitation	of	the	original	MD4xML5	model	of	anergy	is	the	absence	of	competition	with	non-HEL-specific	B	cells.	In	MD4xML5	mice,	HEL-specific	B	cells	are	found	in	the	splenic	follicles	 but	 not	 in	marginal	 zones.	 In	mixed	 BM	 chimera	where	 Ig	 transgenic	 B	 cells	represent	 a	 minor	 fraction,	 anergic	 B	 cells	 do	 not	 enter	 splenic	 follicles	 and	 have	 a	reduced	lifespan	of	less	than	3	days	[10].	In	class-switch	recombination	competent	HEL	transgenic	(SWHEL-tg)	mice,	in	contrast	to	HEL-tg	mice,	HEL-specific	B	cells	are	capable	to	 switch	 antibody	 isotypes	 to	 IgG.	 Moreover,	 due	 to	 the	 targeted	 insertion	 at	 the	
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physiological	 site	 in	 the	 IgH	 locus	 and	possibly	due	 to	 the	 instability	of	 rearranged	V-regions	 in	 early	 B-cell	 development,	 a	 large	 population	 of	 “competing”	 non-lysozyme-binding	 B	 cells	 is	 present	 in	 these	 mice.	 Increased	 competition	 effects	 migratory	properties	and	results	in	localization	of	HEL-specific	B	cells	to	extra-follicular	locations	(PALS).	 Additionally,	 HEL-specific	 SWHEL	 x	ML5	 B	 cells	 show	 an	 immature	 phenotype	(CD21/CD35lo	CD23lo).	This	model	more	closely	resembles	a	physiologic	situation	where	self-reactive	 B	 cells	 represent	 only	 a	 small	 population	 and	 competition	with	 non-self-reactive	 cells	 is	 high.	HEL-specific	B	 cells	 in	 SWHEL	 x	ML5	mice	 are	 anergic	 but	 can	be	stimulated	 to	 secrete	 class-switched	 IgG	 antibodies	 upon	 BCR-independent	 CD40	stimulation	 in	vitro.	 Interestingly,	 in	 this	model	 the	accumulation	of	 immature	anergic	SWHEL	x	ML5	B	cells	can’t	be	attributed	simply	to	the	higher	level	of	receptor	occupancy	because	MD4xAL3	mice,	which	express	higher	concentrations	of	soluble	HEL	compared	to	 MD4xML5	 mice,	 have	 HEL-specific	 B	 cells	 showing	 a	 more	 mature	 phenotype	(CD21/CD35int	 CD23hi)	 despite	 almost	 complete	 receptor	 occupancy	 (89%)	 which	localize	in	splenic	follicles	[9].	
iv) Clonal	deletion	in	the	periphery	Mechanisms	 that	 ensure	 the	 establishment	 of	 self-tolerance	 in	 the	 primary	 lymphatic	organs	(central	tolerance)	are	not	perfect	as	evident	from	the	presence	of	autoantibody	producing	B	cells	 in	 the	periphery	 [11].	Since	 tolerance	 induction	 is	an	antigen	driven	process,	 tolerogenic	 antigens	 need	 to	 be	 present	 during	 lymphocyte	 development	 at	above-threshold	concentrations	at	the	sites	of	tolerance	induction	(in	the	bone	marrow	for	B	cells	and	in	the	thymus	for	T	cells).	For	immature	B	cells,	the	tolerogenic	antigen	has	to	be	either	present	at	very	high	concentrations	or	in	a	multivalent	form	that	causes	extensive	cross-linking	of	BCRs.	Antigens	that	are	expressed	only	in	discrete	tissues	with	
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no	 access	 to	 primary	 lymphatic	 organs	 do	 not	 induce	 tolerance	 through	 central	tolerance	mechanisms.	 Furthermore,	 in	 contrast	 to	 T	 cells,	 B	 cells	might	 experience	 a	second	wave	of	diversification	by	 somatic	hypermutation	 in	germinal	 center	 reactions	after	 they	 left	 the	 bone	 marrow.	 This	 implicates	 the	 need	 for	 additional	 tolerance	mechanisms	 to	 control	 peripheral	 mature	 B	 cells	 that	 escaped	 central	 tolerance	mechanisms	or	have	altered	their	antigen	receptors	through	hypermutation.	
Non-tolerant	mature	HEL-specific	B	cells	are	rendered	unresponsive	when	transferred	to	a	HEL-tg	host	(ML5).	Moreover,	these	HEL-specific	B	cells	down-regulate	surface	IgM	similar	 to	 B	 cells	 in	 HEL-Dbl-tg	 mice	 and	 do	 not	 respond	 to	 T	 cell-dependent	immunization	[8].	This	indicates	that	in	mature	B	cells,	tolerance	can	be	induced	in	the	periphery	depending	on	the	concentration	of	the	tolerogenic	antigen.	
The	 deletion	 of	 autoreactive	 B	 cells	 in	 response	 to	 antigens	 expressed	 exclusively	 at	peripheral	 sites	was	 demonstrated	 in	 3-83tg	mice	with	 liver	 specific	 expression	 of	 Kb	(MT-Kb/3-83tg	mice)	[12].	Such	mice	deleted	Kb-specific	B	cells	in	the	periphery	but	not	in	 the	bone	marrow,	 thus	only	 at	 sites	where	antigen	was	encountered.	The	 complete	absence	of	Kb-specific	B	cells	in	LNs	reflects	the	efficient	deletion	of	the	recirculating	B	cell	pool	and	suggests	that	those	cells	found	in	the	spleen	are	newly	formed	B	cells	from	bone	marrow.	In	contrast,	peripheral	deletion	of	Kb-specific	B	cells	is	not	observed	when	Kb	 is	 expressed	 under	 the	 keratin	 promoter	 in	 the	 periphery	 of	 3-83tg	 mice.	 Similar	findings	(no	tolerance	induction	to	peripherally	expressed	antigens)	were	obtained	from	HEL-Dbl-tg	mice	expressing	HEL	under	control	of	rat	thyroglobulin	promoter	(rTg)	[13].	The	opposing	outcome	of	tolerance	induction	in	the	MT-Kb	and	rTg-Kb	model	may	be	a	consequence	 of	 different	 accessibility	 of	 B	 cells	 to	 the	 antigens	 as	 well	 as	 variable	capacity	of	liver	and	thyroid	cells	to	present	those	antigens.	
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Further	 evidence	 for	 a	 differential	 regulation	 of	 tolerance	 induction	 in	 respect	 to	 the	autoantigen	stems	from	autoimmune-prone,	Fas-deficient,	MRL/lpr	H-2d	mice	carrying	the	 same	 MT-Kb	 and	 3-83	 transgenes	 [14].	 Although	 Fas	 deficient,	 double-transgenic	mice	efficiently	deleted	3-83	specific	B	cells,	 they	produced	elevated	 levels	of	 IgG	anti-chromatin	antibodies.	This	indicates	that	induction	of	tolerance	to	membrane-associated	autoantigens	seems	to	be	differentially	regulated	compared	to	nuclear	antigens.	
Under	normal	physiological	conditions,	most	immature	B	cells	arriving	in	the	spleen	are	negatively	 selected	 and	die	by	 apoptosis	during	 transition	 from	 immature	T1	 stage	 to	the	more	mature	T2	stage	[15,	16].	B	cell	activating	factor	(BAFF),	is	a	limiting	factor	and	critically	regulates	this	transition	and	maturation	process	[17,	18].	It	was	shown	that	B	cells,	from	the	immature	stage	in	the	bone	marrow	up	to	mature	splenic	B	cells,	respond	to	 BAFF	 either	 by	 phenotypic	 maturation	 or	 increased	 Bcl-2	 mediated	 survival	 [19].	Usually,	anergic	self-reactive	B	cells	have	a	life	span	of	2	to	3	days	and	are	excluded	from	splenic	follicular	and	marginal	zones	due	to	extensive	competition	with	non-self	reactive	B	 cells.	 In	 situations	where	BAFF	 is	 available	 in	 excessive	 amounts	 (in	BAFF-tg	mice),	self-reactive	B	cells	are	rescued	through	BAFF	generated	survival	signals.	This	leads	to	the	development	of	self-reactive	B	cells	with	intermediate	affinity	beyond	the	T2	stage	and	their	localization	in	splenic	follicular	and	marginal	zones	[20].	Although	high-affinity	autoreactive	B	cells	are	efficiently	deleted,	B	cells	with	 intermediate	affinity	 remain	at	sites	where	they	can	receive	T	cell	help	or	mitogenic	stimulation	e.g.	by	LPS.	Thus,	excess	of	BAFF	can	rescue	anergic	self-reactive	B	cells	with	low-affinity	receptors	from	deletion	in	the	periphery	and	contributes	significantly	to	the	development	of	antibody-mediated	autoimmune	diseases.	
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b) T	cell	Tolerance	
The	 thymus	 fulfills	 two	 important	 tasks	 for	 the	 establishment	 of	 self-tolerance.	 First,	autoreactive	 specificities	 are	 removed	 from	 the	 developing	 T	 cell	 repertoire	 by	 the	central	 mechanisms	 of	 receptor	 editing	 and	 negative	 selection	 (recessive	 tolerance).	Second,	 the	 thymus	 produces	 regulatory	 T	 cells	 (Tregs)	 with	 suppressive	 capacity	 in	order	 to	 control	 autoreactive	 T	 cells	 that	 escaped	 negative	 selection	 (dominant	tolerance).	 For	 this,	 the	 thymus	 provides	 a	 specialized	 microenvironment	 of	 distinct	cortical	 and	 medullar	 compartments	 through	 which	 thymocytes	 pass	 in	 an	 ordered	sequence	during	their	development.	Two	transcription	factors	play	a	central	role	for	the	induction	of	T	cell	tolerance:	autoimmune	regulator	(AIRE)	and	forkhead-box-protein	P3	(FoxP3).	 Mutations	 in	 the	 genes	 encoding	 these	 transcription	 factors	 result	 in	 the	monogenetic	 disease	 autoimmune	 polyendocrinopathy	 syndrome	 type	 1	 (APS-1)	 and	immune	 dysregulation,	 polyendocrinopathy,	 enteropathy,	 X-linked	 inheritance	syndrome	(IPEX),	respectively	[21,	22].	
Selection	processes	in	the	thymus	reflect	important	differences	between	B	and	T	cells	in	regard	to	development	(release	of	fully	mature	T	cells,	CD4/CD8	lineage	commitment),	receptor	 formation	 (induction	 of	 allelic	 exclusion)	 and	 antigen	 recognition	 (MHC-restriction).	ERK	signaling	is	an	important	factor	in	the	selection	of	T	cell.	Low-affinity	T	cell	receptor	(TCR)	interactions	generate	sustained	ERK	activation	and	lead	to	positive	selection	 of	 T	 cells,	whereas	 high-affinity	 interactions	 induce	 transient	 ERK	 activation	and	promote	negative	selection	resulting	 in	 the	elimination	of	potentially	dangerous	T	cells	[23].	
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i) Positive	and	negative	selection	During	 T	 cell	 development,	 self-tolerant	 and	 self-MHC	 restricted	 thymocytes	 are	selected	 through	 interactions	 with	 (self-)	 antigen	 presenting	 cells	 (APC)	 of	 non-hematopoietic	 origin.	 This	 selection	 process	 takes	 place	 in	 specialized	microenvironments	 of	 the	 thymus	 and	 is	 mediated	 by	 cortical	 thymic	 epithelial	 cells	(cTECs)	and	medullary	 thymic	epithelial	 cells	 (mTECs)	as	well	as	dendritic	 cells	 (DCs)	[24].	 In	 the	 cortex,	 double-positive	 (DP)	 thymocytes	 are	 positively	 selected	 if	 they	express	 an	 antigen	 receptor	 that	 can	 recognize	 self-peptide:self-MHC	 (self-pMHC)	complexes	 presented	 by	 cTECs	 [25,	 26].	 Thus,	 during	 positive	 selection,	 self-MHC	restricted	thymocytes	are	selected	to	survive	and	mature	[27].	Both,	the	MHC	molecule	and	 the	 presented	 peptide	 strongly	 influence	 the	 selection	 outcome	 and	 therefor	contribute	 to	 the	 formation	 of	 the	 TCR	 repertoire	 [28-30].	 Peptide	 ligands	 with	 the	capacity	to	promote	positive	selection	of	thymocytes	were	found	to	be	of	low	affinity	for	the	 TCR,	meaning	 they	 inhibit	 T	 cell	 responses	 or	 at	 best	 induce	weak	 stimulation	 of	mature	T	cells	[31].	
The	affinity	hypothesis	has	been	put	forward	to	explain	the	opposing	outcome	that	can	result	 from	 TCR	 signaling	 in	 developing	 thymocytes.	 This	 concept	 describes	 that	TCR/co-receptor/pMHC	 interaction	 of	 low	 or	 intermediate	 affinity	 result	 in	 survival	(positive	 selection)	 whereas	 interactions	 with	 apparent	 affinity	 above	 a	 certain	threshold	induce	apoptosis	(negative	selection)	of	the	thymocyte.	It	 is	thought	that	the	thymocyte	 integrates	 TCR	 signals	 by	 kinetic	 proofreading	 (connecting	 the	 apparent	affinity	 to	 the	 dissociation	 rate	 and	 the	 half-life	 of	 the	 TCR/co-receptor/pMHC	interactions	 (dwell	 time))	 and	 serial	 triggering.	 High	 affinity	 interactions	 are	characterized	by	slow	dissociation	rates	and	long	half-lives	that	result	in	full	“zippering”	
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of	TCR	and	co-receptors	leading	to	complete	phosphorylation	of	CD3	containing	ITAMs	whereas	 low	 affinity	 interactions	 result	 in	 only	 partial	 “zippering”	 and	 insufficient	activation	 of	 the	 CD3	 complex	 [32].	 It	 was	 shown	 that	 MHC-I	 restricted	 thymocytes	display	 an	 universal	 apparent	 affinity	 threshold	 for	 negative	 selection	 with	 a	dissociation	constant	(Kd)	~	6	µM	and	half-life	(t1/2)	of	1	-	3	seconds	[33].	The	apparent	affinity	 of	 MHC-I	 restricted	 TCR/pMHC	 interactions	 is	 particularly	 influenced	 by	 co-receptor	 binding	 (10	 -15	 fold	 increased	 by	 CD8)	 in	 contrast	 to	 MHC-II	 restricted	interactions	where	CD4	contribution	 is	weak	 (Kd	of	10	–	60µM	with	or	without	CD4).	Intracellular	 signaling	 events	 following	 high	 or	 low	 affinity	 interactions	 differ	 in	 the	compartmentalization	of	Ras/MAPK	signaling	pathway	components	and	the	kinetics	of	Erk	activation.	Low	affinity	 interactions	with	 fast	off-rates	are	characterized	by	a	slow	accumulation	of	activated	Erk	at	the	Golgi	whereas	high	affinity	 interactions	with	slow	off-rates	 induced	 rapid	 localization	 of	 activated	 Erk	 at	 the	 plasma	 membrane.	 In	contrast,	 the	 activation	 kinetics	 and	 the	 localization	 of	 Jun,	 another	 important	 MAPK	downstream	 of	 TCR	 signaling,	 is	 similar	 for	 high	 and	 low	 affinity	 signaling	 [23].	 This	compartmentalization	of	activated	Erk	and	Jun	forms	the	basis	for	the	different	selection	outcome	in	response	to	high	and	low	affinity	TCR/pMHC	interactions.	
The	 cytosolic	 proteasomal	 degradation	 machinery	 of	 cTECs	 contains	 the	 ß5t	 subunit	(processing	of	peptides	presented	on	MHC-I)	and	together	with	 lysosomal	Cathepsin	L	(processing	 of	 peptides	 presented	 on	 MHC-II)	 cTECs	 have	 the	 ability	 process	 and	present	 sets	 of	 peptides	 that	 are	 unique	 to	 this	 cell	 type	 [34,	 35].	 Commitment	 of	DP	thymocytes	 to	 either	 the	CD8+	 or	 the	CD4+	T	 cell	 lineage	depends	on	 interaction	with	MHC-I	 or	 MHC-II	 molecules,	 respectively,	 and	 is	 controlled	 by	 the	 activity	 of	 the	 co-receptor	 associated	 tyrosine	 kinase	 Lck	 [36-38].	 Furthermore,	 positive	 selection	
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terminates	 further	 α-chain	 rearrangement	 through	 down	 regulation	 of	 RAG	 protein	expression,	promotes	survival	by	inducing	Bcl-2	and	leads	to	developmental	progression	to	 the	 single-positive	 (SP)	 stage	 [39,	 40].	 The	 majority	 of	 DP	 thymocytes	 will	 die	 by	programmed	cell	death	within	3	 to	4	days	because	their	receptors	do	not	bind	to	self-pMHC,	hence,	no	survival	signal	is	transmitted	(death	by	neglect)	[41].		
Subsequent	 to	 positive	 selection,	 thymocytes	 undergo	 phenotypic	 changes	 associated	with	 maturation	 (e.g.	 TCR	 upregulation,	 CD69	 expression)	 and	 migrate	 to	 medullary	regions	where	 development	 is	 completed.	 There,	 SP	 thymocytes	 encounter	mTECs	 as	well	as	DCs	of	 intra-	or	extrathymic	origin	 [42,	43].	mTECs	have	 the	unique	 feature	 to	express	tissue-restricted	antigens	(TRAs)	from	distinct	tissues	under	the	control	of	AIRE	and	 can	 present	 the	 corresponding	 peptides	 on	 MHC	 molecules	 [44].	 Expression	 of	peripheral	antigens	is	an	essential	part	of	central	tolerance	mechanisms	to	promote	self-tolerance	in	the	T	cell	compartment.	Strong	recognition	of	self-pMHC	complexes	by	the	TCR	leads	to	 thymocyte	death	by	apoptosis	(negative	selection)	or	might	 induces	Treg	lineage	 deviation	 (agonist	 selection)	 [45,	 46].	 DCs	 in	 the	 thymic	 medulla	 are	 potent	mediators	 of	 negative	 selection	 through	 induction	 of	 apoptosis	 via	 co-stimulatory	molecules	 [47,	48].	 In	order	 to	complete	 thymic	selection,	SP	 thymocytes	reside	 in	 the	medulla	for	another	4	to	5	days	to	scan	multiple	mTECs	for	potential	high	affinity	self-antigens.	Thereafter,	 thymocytes	are	exported	as	 fully	 functional	mature	T	cells	 to	 the	periphery.	
The	 requirements	 for	 positive	 selection	 and	 the	 influence	 of	MHC	molecules	 together	with	 the	 presented	 peptides	 on	 the	 selection	 of	 the	 TCR	 repertoire	 have	 been	demonstrated	in	several	experimental	systems.	
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The	 thymus	 selects	 a	 repertoire	 of	 TCRs	 biased	 to	 recognize	 peptides	 presented	 in	combination	 with	 allelic	 variants	 of	 MHC	 molecules	 (haplotype)	 expressed	 by	radioresistant	cortical	thymic	epithelial	cells	(cTECs).	Transfer	of	F1	bone	marrow	into	lethally	 irradiated	 parental	 recipient	 mice	 provided	 experimental	 evidence	 that	thymocytes	 are	 “educated”	 in	 the	 thymus	 and	 restricted	 to	 MHC	 molecules	 of	 the	parental	 haplotype,	 expressed	 on	 radioresistant	 thymic	 stromal	 cells.	 F1	 T	 cells	 from	irradiation	chimaera	(F1	H-2b/d	!	BALB/c	H-2d/d)	that	were	immunized	with	syngeneic	minor	antigens	(B10	H-2b/d)	could	only	lyse	target	cells	expressing	the	MHC	haplotype	of	the	 recipient	 strain	 but	 not	 target	 cells	 expressing	 the	 MHC	 haplotype	 of	 the	 other	parent	 [49].	 Further	 support	 for	 self-MHC	 restriction	 was	 provided	 by	 studies	investigating	 the	selection	of	TCR	transgenic	 thymocytes	on	different	MHC	haplotypes.	The	2C	TCR	is	specific	for	Ld	antigen	and	is	efficiently	positively	selected	by	H-2Kb	in	the	absence	of	its	high	affinity	antigen,	Ld.	It	was	shown	that	the	selection	in	an	autoimmune	environment	 (H-2d,	 expressing	 Ld)	 or	 a	 non-selecting	 environment	 (H-2s,	 lacking	 Kb)	generates	comparable	fractions	of	2C+	CD8+	T	cells	in	the	periphery	but	those	generated	on	 the	 H-2d	 background	 are	 functionally	 inactive.	 In	 the	 thymus	 of	 H-2d	 mice,	 2C	thymocytes	 are	 found	 mainly	 in	 the	 double-negative	 population	 whereas	 in	 the	 H-2s	mice,	DP	thymocytes	express	the	2C	TCR.	There	is	no	deletion	of	2C+	thymocytes	at	the	DP	stage	in	H-2s	mice	but	positive	selection	is	also	not	possible	because	of	the	lack	of	H-2b	[50].	
Studies	with	 irradiated	 bone	marrow	 chimeras	 reconstituted	with	 bone	marrow	 from	mice	carrying	the	transgenic	TCR	specific	for	the	male	antigen	(H-Y),	show	that	antigen	specific	 T	 cells	 are	 only	 positively	 selected	 if	 they	 mature	 in	 an	 environment	 that	provides	 the	 appropriate	 MHC.	 Since	 H-Y	 specific	 TCRs	 are	 restricted	 to	 peptide	
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presentation	by	H-2Db,	positive	selection	of	the	H-Y	specific	receptor	is	only	achieved	in	mice	expressing	H-2Db	molecule	(e.g.	B6,	BDF1,	B10.HTG).	In	the	thymus	of	non-H-2Db	recipients	 (B10.BR	(H-2Dk),	B10.D2	(H-2Dd)),	H-Y	specific	 thymocytes	are	not	selected	because	 of	 the	 lack	 of	 H-2Db	 expression.	 However,	 thymocytes	 that	 could	 edit	 their	receptor	 to	 recognize	H-2Dk	 or	H-2Dd	were	 selected.	 These	 thymocytes	 expressing	 an	edited	TCR	still	express	the	transgenic	β-chain	but	in	combination	with	an	endogenous	α-chain	[51].	Efficient	receptor	editing	was	demonstrated	in	immature	OT-I	transgenic	T	cells	 in	 response	 to	 peptides	 of	 ovalbumin	 (OVAp)	 presented	 on	 the	 cortical	 thymic	epithelium.	 Thymocytes	 in	 such	 mice	 are	 not	 deleted	 because	 they	 replace	 the	transgenic	 α-chain	 by	 expression	 of	 an	 endogenous	 α-chain.	 On	 a	 RAG	 deficient	background	 where	 rearrangement	 of	 endogenous	 α-chain	 genes	 is	 inhibited	 OT-I	transgenic	TCRs	are	efficiently	deleted	in	response	to	OVAp	[52].	
In	 male	 H-Y	 TCR	 transgenic	 mice,	 deletion	 of	 developing	 TCR	 transgenic	 thymocytes	occurs	at	the	DP	stage	upon	recognition	of	that	male	antigen.	CD8+	T	cells	 found	in	the	periphery	of	these	mice,	that	escaped	deletion,	show	reduced	CD8	expression	and	do	not	differentiate	into	cytotoxic	T	lymphocytes	(CTLs)	in	response	to	male	(H-Y	expressing)	stimulator	cells.	Transgenic	T	cells	in	the	periphery	are	mainly	present	in	a	population	of	T	cells	expressing	neither	CD4	nor	CD8.	The	occurrence	of	such	T	cell	populations	in	TCR	transgenic	H-2d	SCID	mice	 indicates	a	selection	process	 independent	of	H-2b	molecules	[38]	[53].	
Fetal	thymus	organ	cultures	(FTOCs)	prepared	from	non-transgenic	β2m-/-	or	OT-I	TCR	transgenic	 mice	 provide	 an	 elegant	 tool	 to	 investigate	 the	 peptide	 requirements	 for	positive	selection	of	a	specific	TCR.	Using	such	FTOC	approaches	it	was	shown	that	OT-I	specific	 CD8+	 T	 cells	 could	 only	 be	 positively	 selected	 if	 the	 required	 Kb	 molecule	 is	
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present.	 Selection	 on	 the	 variant	 Kbm1	 protein	 was	 not	 possible.	 Moreover,	 positive	selection	is	very	sensitive	to	MHC	density	and	peptide	concentration	as	well	as	peptide	specificity.	In	FTOC	it	was	also	shown	that	variants	of	the	antigenic	peptides	are	able	to	induce	 positive	 selection	 and	 functional	 maturation	 of	 OVAp	 specific	 thymocytes.	Interestingly,	 all	 these	 antigenic	 variants	 that	 induce	 positive	 selection	 are	 also	antagonists	that	can	inhibit	CTL	dependent	lysis.	One	variant	peptide	(E1)	was	shown	to	mediate	positive	selection	of	the	OT-I	specific	receptor	at	low	ligand	concentration	(β2m	
-/-)	and	negative	selection	at	high	concentrations	(β2m	+/-)[31,	54].	
ii) Promiscuous	gene	expression	Thymic	medullary	 regions	 provide	 a	 special	 environment	 for	 the	 induction	 of	 central	tolerance.	There,	various	APCs	of	extra-	and	intra	thymic	origin	can	be	found	that	act	in	concert	 to	 promote	 negative	 selection	 of	 self-reactive	 receptors.	 Thymocytes	 are	selected	in	response	to	self-antigens	derived	from	various	sources.	mTECs	have	a	pivotal	role	 in	 the	 induction	 of	 self-tolerance	 due	 to	 the	 ability	 to	 express	 antigens	 that	 are	usually	restricted	to	cells	of	specific	tissues,	so	called	tissue-restricted	antigens	(TRAs).	This	 promiscuous	 gene	 expression	 of	 TRAs	 is	 mediated	 by	 AIRE	 proteins	 interacting	with	 other	 transcription	 factors	 to	 promote	 DNA	 accessibility	 of	 normally	 closed	chromatin	 regions.	 The	 molecular	 details,	 however,	 are	 still	 not	 fully	 understood.	Although,	 each	 specific	 TRA	 is	 only	 expressed	 by	 a	 fraction	 of	 mTECs	 (1	 -	 3%),	 the	repertoire	 of	 peripheral	 self-antigens	 is	 largely	 represented	 by	 this	 AIRE	 dependent	expression.	Indirect	presentation	of	TRAs	that	have	been	transferred	to	DCs	increase	the	chance	 that	 thymocytes	 interact	 with	 rare	 TRAs	 during	 selection	 in	 the	 medulla.	Promiscuous	gene	expression	might	contribute	 to	generation	of	Tregs	specific	 for	rare	self-antigens.	 Central	 tolerance	 critically	 depends	 on	 AIRE	 and	 the	 regulation	 of	
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promiscuous	gene	expression.	AIRE	deficiency	in	mice	leads	to	multi-organ	autoimmune	disease	with	 lymphocyte	 infiltration	 resembling	 the	 rare	 human	 autoimmune	 disease	APS-1	[55,	56].	
iii) Treg	development	in	the	thymus		Tregs	 (referring	 to	 natural	 or	 thymus	 derived	 Tregs	 unless	 otherwise	 specified)	represent	 an	 important	 subpopulation	 of	 suppressive	 CD4+	 T	 cells	 whose	 activity	 is	dependent	on	 their	 expression	of	 the	 transcription	 factor	FoxP3	 [57-60].	Tregs	derive	from	the	same	progenitor	cells	and	also	share	the	same	maturation	and	differentiation	process	 as	 conventional	 T	 cells	 in	 the	 thymus.	 The	 requirement	 for	 IL-2	 for	 the	development	 of	 Tregs	 in	 the	 thymus	 has	 been	 controversial	 due	 to	 the	 functional	redundancy	of	IL7	and	IL15.	IL-2-/-	and	IL-2Rα-/-	mice	have	only	mildly	reduced	numbers	of	FoxP3+	 thymocytes,	but	 in	CD132-/-	mice	 (common	γ-chain	deficiency	 (SCID))	 these	Tregs	 are	 practically	 absent,	 suggesting	 a	 critical	 role	 of	 common	 γ-chain	 associated	signaling	 pathways	 involving	 STAT	 transcription	 factors.	 In	 agonist-driven	 TCR	transgenic	mouse	models	of	Treg	differentiation,	however,	 it	was	shown	that	 IL-2	and	IL-2Rα	 expression	 are	 not	 required	 for	 the	 generation	 of	 Tregs	 [61].	 The	 selection	process	of	Tregs	depends	on	the	affinity	of	the	TCR	for	a	specific	peptide.	It	was	shown	that	 in	 thymocytes	expressing	TCRs	with	high	affinity	 for	 self-antigens	 that	 is	 close	 to	the	 threshold	 affinity	 for	 negative	 selection,	 Treg	 differentiation	 is	 favored	 [62].	Although	FoxP3	is	the	lineage	specific	transcription	factor	and	its	expression	is	essential	for	 the	 regulatory	 function	 of	 Tregs,	 commitment	 to	 the	 Treg	 lineage	 in	 the	 thymus	seems	to	be	dependent	on	co-stimulatory	CD28	signaling,	rather	than	just	the	induction	of	FoxP3	expression	 [63].	 It	was	shown	that	AIRE+	TRA	presenting	mTECs,	expressing	abundant	 co-stimulatory	molecules,	 promote	 the	 differentiation	 of	 TRA-specific	 Tregs	
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and	that	under	conditions	of	low	antigen	concentrations,	Treg	differentiation	is	favored	over	 negative	 selection,	 i.e.	 deletion	 [64-66].	 Moreover,	 mTECs	 are	 a	 source	 for	transforming	growth	factor	(TGF)-β	and	express	members	of	the	tumor-necrosis	factor	receptor	 (TNFR)	 family,	 including	 OX40	 (CD134)	 and	 GITR	 (CD357),	 which	 are	 also	required	 for	 the	 induction	 of	 Treg	 differentiation.	 Any	 defect	 that	 results	 in	 a	compromised	 Treg	 compartment	 can	 potentially	 induce	 severe	 multi-organ	autoimmunity	[67].	
iv) Treg	conversion	in	the	periphery	Besides	 the	 generation	 of	 Tregs	 by	de	novo	 pathways	 in	 the	 thymus,	 they	 can	 also	 be	differentiated	 under	 certain	 conditions	 from	 naïve	 CD4+	 T	 cell	 populations	 in	 the	periphery	[68].	Conversion	of	naïve	CD4+	T	cells	into	induced	Tregs	(iTregs)	is	induced	by	stimulation	with	agonist	peptides	present	at	low	concentrations	in	the	absence	of	co-stimulation.	 Presence	of	TGF-β	 can	 also	promote	 conversion	 into	 iTregs	by	 stabilizing	FoxP3	expression	and	inhibiting	CD4+	T	cell	proliferation.	Retinoic	acid	produced	by	gut-resident	DCs	further	contributes	to	iTreg	conversion	[69].	 iTregs	can	express	the	same	levels	of	FoxP3	and	have	equal	suppressive	capacity	compared	to	thymus	derived	Tregs.	The	conversion	of	conventional	CD4+	T	cells	 into	 iTregs	contributes	to	antigen-specific	tolerance	 in	 the	mature	 T	 cell	 compartment	 and	 is	 likely	 to	 occur	 in	 response	 to	 gut	associated	 non-self	 antigens	 [70].	 The	 conversion	 of	 high-affinity	 self-reactive	 T	 cells	into	iTregs	is	suggested	to	represent	another	mechanism	for	induction	of	self-tolerance	under	physiological	conditions.	However,	in	inflammatory	environments	with	abundant	IL-6	and	TGF-β,	 such	potentially	dangerous	T	cells	may	 instead	differentiate	along	 the	Th17	lineage	and	possibly	induce	autoimmunity	when	activated	by	self-antigen	[71,	72].	
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iTregs	are	mainly	found	in	mucosal	tissue	where	they	control	immunity	to	food-antigens	or	components	of	the	intestinal	microbiota	[73].	
2. Systemic	Lupus	Erythematous	
a) SLE	in	man	
Systemic	 lupus	 erythematous	 (SLE)	 is	 the	 prototypical	 autoimmune	 disease	characterized	 by	 loss	 of	 B	 cell	 tolerance	 leading	 to	 production	 of	 pathogenic	autoantibodies	and	their	formation	of	immune	complexes	with	self-antigens.	Human	SLE	presents	as	a	variable	systemic	disease	of	unpredictable	course	characterized	by	phases	of	 flares	and	remissions	 [74].	Almost	all	organ	systems	can	be	affected	and	symptoms	manifest	 in	 a	 diverse	 array	 of	 mucocutaneous,	 musculoskeletal,	 pleuropulmonary,	cardiovascular	 and	 hematologic	 alterations	 partially	 overlapping	 with	 other	autoimmune	diseases.	Most	prominent	 is	 the	development	of	 lupus	nephritis	 resulting	from	deposition	of	circulating	immune	complexes	in	the	kidneys	causing	high	mortality	in	 patients	 suffering	 from	 SLE.	 The	 susceptibility	 of	 individuals	 to	 develop	 SLE	 is	significantly	 influenced	by	genetic	predisposition	and	environmental	 factors.	For	SLE	a	gender	bias	can	be	observed	with	women	being	affected	ten	times	more	often	than	men.	The	concordance	rate	for	SLE	in	monozygotic	twins	is	between	20	-	40%	in	contrast	to	2	-	 5%	 for	 dizygotic	 twins	 and	 other	 siblings,	 arguing	 for	 a	 strong	 genetic	 influence	 on	diseases	susceptibility.	Certain	MHC-II	alleles,	e.g.	HLA-DR2	and	HLA-DR3,	were	shown	to	be	associated	with	SLE	and	confer	increased	risk	to	develop	the	disease	[75].	Genome	wide	 association	 studies	 (GWAS)	 performed	 on	 SLE	 cohorts	 identified	 several	 single	nucleotide	 polymorphisms	 (SNP)	 in	 genes	 of	 important	 biological	 pathways	 that	 are	dysregulated	 in	SLE	patients	 [76].	To	date	more	than	20	 loci	have	been	 identified	that	
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are	strongly	associated	with	the	development	of	SLE.	Typical	susceptibility	genes	found	in	 these	 loci	 are	 involved	 in	 immune	 complex	 processing	 and	 activation	 of	 the	complement	 cascade	 (FCGR2	 or	 C1Q),	 lymphocyte	 signaling	 and	 signal	 transduction	(HLA-DR,	BTK,	PTPN22)	or	other	toll-like	receptor	(TLR)-	or	interferon	(IFN)-mediated	innate	 immune	 pathways	 (IRAK1,	 IRF5,	 TREX1).	 The	 synergistic	 effect	 of	 multiple	susceptibility	 genes	 in	 combination	 with	 environmental	 factors	 like	 UV-irradiation,	drugs	 or	 viral	 infection	 can	 lead	 to	 a	 break	 of	 tolerance	 and	 subsequently	 to	autoantibody	 production	 through	 the	 activation	 of	 autoreactive	 lymphocytes.	 Once	tolerance	is	broken	and	autoantibodies	are	produced,	especially	to	nucleic	acids,	T	cell	independent	 but	 TLR-mediated	 mechanisms	 sustain	 and	 amplify	 the	 inflammatory	response	 by	 stimulating	 type-I	 IFN	 production.	 Defective	 clearance	 of	 apoptotic	 cell	material	promotes	the	development	of	SLE	as	demonstrated	by	the	rare	C1q	deficiency.	This	defect	is	the	only	known	monogenetic	alteration	leading	to	SLE	in	more	then	90%	of	 the	patients	 carrying	a	C1q	null	mutation	 [77].	Effector	 cells	 (e.g.	macrophages	and	neutrophils)	recruited	to	the	site	of	immune	complex	deposition	meditate	tissue	damage	through	 the	 release	 of	 reactive	 oxygen	 intermediates	 or	 inflammatory	 cytokines,	including	 TNF-α	 and	 IFN-α.	 Dysregulated	 peripheral	 tolerance	mechanisms	 represent	another	important	aspect	in	the	pathogenesis	of	 lupus.	In	many	SLE	patients	there	is	a	quantitative	 or	 qualitative	 defect	 in	 regulatory	 T	 cells	 resulting	 from	 disturbed,	 IL-2	dependent,	 homeostatic	 proliferation	 leading	 to	 an	 imbalanced	 ratio	 of	 effector	 and	regulatory	T	cells	[78,	79].	
Contributions	from	mouse	models	of	lupus	as	well	as	deeper	insights	into	genetic	factors	obtained	from	GWAS	advanced	the	understanding	of	cellular	and	molecular	mechanism	of	 this	 autoimmune	 disease	 and	 led	 to	 an	 improved	 treatment	 of	 SLE.	 However,	
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additional	specific	therapies	are	still	needed	since	lupus	is	a	very	heterogeneous	disease.	Traditional	 approaches	 for	 SLE	 therapy	 include	 general	 anti-inflammatory	 and	immunosuppressive	 drugs	 like	 corticosteroids,	 cyclophosphamide	 and	 azathioprine.	 B	cells	 are	 central	 to	 the	 pathogenesis	 of	 SLE,	 not	 only	 because	 of	 their	 production	 of	autoantibodies,	but	also	because	B	cells	 contribute	 to	 the	activation	of	T	cells	 through	autoantigen	presentation	and	co-stimulatory	signaling,	making	them	a	good	therapeutic	target	 [80].	Rituximab,	 a	 chimeric	mouse/human	monoclonal	 antibody	 targeting	CD20	on	B	cells,	was	shown	to	efficiently	deplete	B	cells	at	all	maturational	stages	and	reduce	disease	symptoms	in	mice.	However,	 in	placebo-controlled	phase	II/III	clinical	trials	 in	SLE,	rituximab	failed	to	meet	the	primary	and	secondary	endpoints.	A	reason	might	be	that	rituximab	does	not	deplete	plasma	cells,	the	primary	source	of	antibody	production	[81].	
Interfering	 with	 BAFF	 signaling	 is	 another	 promising	 therapeutic	 approach	 in	 SLE.	 B	cells	 critically	 depend	on	BAFF	 as	 a	 survival	 factor	 from	 the	 immature	 stage	until	 the	plasma	cell	stage.	Increased	BAFF	levels,	as	found	in	SLE	patients,	promote	the	survival	of	autoreactive	B	cells	and	lead	to	macrophage	activation.	Treatment	with	belimumab,	a	fully	human	monoclonal	 antibody	against	BAFF,	decreased	 total	numbers	of	B	 cells	 as	well	as	serum	Ig	levels	and	anti-DNA	specific	IgG	titers	in	two	phase	III	studies	leading	to	decreased	 SLE	 activity	 according	 to	 criteria	 of	 the	 SLE	disease	 activity	 index	 [82,	 83].	Belimumab	 binds	 the	 soluble	 form	 of	 BAFF	 (also	 called	 BLyS	 for	 B-lymphocyte	stimulator)	and	inhibits	signaling	through	BAFF-R	and	TACI.	
Several	other	 therapies	 targeting	co-stimulatory	pathways	 that	mediate	activation	and	differentiation	in	B	cells	and	T	cells	are	under	development.	In	murine	lupus	models,	the	inhibition	of	T/B	cell	interaction	by	neutralizing	anti-CD40L	antibody	showed	a	positive	
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effect	 through	 diminished	 germinal	 center	 reactions.	 In	 clinical	 trials	 however,	 anti-CD40L	treatment	was	associated	with	increased	thrombotic	events	[84,	85].	Abatacept,	a	fusion	protein	of	the	extracellular	domain	of	CTLA-4	and	IgG1	constant	region,	binds	to	B7	on	APCs	and	inhibits	co-stimulatory	interaction	with	CD28	expressing	T	cells.	Clinical	trials	with	abatacept	in	rheumatoid	arthritis	or	psoriasis	demonstrated	safety	for	human	use	and	also	in	murine	SLE	models	the	treatment	showed	a	positive	effect	on	the	disease	[86].	 Recently,	 a	 small	 retrospective	 study	 including	 11	 SLE	 patients	 with	 refractory	disease	 indicated	 a	 beneficial	 clinical	 effect	 of	 abatacept	 although	 primary	 endpoints	were	 not	 met	 [87].	 The	 induced	 co-stimulator	 (ICOS)	 pathway	 represents	 another	promising	target	for	therapeutic	intervention	due	to	its	central	role	in	T	cell	dependent	differentiation	of	B	cells	into	memory	and	antibody	secreting	plasma	cells.	Notably,	CD4+	and	CD8+	T	cells	of	SLE	patients	were	shown	to	express	elevated	levels	of	ICOS	on	their	surface.	
b) Animal	models	of	SLE	
The	 use	 of	 mouse	 models	 has	 always	 been	 an	 important	 and	 indispensible	 pillar	 of	preclinical	 research	 in	 order	 to	 advance	 the	 understanding	 of	 etiology	 and	 disease	promoting	 mechanisms	 of	 autoimmune	 diseases	 and,	 of	 course,	 for	 the	 evaluation	 of	potential	 therapeutic	 treatments.	 Systemic	 autoimmune	 diseases	 in	 humans	 can	manifest	by	diverse	 symptoms	with	varying	 severity	 from	patient	 to	patient.	By	using	only	 one	 mouse	 model	 it	 is	 impossible	 to	 recapitulate	 the	 diversity	 of	 human	autoimmune	symptoms.	The	main	 reason	might	be	 the	genetic	diversity	of	 the	human	population	 in	 contrast	 to	 inbred	 laboratory	 mouse	 strains.	 Nevertheless,	 each	mouse	model	has	proven	its	value	by	unraveling	the	contribution	of	specific	alterations	in	genes	or	 pathways	 leading	 to	 the	 induction	 or	 promotion	 of	 autoimmunity.	 For	 SLE,	 the	
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prototypic	 systemic	 autoimmune	disease,	many	mouse	models	 exist	 and	each	of	 them	shares	a	subset	of	lupus-like	symptoms	with	the	human	disease	[88].	The	typical	lupus-like	 symptoms	 include	 autoantibody	 production,	 lymphoid	 hyperactivity	 and	glomerulonephritis.	
i) (NZWxNZB)F1	The	 classical	 and	 oldest	 SLE	mouse	model	 is	 the	 F1	 hybrid	 of	 the	New	Zealand	Black	(NZB)	 and	 New	 Zealand	White	 (NZW)	 strain	 (NZB/W	 F1),	 belonging	 to	 the	 group	 of	spontaneous	mouse	models	 of	 SLE	 [89].	 The	 parental	 stains	 of	 NZB/W	 F1	 show	 only	limited	 autoimmunity	 which	 is	 severely	 enhanced	 in	 the	 F1	 generation	 leading	 to	lymphadenopathy,	 splenomegaly	 and	 elevated	 serum	 antinuclear	 antibodies	 including	anti-DNA	 IgG	 (mainly	 IgG2	 and	 IgG3).	 Deposition	 of	 immune	 complexes	 and	 the	resulting	failure	in	kidney	function	leads	to	death	within	10	-	12	months.	Although	this	model	 represents	 a	 broad	 spectrum	 of	 SLE	 symptoms,	 autoantibodies	 against	 RNA	containing	complexes	that	are	typically	found	in	human	lupus	are	absent	in	NZB/W	F1	mice.	 On	 the	 other	 hand,	 female	 NZB/W	 F1	 develop	 a	 more	 severe	 SLE-like	 disease	compared	 to	male.	This	 female	bias	 in	 severity	 is	 also	observed	 for	human	 lupus.	 SLE	susceptibility	loci	identified	in	the	NZM2410	strain,	a	strain	derived	from	backcrossing	NZB/W	 F1	 to	 NZW,	 were	 shown	 to	 induce	 SLE-like	 disease	 on	 non-autoimmune	 B6	background	but	only	if	all	three	loci	(Sle1-3)	are	present	[90].	Two	important	receptors	involved	in	B	cell	signaling	and	activation	(FcγR2β	and	CR2)	are	encoded	within	the	Sle1	locus.	 Additionally,	members	 of	 the	 signaling	 lymphocyte	 activation	molecule	 (SLAM)	family	 are	 also	 found	within	 this	 locus.	More	 recently,	 Sle1	 has	 been	 associated	with	decreased	 IL-2	production	 leading	 to	 impaired	Treg	 functionality	 in	 lupus	prone	mice	[91]	and	also	other	polymorphism	in	genes	mapped	to	the	SLE	susceptibility	 loci	 from	
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NZM2410	were	 also	 shown	 to	 correlate	with	 increase	 susceptibility	 for	 lupus	 in	man	[92].	
ii) MRL/lpr	The	MRL/lpr	strain	is	another	commonly	used	mouse	model	for	SLE-like	autoimmunity	and	also	belongs	to	the	group	of	spontaneous	SLE	models.	In	these	mice	a	spontaneous	mutation	occurred	on	chromosome	19	in	the	gene	encoding	the	Fas	receptor	that	results	in	non-functional	 transcripts	due	 to	 alternative	 splicing	of	 the	Fas	 gene	 [93].	MRL/lpr	mice	 develop	 fatal	 autoimmune	 syndrome	 similar	 to	 SLE	 with	 symptoms	 including	lymphadenopathy	 due	 to	 accumulation	 of	 double-negative	 T	 cells,	 circulating	autoantibodies	 against	 several	 self-antigens	 (ss/dsDNA,	 Smith-protein,	 rheumatoid	factor)	 along	with	 immune	 complex	 deposition	 and	 glomerulonephritis	 [94].	MRL/lpr	mice	do	not	show	gender	bias	in	regard	to	disease	severity	as	observed	in	the	NZB/W	F1	model.	A	similar	phenotype	results	from	a	single	amino	acid	mutation	(Leu!Phe)	in	the	gene	 encoding	 FasL	 on	 chromosome	 1.	 The	 gld	 (generalized	 lymphoproliferative	disorder)	mutation	 prevents	 interaction	 of	 FasL	with	 the	 FAS	 receptor	 and	 results	 in	defective	Fas-mediated	apoptosis	and	systemic	autoimmunity	[95].	In	humans,	defective	Fas	signaling	causes	the	autoimmune	lymphoproliferative	syndrome	(ALPS)	[96].	
iii) BXSB/Yaa	The	 BXSB/Yaa	 strain	 is	 characterized	 by	 high	 penetrance	 of	 SLE-like	 symptoms	 but,	interestingly,	 with	 greater	 severity	 in	 males.	 Male	 BXSB/Yaa	 mice	 have	 a	 lifespan	 of	roughly	 5	 months	 in	 contrast	 to	 females	 with	 about	 14	 months	 [97].	 The	 lupus-like	phenotype	of	BXSB/Yaa	mice	is	caused	by	a	translocation	of	the	telomeric	end	of	the	X	chromosome	 to	 the	 Y	 chromosome,	 the	 so-called	 Y-linked	 autoimmune	 accelerator	(Yaa).	Yaa	leads	to	the	duplication	of	several	genes,	among	others	the	gene	encoding	for	
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TLR	7,	a	pattern	recognition	receptor	for	nucleic	acids	that	can	provide	signal	2	for	the	activation	of	autoreactive	B	cells	[98].	B6	mice	with	the	Yaa	translocation	do	not	develop	overt	autoimmunity	due	to	functional	compensatory	mechanisms	on	the	B6	background.	But	in	addition	with	the	SLE	susceptibility	locus	Sle1,	B6/Yaa/Sle1	mice	develop	severe	SLE-like	autoimmunity.	Another	susceptibility	 locus	identified	in	BXSB	mice	is	Bsx2	on	chromosome	1	that	overlaps	with	Sle1	and	seems	to	be	a	major	contributor	to	disease	development	by	encoding	genes	 important	 in	clearance	of	apoptotic	cell	material	 [99].	The	genetic	background	has	considerable	influence	on	disease	development,	which	can	be	nicely	demonstrated	in	the	BXSB/Yaa	model.	BXSB/Yaa	mice	on	a	H-2d/d	background	show	 less	 severe	 disease	 symptoms	 compared	 to	 congenic	mice	 on	 a	H-2b/d	 or	H-2b/b	BSXB	background	which	display	full-blown	disease.	In	contrast,	mice	carrying	Yaa	on	a	B6	background	 (also	H-2b/b)	 do	not	 show	 signs	 of	 autoimmunity	 indicating	 that	 other	non-MHC-linked	loci	from	the	BXSB	background	have	a	great	influence	on	the	induction	and	the	severity	of	the	disease	[100,	101].	
c) Murine	 chronic	 Graft-versus-Host	 Disease	 as	model	 for	
SLE	
The	 induction	 of	 chronic	 Graft-versus-Host	 Disease	 (cGvHD)	 is	 a	well-established	 and	widely	 used	 model	 for	 murine	 lupus.	 The	 cGvHD	 model	 is	 based	 on	 MHC-disparate	donor	 lymphocytes	 that,	 upon	 intravenous	 (i.v.)	 injection	 into	 otherwise	 non-autoimmune	 recipient	 strains,	 break	 host	 tolerance	 to	 autoantigens	 by	 stimulation	 of	autoreactive	B	cells.	For	this,	alloreactive	donor	CD4+	T	cells	are	required	and	sufficient	[102,	103].	The	MHC-disparity	between	donor	and	host	strains	has	to	be	combined	in	a	way	 that	 donor	 lymphocytes	 are	 activated	 upon	 recognition	 of	 foreign	 host	 MHC	structures	 but	 the	 immune	 system	 of	 the	 recipient	 is	 tolerant	 to	 the	 donor	 allograft	
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allowing	 for	 persistent	 donor	 T	 cell	 engraftment	 and	 stimulation.	 There	 are	 various	combinations	of	strains	where	a	single	injection	of	donor	lymphocytes	induces	a	robust	SLE-like	cGvHD.	One	combination	is	the	transfer	of	either	parental	CD4+	T	cells	into	the	semi-allogeneic	F1	generation	(p!F1)	leading	to	lupus-like	symptoms	in	mice.	An	acute	course	 of	 GvHD	 can	 be	 observed	 in	 the	 p!F1	model	 when	 CD8+	 T	 cells	 are	 present	within	 the	 donor	 inoculum	 and	 cells	 are	 transferred	 between	 strains	mismatched	 for	MHC-I	 and	 MHC-II	 proteins	 [104].	 The	 developing	 acute	 Graft-versus-Host	 Disease	(aGvHD)	 is	 characterized	 by	 an	 initial	 stimulatory	 phase	 followed	 by	 CD8+	 T	 cell	mediated	 elimination	 of	 the	 host	 immune	 system	within	 a	 few	weeks	 after	 induction.	This	 process	 is	 accompanied	 by	 severe	 weight	 loss.	 An	 exception	 to	 the	 above-mentioned	requirements	of	the	p!	F1	model	for	the	induction	of	cGvHD	is	the	injection	of	 parental	 lymphocytes	 from	 the	 DBA/2	 strain	 into	 BDF1	 mice	 [105].	 Despite	 the	presence	 of	 both	 CD4+	 and	 CD8+	 T	 cells	 in	 the	 donor	 inoculum	 and	 the	 transfer	 into	MHC-I	and	MHC-II	mismatched	recipients,	chronic	GvHD	ensues.	This	model	was	shown	to	be	valuable	for	the	screening	of	agents	capable	to	promote	CD8+	T	cells	responses	and	thereby	“reverting”	the	chronic	course	of	the	disease	into	an	rather	acute	one	[106].	 It	was	 shown	 that	 IL-21	 is	 an	 interesting	 candidate	 for	 the	 modulation	 of	 CD8+	 T	 cell	activity	 in	 cGvHD	 settings.	 Administration	 of	 IL-21	 to	 BDF1	 mice	 undergoing	 cGvHD	upon	 injection	 of	 DBA/2	 lymphocytes	 resulted	 in	 reduced	 SLE-like	 symptoms	 due	 to	enhanced	 CTL	 differentiation	 and	 a	 reduction	 of	 autoreactive	 B	 cells	 [107].	 Similar	results	were	obtained	from	aGvHD	studies	where	IL-21R-/-	donor	lymphocytes	from	B6	IL-21R	deficient	mice	were	 injected	 into	BDF1	mice.	Such	mice	develop	milder	cGvHD	due	to	the	absence	of	IL-21R	signaling.	Donor	CD8+	T	cells	do	not	efficiently	differentiate	into	CTLs	and	additionally,	 the	stimulation	of	host	B	cells	by	donor	CD4+	T	cells	 is	 less	efficient	since	these	interaction	depend	on	IL-21	signaling	as	well	[108].	
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Induced	 models	 have	 the	 advantage	 over	 spontaneous	 models	 that	 disease	 initiating	/tolerance	breaking	events	 leading	 to	SLE-like	symptoms	can	be	better	controlled	and	manipulated.	Autoantibody	production	is	detected	in	cGvHD	models	as	early	as	10	-	14	days	after	disease	 induction	whereas	 in	spontaneous	models	 it	 takes	several	weeks	 to	months	after	birth	to	develop	such	symptoms.	Furthermore,	as	already	described	above,	tolerance	breaking	mechanisms	leading	to	disease	development	in	spontaneous	models	are	 the	result	of	multiple	genetic	 factors.	For	 induced	cGvHD	models	 the	antigens	 that	initially	 lead	to	beaking	tolerance	are	encoded	by	MHC	peptides.	Another	advantage	of	induced	 models	 is	 the	 disease-driving	 alloreactive	 donor	 T	 cell	 population,	 which	 is	relatively	 easy	 to	 observe	 because	 of	 polyclonal	 activation	 and	 expansion;	 this	 is	 in	contrast	 to	 the	 rather	 rare	 events	 of	 T	 cell	 tolerance	 breakdown,	 which	 occur	 in	spontaneous	models.	 Since	many	knock-out	mice	 are	 available	 on	 the	B6	background,	the	transfer	of	CD8+	T	cell	depleted	B6	lymphocytes	represents	an	interesting	and	useful	model	 system	 to	 investigate	 the	 influence	 of	 several	 genetic	 alterations	 on	 disease	development.		
3. Interleukin-2	
a) IL-2	signaling	and	function	
Interleukin-2	(IL-2),	a	15	kDa	four-alpha-helical	bundle	cytokine	belonging	to	the	type-I	family	of	cytokines	was	one	of	the	first	cytokines	discovered	[109].	While	activated	CD4	T	cells	are	the	main	source	of	IL-2,	CD8+	T	cells,	NK	cells	and	DCs	also	secrete	IL-2,	but	to	a	 lesser	 extent.	 TCR	 signaling	 in	 the	 presence	 of	 co-stimulation	 leads	 to	 rapid	 (within	hours)	 and	 transient	 (for	 approximately	 2	 days)	 production	 of	 IL-2.	 Transcriptional	activation	of	the	IL-2	gene	is	regulated	by	cooperative	binding	of	AP-1,	NFκB	(p65/rel),	
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Oct-1	and	NFAT	transcription	factors	to	the	promoter/enhancer	regions	approximately	500bp	 upstream	 of	 the	 transcriptional	 start	 site	 of	 the	 IL-2	 gene.	 Transcriptional	silencing	of	 the	IL-2	gene	 is	accomplished	by	a	negative	auto-regulatory	 feedback	 loop	which	depends	on	IL-2	signaling-induced	Blimp-1	expression	[110].	The	important	role	of	 Blimp-1	 in	 the	 regulation	 of	 IL-2	 expression	 has	 been	 demonstrated	 by	 ectopic	expression	of	Blimp-1	in	activated	T	cells	leading	to	inhibition	of	IL-2	production	and	in	Blimp-1	deficient	T	cells	where	the	lack	of	negative	regulation	results	in	augmented	IL-2	production	[111,	112].	Moreover,	central	memory	T	cells	express	low	levels	of	Blimp-1	indicating	 a	 role	 for	 IL-2-induced	Blimp-1	 expression	 in	 the	 control	 of	memory	T	 cell	differentiation.	Additionally,	 low	Blim-1	expression	 in	memory	T	cells	allows	 for	rapid	and	 augmented	 IL-2	 expression	 upon	 stimulation	 [113].	 Prolonged	 TCR	 stimulation	together	with	IL-2	signaling	induces	the	expression	of	Fas	and	FasL	on	T	cells,	mediating	activation	induced	cell	death	in	these	cells	[114].	
Based	on	early	in	vitro	studies,	the	biological	importance	of	IL-2	was	first	described	as	a	T	cell	proliferation	factor	essential	for	appropriate	expansion	of	T	cell	populations	upon	activation.	However,	with	the	availability	of	the	first	knockout	mice	where	IL-2	signaling	was	 interrupted	 (IL-2-/-	 or	 IL-2R-/-)	 it	 was	 shown	 that	 IL-2	 signaling	 is	 crucial	 for	maintenance	of	self-tolerance	since	these	knockout	mice	developed	severe	autoimmune	symptoms	 instead	 of	 an	 expected	 immunodeficiency	 as	 predicted	 from	 the	 original	 in	
vitro	 observations	 [115,	 116].	 The	 resulting	 autoimmunity	 is	 primarily	 caused	 by	impaired	 Treg	 homeostasis	 and	 the	 associated	 defect	 in	 regulatory	 function,	 which	critically	depends	on	IL-2	[59].	
Responsiveness	 to	 IL-2	 requires	 the	expression	of	 either	 the	dimeric,	 low-affinity	 IL-2	receptor	 (IL-2Rβγc)	 or	 the	 trimeric,	 high-affinity	 IL-2	 receptor	 (IL-2Rαβγc)	 [117].	 The	
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low-affinity	IL-2	receptor	is	composed	of	the	common	γ-chain	(γc;	CD132),	which	is	also	found	in	receptors	for	other	members	of	the	type-I	cytokine	family	(e.g.	IL-4,	IL-7,	IL-9,	IL-15,	 IL-21)	 and	 the	 IL-2	 receptor	 β-chain	 (IL-2Rβ;	 also	 known	 as	 CD122),	 which	 is	shared	 only	 with	 the	 IL-15	 receptor.	 In	 order	 to	 form	 the	 high-affinity	 IL-2	 receptor,	expression	 of	 IL-2	 receptor	 α-chain	 (IL-2Rα;	 also	 known	 as	 CD25)	 is	 required.	Association	 of	 the	 α-chain	 protein	 (CD25)	 to	 the	 dimeric,	 low-affinity	 IL-2	 receptor	increases	the	overall	affinity	of	the	receptor	for	IL-2	up	to	100-fold	with	a	dissociation	constant	of	Kd	10-11.	CD25	only	functions	to	establish	high-affinity	binding	to	IL-2,	since	it	 lacks	 a	 cytoplasmic	 tail	 it	 is	 not	 involved	 in	 downstream	 signal	 transduction.	 The	binding	of	IL-2	to	the	trimeric	IL-2	receptor	is	suggested	to	occur	in	a	step-wise	manner	with	 IL-2	 first	binding	 to	CD25	and	subsequent	 recruitment	of	 the	 two	other	 receptor	components	to	the	complex	[118].	Transduction	of	IL-2	signals	critically	depends	on	the	β-chain	and	the	common	γ-chain	subunit	of	the	IL-2	receptor	which	are	associated	with	JAK	 (1/3)	 proteins.	 Knockout	 mice	 deficient	 for	 either	 of	 these	 two	 IL-2	 receptor	subunits	 show	 severe	 immune-regulatory	 defects.	 Autoimmune	 symptoms	 have	 been	observed	 in	 IL-2R	β-chain	deficient	mice,	while	a	 severe	combined	 immune	deficiency	(SCID)	phenotype	is	present	in	IL-2R	γ-chain	knockout	animals.	[116,	119].	Engagement	of	the	IL-2	receptor	activates	several	downstream	signaling	pathways	including	STAT5	signaling,	 the	 PI3K-Akt-mTOR	 pathway	 and	 also	 the	 Ras-Raf-Mek-Erk	 axis	 (MAPK	pathway);	 this	 promotes	 cell	 growth	 and	 survival	 as	 well	 as	 the	 expression	 of	 target	genes	 like	 CD25	 [120].	 Upon	 binding	 of	 IL-2	 to	 its	 receptor	 and	 initiation	 of	 signal	transduction,	 the	 quaternary	 IL-2/IL-2R	 complex	 is	 rapidly	 internalized	 followed	 by	degradation	of	IL-2,	CD122	and	CD132	whereas	CD25	can	be	recycled	to	the	cell	surface	[121].	 IL-2	 can	 also	 be	 presented	 in	 trans	 by	 CD25	 expressing	 DCs,	 however,	 the	biological	importance	of	this	mechanism	is	still	not	fully	understood.	
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The	 expression	 of	 high-	 and	 low-affinity	 IL-2	 receptors	 and	 the	 respective	 subunits	varies	 significantly	 across	 different	 cells	 of	 the	 immune	 system.	 Naïve	 CD4+	 T	 cell	express	hardly	any	dimeric	IL-2	receptor	whereas	naïve	CD8+	T	cells	or	memory	CD4+	T	cells	 express	 significantly	 but	 low	 amounts	 of	 dimeric	 IL-2	 receptor.	Memory	 CD8+	 T	cells	 typically	 express	high	 levels	 of	 dimeric	 IL-2	 receptor	making	 them	responsive	 to	exogenously	administrated	IL-2,	but	their	sensitivity	to	endogenous	IL-2	concentrations	is	relatively	low	[122].	Upon	activation,	T	cells	start	to	express	transiently	high	levels	of	CD25	and	CD122	rendering	 them	highly	 sensitive	 to	 IL-2.	Tregs	 constitutively	express	high	levels	of	CD25	and	are	critically	dependent	on	IL-2	produced	by	other	T	cells.	
IL-2	 signaling	 and	 the	 ensuing	 activation	 of	 STAT5	 is	 also	 an	 important	 factor	 during	differentiation	of	CD4+	helper	T	cell	subsets	[123].	IL-2	signaling	in	Th1	cells	induces	the	upregulation	of	IL-12Rβ2	on	the	cell	surface	along	with	increased	intracellular	levels	of	the	 transcription	 factor	 T-bet,	 resulting	 in	 increased	 IFN-γ	 production.	 In	 Th2	 cells,	enhanced	expression	of	IL-4Rα	and	enhanced	production	of	the	subset	specific	cytokines	IL-4,	 IL-5	 and	 IL-13	 is	 observed	 in	 response	 to	 IL-2.	 In	 regulatory	 T	 cells,	 which	 are	unable	 to	 produce	 IL-2	 by	 themselves	 and	 therefore	 depend	 on	 IL-2	 from	 other	 cell	sources,	STAT5	signaling	maintains	expression	of	intracellular	FoxP3	and	high	levels	of	CD25	 on	 the	 surface	 [124].	 In	 contrast,	 differentiation	 along	 the	 Th17	 lineage	 is	negatively	 regulated	 by	 IL-2	 signaling.	 IL-2	 induced	 STAT5	 activation	 leads	 to	downregulation	 of	 IL-6Rβ	 expression	 and	 subsequent	 decreased	 STAT3	 signaling	 and	RoRγt	expression.	Additionally,	STAT5	competes	with	STAT3	 for	binding	at	regulatory	regions	 in	 the	 IL-17	 gene	 locus	 [123].	 Follicular	 helper	 T	 (Tfh)	 cells	 are	 suggested	 to	differentiate	 mainly	 from	 naïve	 CD4+	 T	 cells	 expressing	 low	 levels	 of	 CD25.	 Upon	antigen-specific	activation	by	DCs	in	secondary	lymphatic	organs,	IL-2	signaling	induces	
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expression	of	B	cell	lymphoma	6	protein	(Bcl-6)	and	CXC	chemokine	receptor	5	(CXCR5)	mediating	the	differentiation	into	Tfh	cells	and	localization	to	the	B	cell	follicle	[125].	
Beside	IL-2’s	primary	role	in	maintaining	the	Treg	subset	and	“dominant	tolerance”,	it	is	also	 critical	 for	 the	 generation	 of	 optimal	 CD8+	 T	 cell	 responses	 to	 infections.	 IL-2	directly	affects	several	aspects	of	the	immune	response	including	the	primary	expansion	of	antigen-specific	T	cells,	the	contraction	phase	after	the	clearance	of	the	pathogen	and	the	 generation	 of	 T	 cell	 memory.	 IL-2-/-	mice	 show	 a	 3-fold	 reduction	 in	 CD8+	 T	 cell	expansion	 after	 acute	 viral	 infection	 and	 impaired	 viral	 clearance	 compared	 to	 IL-2	sufficient	mice	[126].	Studies	with	bone	marrow	chimeric	mice	containing	a	mixture	of	CD25-/-	and	normal	CD8+	T	cells	demonstrate	the	importance	of	IL-2	signaling	during	the	primary	immune	response	beyond	optimal	expansion	of	effector	populations.	Chimeric	mice	 showed,	 similar	 to	 the	 results	 obtained	 from	 IL-2-/-	 mice,	 a	 reduction	 in	 initial	expansion	of	the	CD8+	T	cells	in	the	CD25-/-	population	and	upon	secondary	challenge	an	even	more	compromised	memory	response	[127].	Notably,	IL-2	signaling	in	the	absence	of	 CD25	 during	 primary	 expansion	 results	 in	 impaired	 memory	 generation.	 These	results	 indicate	 that	 IL-2	 is	 a	 critical	 factor	 for	 the	 expansion	 of	 effector	 CD8+	 T	 cell	populations	and	equally	important	for	generation	T	cell	memory.	
The	strength	of	IL-2	signaling	that	CD4+	and	CD8+	antigen-specific	T	cells	receive	during	priming	 is	suggested	 to	directly	affect	 the	memory/effector	 fate	decision.	High	surface	expression	 of	 CD25	 and	 the	 resultant	 enhanced	 IL-2	 signaling	 induces	 T	 cells	 to	differentiate	 into	short-lived	effector	T	cells	expressing	higher	levels	of	Blimp-1.	These	terminal	effecter	cells	do	not	survive	the	contraction	phase	after	the	infection	has	been	cleared.	 On	 the	 other	 hand,	 CD25lo	 T	 cells	 were	 shown	 to	 differentiate	 into	 central	
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memory	 phenotype	 T	 cells	with	 increased	 survival	 and	 expression	 of	 typical	memory	markers	like	IL-7Rα,	CD62L	or	CCR7	[128].	
b) IL-2	therapy	and	IL-2	complexes	
The	use	of	IL-2	as	a	therapeutic	agent	especially	for	autoimmune	diseases	has	not	been	successful	due	to	complications	linked	to	the	pleiotropic	effects	of	IL-2	on	the	immune	system.	Initially	discovered	and	described	as	a	growth	factor	for	activated	T	cells	in	vitro	(T	 cell	 growth	 factor,	 TCGF),	 IL-2	 was	 soon	 used	 in	 clinics	 to	 treat	 carcinoma	 and	melanoma	patients.	However,	 it	was	 soon	noticed	 that	high	doses	of	 IL-2,	which	were	necessary	 to	 archive	 a	 clinical	 response,	 are	 toxic	 and	 induce	 severe	 side	 effects,	including	 pulmonary	 edema	 and	 general	 vascular	 leakage	 syndrome	 due	 to	responsiveness	of	CD25	expressing	endothelial	cells	[129,	130].	Another	reason	for	the	inefficiency	of	IL-2	therapies	at	that	time	(resulting	in	low	response	rate	in	many	clinical	trails)	was	probably	due	to	the	effect	of	IL-2	on	Tregs,	which	might	have	suppressed	the	desired	anti-tumor	activity.	
That	IL-2	had	a	potential	therapeutic	benefit	in	autoimmune	settings	was	shown	in	the	1990s	by	 in	vivo	studies	in	MRL/lpr	mice	infected	with	an	IL-2	producing	recombinant	vaccinia	 virus.	 However,	 IL-2	 was	 only	 approved	 for	 immunotherapy	 of	 several	carcinoma	 and	metastatic	melanoma	 by	 the	US	 Food	 and	Drug	Administration	 (FDA).	Despite	 the	 long	established	positive	effect	on	autoimmunity,	 the	 first	 clinical	 trials	 in	order	 to	 investigate	 the	 potential	 of	 IL-2-mediated	 Treg	 stimulation	 in	 autoimmune	settings	were	not	conducted	before	2010	[131].	
The	pitfall	of	IL-2	in	immunotherapy,	besides	its	toxicity	at	clinically	relevant	doses	and	the	short	half-life	time	in	circulation,	is	also	the	variable	responsiveness	of	immune	cells	
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to	 IL-2,	 especially	 T	 cells,	 due	 to	 the	 heterogeneous	 expression	 of	 IL-2	 receptor	components	(CD25,	CD122	and	CD132).	For	a	specific	therapy,	it	would	be	preferable	to	selectively	stimulate	specific	subsets	of	T	cells	with	appropriate	effector	functions.	This	would	require	a	specific	expansion	of	tumor-specific	CD8+	T	cells	in	the	setting	of	cancer	immunotherapy,	or	regulatory	T	cells	in	case	of	autoimmunity,	inflammation	or	allograft	immunity.	Coupling	of	IL-2	to	monoclonal	antibodies	(mAb)	not	only	prolongs	the	half-life	in	the	circulation	and	thus	biological	availability,	but	it	was	also	shown	to	restrict	the	biological	 activity	 of	 IL-2	 to	 specific	 populations	 of	 IL-2	 receptor-expressing	 cells	depending	on	the	epitope-specificity	of	the	anti-IL-2	mAb	[122,	132,	133].	
The	mAb	S4B6	and	the	IL-2R	α	chain	bind	the	IL-2	molecule	at	the	same	site	(amino	acid	26	 -	 45	 of	murine	 IL-2)	 [134].	 A	 conformational	 change	 in	 the	 IL-2	molecule	 induced	through	S4B6	binding	increases	its’	affinity	for	the	dimeric	IL-2	receptor.	The	binding	of	S4B6	to	IL-2	is	suggested	mimic	the	binding	of	CD25	to	IL-2	since	similar	conformational	changes	in	the	IL-2	molecule	are	observed	upon	interaction	with	CD25	[135].	Thus,	by	preventing	 interaction	between	CD25	and	 IL-2,	 the	 S4B6/IL-2	 complex	 “concentrates”	its	 biological	 activity	 on	 cells	 expressing	 the	 low-affinity	 dimeric	 IL-2	 receptor	 e.g.	CD122hi	 memory	 phenotype	 CD8+	 T	 cells	 or	 NK	 cells.	 Initial	 studies	 showed	 that	S4B6/IL-2	complexes	substantially	increase	the	absolute	number	of	memory	phenotype	CD8+	T	cells	and,	to	a	lesser	extent,	NK	cells	in	spleen	and	lymph	nodes	of	mice	after	one	week	of	daily	injections	[122].	Similar	results	were	obtained	with	mAb	JES6-5/IL-2	and	mAb	602/hIL-2	complexes.	In	a	mouse	model	of	pulmonary	melanoma,	treatment	with	S4B6/IL-2	 complexes	 improved	 the	 antitumor	 response	 without	 IL-2-mediated	pulmonary	edema	at	concentrations	where	normal	IL-2	showed	no	effect	[130].	
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Another	 anti-IL-2	mAb	 that	modulates	 receptor	 interactions	with	 IL-2	 is	 JES6-1.	 JES6-1/IL-2	complexes	restrict	 the	biological	activity	to	cells	expressing	high	 levels	of	CD25	resulting	 in	 a	 selective	 expansion	 of	 regulatory	T	 cells	when	 injected	 into	mice	 [122].	When	 complexed	 with	 JES6-1,	 IL-2	 epitopes	 for	 binding	 of	 CD122	 and	 CD132	 are	blocked,	thus	only	the	interactions	with	CD25	can	take	place.	Binding	of	CD25	to	JES6-1/IL-2	complexes	causes	JES6-1	to	dissociate	from	the	complexes.	This	renders	binding	sites	for	CD122	and	CD132	accessible	again	and	formation	of	high-affinity	IL-2	receptors	can	take	place	[135].	Transcriptional	 feedback	 loops	further	augment	the	selectivity	of	JES6-1/IL-2	complexes	for	cells	expressing	CD25	by	increasing	surface	CD25	expression,	which	is	not	observed	in	response	to	S4B6/IL-2	signaling.	In	vivo	administration	of	JES6-1/IL-2	complexes	to	non-immunized	mice	selectively	expands	Tregs	although	activated	antigen-specific	CD8+	T	cells	respond	to	JES6-1/IL-2	treatment	with	a	more	pronounced	expansion	 compared	 to	 S4B6/IL-2	 treatment	 [136].	The	 therapeutic	potential	 of	 JES6-1/IL-2	 treatment	was	 demonstrated	 in	 several	mouse	models	 of	 autoimmune	 disease	including	colitis	and	experimental	autoimmune	encephalomyelitis	(EAE).	Furthermore,	JES6/IL-2	treatment	induced	tolerance	to	a	pancreatic	islet	allograft	across	a	full	MHC-mismatch	 without	 preconditioning	 with	 immunosuppressive	 regimes;	 suggesting	 that	JES6-1/IL-2	complexes	might	be	useful	in	a	clinical	setting	of	organ	transplantation	[137,	138].	
JES6-1/IL-2	 complexes	 show	 superior	 specificity	 over	 S4B6/IL-2	 complexes	 regarding	the	 expansion	 of	 CD4+	CD25+	 regulatory	 T	 cells	 and	memory	 phenotype	 CD8+	 T	 cells.	JES6-1/IL-2	 complexes	 specifically	 expand	 the	 absolute	 numbers	 of	 Tregs	 whereas	S4B6/IL-2	 complexes	 expand	both	CD8+	T	 cells	 and	Tregs	 to	 a	 similar	 extent	 as	 JES6-1/IL-2	complexes	[122].	Thus,	in	normal	mice,	Tregs	respond	similarly	to	S4B6/IL-2	and	
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JES6-1/IL-2	treatment	with	regard	to	proliferation	and	expansion.	However,	in	spleens	of	 14	 weeks	 old	 MRL/lpr	 mice	 that	 received	 IL-2/mAb	 complexes,	 only	 JES6/IL-2	complexes	mediated	Treg	expansion	[139].	
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Materials	and	Methods	
Mice	(C57BL/6	 x	 DBA/2)F1	 (BDF1),	 DBA/2,	 (C57BL/6-Tg(TcraTcrb)1100Mjb	 x	 DBA/2)F1	(OT1-BDF1),	(C57BL/6-Tg(TcraTcrb)425Cbn	x	DBA/2)F1	(OT2-BDF1)	were	bred	in	our	animal	facility.	All	mice	were	maintained	under	specific	pathogen	fee	conditions	in	our	animal	facility.	For	experiments	and	analysis,	age-	and	sex-matched	mice	between	8	and	12	 weeks	 of	 age	 were	 used.	 Mice	 were	 sacrificed	 by	 CO2	inhalation	 and	 organs	 were	removed	 by	 standard	 procedures.	 Animal	 experiments	 were	 carried	 out	 within	institutional	 guidelines	 (authorization	 number	 1888	 and	 2434)	 from	 Cantonal	Veterinarian	Office,	Basel).	
Preparation	of	donor	cells	and	induction	of	GvHD	For	 the	preparation	of	 donor	 cells,	 spleen	 and	LN	 (cervical,	 axillary,	 brachial,	 inguinal	and	mesenteric)	were	 removed	 from	DBA/2	mice	and	gently	passed	 through	a	40	µm	nylon	mesh	 to	 obtain	 single	 cell	 suspensions	 in	 serum-free	 (SF)	 IMDM	 supplemented	with	 2%	 FCS	 (MP	 Biomedical,	 USA)	 and	 0.5%	 Ciproxin	 (Bayer	 AG,	 CH).	 Spleen	 cell	suspensions	 were	 treated	 with	 ACK	 buffer	 in	 order	 to	 lyse	 erythrocytes.	 Single	 cell	suspensions	were	pooled,	counted	by	Trypan	blue	exclusion	and	washed	in	serum-free	DMEM	 (Sigma-Aldrich,	 USA)	 prior	 to	 injection.	 GvHD	was	 induced	 by	 i.v.	 injection	 of	70x106	DBA/2	lymphocytes	in	a	volume	of	200	µl	SF-IMEM.	
Depletion	of	donor	CD8+	T	cells	In	 order	 to	 obtain	 donor	 cell	 suspensions	 depleted	 of	 CD8+	 T	 cells,	 DBA/2	mice	were	injected	 i.v.	with	200	µl	of	1	mg/ml	YTS-156,	a	 rat	anti-mouse	mAb	specific	 for	CD8β,	four	 days	 before	 donor	 cell	 suspensions	 are	 prepared	 from	 these	mice.	 YTS-156	was	
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purified	 from	 a	 hybridoma	 culture	 supernatant	 according	 to	 standard	 procedures.	Efficiency	 of	 CD8+	 T	 cell	 depletion	 was	 confirmed	 by	 flow	 cytometry	 analysis	 using	fluorescent-labeled	anti-CD8α	specific	mAb	(53-6.7).	
Preparation	of	IL-2	complexes	For	a	single	injection,	2.5	µg	rIL-2	and	7.5	µg	anti-IL-2	mAb	JES6.1A12	(BioXCell,	USA)	or	S4B6	 (purified	 from	 hybridoma	 culture	 supernatants	 by	 standard	 procedures)	 were	mixed	to	prepare	the	IL-2	complexes.	After	30	min	incubation	at	37°C,	the	volume	was	adjusted	to	200	µl	with	sterile	PBS	and	injected	i.p.	into	mice.	In	control	mice	cGvHD	was	left	untreated.	
Detection	of	autologous	IgG	anti-erythrocyte	antibodies	(anti-RBC)	For	the	detection	of	anti-RBC	in	the	blood	of	cGvHD	mice,	Coombs	test	was	performed	as	described	 elsewhere	 [140].	 Briefly,	 100µl	 heparinized	 blood	 was	 first	 diluted	 1:20	 in	PBS	containing	2%	FCS	and	0.1%	of	1	M	NaN3.	25	µl	of	diluted	blood	was	incubated	with	50µl	 of	 1:200	 diluted	 fluorescein	 isothiocyanate	 (FITC)-labeled	 goat	 anti-mouse	 IgG	antibody	 (Jackson	 ImmunoResearch)	 for	30	min	at	4°C.	Cells	were	washed	and	bound	antibody	was	detected	using	 a	 FACSCalibur	 (BD	Bioscience,	USA)	machine.	Mice	were	scored	positive	when	the	median	of	fluorescence	intensity	was	increased	more	than	2-fold	compared	to	healthy	controls.	
Detection	of	anti-nuclear	antibodies	(ANA)	For	detection	of	ANA	 in	 sera	of	 cGvHD	mice,	 8µm	snap-frozen	 sections	obtained	 from	kidneys	of	RAG2-/-	mice	were	used.	 Sections	were	 first	 incubated	with	80µl	 sera	 from	cGvHD	mice	 at	 dilutions	 1:20	 to	 1:5120	 for	 30	min	 at	 room	 temperature	 (RT)	 in	 the	dark.	After	washing,	bound	ANA	was	detected	by	incubation	with	80µl	of	a	1:200	diluted	
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FITC-labeled	goat	anti-mouse	IgG	antibody	for	30	min	at	RT	 in	the	dark.	The	titer	was	determined	by	using	a	fluorescent	microscope	(Zeiss	Axioscope)	and	was	defined	as	the	highest	dilution	that	still	gave	a	specific	nuclear	staining.	Mice	showing	titers	lower	than	1:20	were	considered	as	negative	for	ANA.	
Measurement	of	proteinuria	Proteinuria	 was	 determined	 semi-quantitatively	 in	 weekly	 intervals	 using	 Albustix	(Siemens	 Healthcare	 Diagnostics	 Inc.,	 USA).	 Elevated	 protein	 levels	 in	 the	 urine	 are	indicative	 of	 failure	 in	 kidney	 function	 [141].	 Mice	 were	 scored	 positive	 when	 a	concentration	>3	mg/ml	was	indicated	by	color	change	of	the	Albustix.	
Immunhistological	analysis	Kidneys	 from	 proteinuria	 positive	 mice	 were	 embedded	 in	 OCT-compound	 (Sakura	Finetek,	NL)	and	snap-frozen	on	dry	 ice.	8	µm	sections	were	prepared	on	glass	 slides,	fixed	in	acetone	for	10min	and	dried.	For	the	detection	of	immune	complex	deposition	in	the	glomeruli,	sections	were	incubated	with	FITC-labeled	goat	anti-mouse	IgG	antibody	for	 30	 min	 at	 RT.	 For	 the	 detection	 of	 complement	 deposition,	 kidney	 section	 from	cGvHD	mice	were	incubated	for	30	min	at	RT	in	the	dark	with	FITC-labeled	anti-C3	mAb	(a	kind	gift	of	Dr.	S.	Izui,	University	of	Geneva)	diluted	1:100	in	FACS	Buffer.	Bound	FITC-labeled	mAb	was	detected	using	a	fluorescent	microscope.	
Flow	cytometry	For	 analysis	 by	 flow	 cytometry,	 lymphoid	 organs	 were	 removed	 and	 single	 cell	suspensions	was	prepared	by	 gently	passing	 the	organs	 through	 a	40	µm	nylon	mesh	into	 SF-IMDM	 containing	 2%	 FCS	 and	 0.5%	 Ciproxin.	 In	 order	 to	 lyse	 erythrocytes,	spleen	cell	suspensions	were	treated	with	ACK	buffer	for	approximately	1	min.	Stainings	
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were	performed	in	a	96-well	round	bottom	plate	in	a	total	volume	of	100	µl	containing	50	 µl	 cell	 suspension	 (1-2x107	 cells/ml)	 and	 50	 µl	 diluted	 antibody	 mix.	 Cells	 were	incubated	for	30	min	at	4°C	in	the	dark.	Cells	were	washed	with	FACS	buffer	to	remove	unbound	antibodies.	When	biotinylated	antibodies	were	used,	a	second	staining	step	(20	min,	 4°C,	 in	 the	 dark)	 was	 performed	 for	 the	 binding	 of	 streptavidin-coupled	fluorochromes.	If	applicable,	cells	were	resuspended	in	FACS	buffer	containing	5	μg/ml	propidium	 iodide	 (Sigma-Aldrich,	 USA).	 Intracellular	 stainings	 were	 performed	according	 to	 standard	 procedure.	 In	 brief,	 subsequent	 to	 surface	 stainings,	 cells	were	fixed	 either	 with	 PBS	 containing	 2%	 paraformaldehyde	 or	 with	 fix/perm	 buffer	(eBioscience,	 USA)	 followed	 by	 intracellular	 stainings	 in	 FACS	 buffer	 containing	 0.5%	saponin	 (Sigma-Aldrich,	 USA)	 or	 in	 permeabilisation	 buffer	 (eBioscience,	 USA).	Intracellular	stainings	were	incubated	for	30	min	at	4°C	in	the	dark	followed	by	washing	steps	in	FACS	buffer	to	remove	unbound	antibodies.	Flow	cytometry	was	performed	on	a	FACSCalibur	or	LSRFortessa	machine	(BD	Bioscience,	USA)	and	data	was	analyzed	using	FlowJo	(Tree	Star,	USA)	software.	
PMA/	ionomycin	stimulation	Single	 cell	 suspensions	 were	 stimulated	 during	 4	 hours	 using	 1	 µg/ml	 ionomycin	(Sigma-Aldrich,	USA)	and	5	ng/ml	phorbol-12-myristate-13-acetate	(PMA)	(Calbiochem,	USA)	in	the	presence	of	10µg/ml	brefeldin	A	(Sigma-Aldrich,	USA).	Cells	were	harvested	and	stained	according	to	standard	intracellular	staining	procedure	(see	above).	
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a) Media	and	Reagents	
ACK	buffer	PBS	
0.15M	NH4Cl	
1mM	KHCO3	
0.1mM	EDTA	
0.22µm	sterile	filtered	
SF-IMDM	176.6g	IMDM	powder	(Gibco)	
30.24g	NaHCO3	(Fluka)	
100ml	Penicillin/Streptomycin	(Sigma-Aldrich)	
100ml	MEM	non-essential	amino	acids	(Sigma-Aldrich)	
10ml	2-Mercaptoethanol	(50mM)	(Fluka)	
30ml	Primatone	(10%)	(Sigma-Aldrich)	
Adjust	to	pH	7.0	with	NaOH	(Fluka)	
Fill	up	to	10l	with	ddH2O	
0.22µm	sterile	filtered	
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FACS	buffer	PBS	
2%	FCS	
0.1%	NaN3		
Antibodies	FITC-	 ,	phycoerythrin-	(PE),	allophycocyanin-	(APC),	Pacific	Blue-	(PB),	Brilliant	Violet-	(BV),	 PE-Cy7-,	 PerCP-Cy5.5	or	biotin-labeled	mAb	 specific	 for	CD4	 (GK1.5),	 CD8α	 (53-6.7),	CD8β	(YTS-156.7.7),	CD25	(PC	61),	CD44	(IM7),	H-2Kb	(Y3),	H-2Kd	(19.191),	TCRβc	(H57-597),	 CD62L	 (Mel-14),	 CXCR5	 (L138D7),	 PD-1	 (RMP1-30),	 various	 Vβ-family	members,	 Vα2	 (B20.1),	 IFN-γ	 (XMG1.2)	 or	 FoxP3	 (FJK-16s)	were	 purchased	 from	 BD	Bioscience,	 eBioscience	or	BioLegend	or	purified	 from	hybridoma	 culture	 supernatant	and	 labeled	 in	 our	 laboratory	 according	 to	 standard	 procedures.	 Antibodies	 were	titrated	and	used	at	the	lowest	dilution	that	gave	the	best	separation.	
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Results	
1. Prophylactic	administration	of	IL-2	complexes	
These	 experiments	 were	 designed	 to	 investigate	 on	 the	 effects	 of	 IL-2	 complexes	(JES6/IL-2	or	S4B6/IL-2)	on	murine	SLE-like	disease	developing	as	a	result	of	cGvHD.	To	study	the	prophylactic	effect	of	IL-2	complexes	we	pretreated	mice	with	IL-2	complexes	before	 the	 disease	 was	 induced.	 The	 therapeutic	 effect	 of	 IL-2	 complexes	 on	 SLE-like	symptoms	was	studied	by	 IL-2	complex	 treatment	after	4	weeks	of	ongoing	disease.	A	graphical	overview	of	 the	administration	protocols	can	be	 found	 in	the	supplementary	material	(Fig.	S1).	
	To	 investigate	 the	 effect	 of	 prophylactic	 (p)	 administration	 of	 IL-2	 complexes	 on	 the	development	of	SLE-like	symptoms	 in	murine	cGvHD,	BDF1	were	pretreated	with	 IL-2	complexes	 (either	 S4B6/IL-2	 or	 JES6/IL-2)	 on	 3	 consecutive	 days	 before	 disease	induction.	Each	mouse	was	injected	i.p.	with	the	indicated	IL-2	complexes	composed	of	2.5	µg	rIL-2	and	7.5	µg	anti-IL-2	mAb	in	200	µl	sterile	PBS.	cGvHD	was	 induced	by	 i.v.	injection	of	70x106	DBA/2	lymphocytes	from	pooled	preparations	of	splenocytes	and	LN	cells.	To	assess	the	development	of	disease	the	presence	of	autoantibodies	to	autologous	erythrocytes	(anti-RBC)	 in	 the	blood,	 the	titers	of	anti-nuclear	antibodies	(ANA)	 in	 the	serum	and	the	incidence	of	proteinuria	were	measured	over	a	period	of	12	weeks.	The	following	 results	 represent	 pooled	 data	 of	 two	 independently	 conducted	 experiments	for	each	prophylactic	administration	protocol.	Groups	contained	in	total	20	(pretreated)	and	19	mice	(untreated	cGvHD)	mice	for	the	prophylactic	treatment	with	JES6/IL-2	or	14	(pretreated)	and	17	(untreated	cGvHD)	for	the	prophylactic	treatment	with	S4B6/IL-2.	
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Prophylactic	 treatment	with	 JES6/IL-2	 complexes	 (pJES6/IL-2)	was	 highly	 efficient	 in	ameliorating	 the	 SLE-like	 symptoms	of	murine	 cGvHD	 in	 all	measured	parameters.	As	shown	 in	Fig.	 1A,	 prophylactic	 JES6/IL-2	 treatment	 results	 in	 a	 reduced	 frequency	 of	anti-RBC	positive	mice	 throughout	 the	 experiment.	 In	 the	 untreated	 cGvHD	group	 the	frequency	of	positive	mice	 increased	progressively,	resulting	 in	58%	(11/19)	anti-RBC	positive	mice	after	12	weeks.	In	contrast,	the	frequency	of	anti-RBC	positive	mice	in	the	JES6/IL-2	prophylactically	treated	group	was	lower	at	all	measured	time	points	and	only	20%	(4/20)	of	JES6/IL-2	pretreated	mice	were	positive	for	anti-RBC	by	12	weeks.	
Prophylactic	JES6/IL-2	treatment	showed	a	similar	effect	on	the	production	of	ANA	(Fig.	
1B).	At	all	time	points,	serum	IgG	ANA	titers	(herein	presented	as	dilution	factor)	were	significantly	lower	in	the	pretreated	group	compared	to	the	control	group.	After	4	weeks	of	 cGvHD,	 the	 ANA	 titers	 of	 the	 prophylactically	 JES6/IL-2	 treated	 group	 were	 on	average	3.5-fold	 lower	compared	 to	 the	control	group	(mean:	404	(untreated	cGvHD);	114	(pJES6/IL-2	treated)).	Over	time,	ANA	titers	in	the	control	group	increased	nearly	4-fold	between	weeks	4	and	12;	however,	ANA	titers	in	the	group	prophylactically	treated	with	JES6/IL-2	complexes	remained	constantly	low	(mean:	97.3	at	8	weeks	and	126.3	at	12	weeks).	By	the	end	of	the	experiment,	ANA	titers	in	the	JES6/IL-2	pretreated	group	were	 on	 average	 10-fold	 lower	 compared	 to	 those	 of	 the	 controls	 (mean:	 1412	(untreated	cGvHD);	126.3	(pJES6/IL-2	treated)).	
Mice	 prophylactically	 treated	 with	 JES6/IL-2	 complexes	 showed	 a	 delayed	 onset	 and	reduced	incidence	of	proteinuria,	which	reflects	the	extent	of	immune	complex	induced	glomerulonephritis	 (ICGN)	(Fig.	 1C).	Whereas	some	mice	 in	 the	control	group	already	showed	 signs	 of	 proteinuria	 after	 4	 weeks	 of	 cGvHD	 induction,	 mice	 prophylactically	treated	with	JES6/IL-2	showed	the	first	signs	of	proteinuria	only	after	7	weeks	of	cGvHD.	
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At	 the	end	of	 the	experiment,	a	 significantly	 lower	 fraction	of	mice	developed	 ICGN	 in	the	 group	 pretreated	 with	 JES6/IL-2	 complexes	 compared	 to	 the	 untreated	 control	group	(untreated	cGvHD:	53%	(10/19);	pJES6/IL-2	treated:	20%	(4/20)).	The	reduced	kidney	 pathology	 was	 confirmed	 by	 immunohistological	 analysis	 of	 ICGN	 positive	kidneys.	 Kidneys	 obtained	 from	 JES6/IL-2	 pretreated	 mice	 (Fig.	 2B)	 stained	 less	intensively	 for	 the	deposition	of	 immune-complexes	 and	 complement	when	 incubated	with	fluorescently	labeled	anti-IgG	or	anti-C3	antibodies.	
In	contrast,	prophylactic	treatment	with	the	S4B6/IL-2	complexes	(pS4B6/IL-2)	induced	stronger	 autoimmune	 symptoms	 and	 a	more	 aggressive	 course	 of	 cGvHD.	 At	 all	 time	points,	a	higher	fraction	of	mice	was	positive	for	the	production	of	anti-RBC	antibodies	in	the	group	receiving	the	prophylactic	S4B6/IL-2	treatment	(Fig.	1D).	After	4	weeks	of	cGvHD	64%	(9/14)	of	mice,	and	after	12	weeks,	100%	(14/14)	of	mice	pretreated	with	S4B6/IL-2	were	positive	for	anti-RBC	antibodies.	In	the	control	group	the	frequency	of	positive	mice	progressively	increased	from	12%	(2/17)	at	4	weeks	to	82%	(14/17)	by	12	 weeks	 of	 cGvHD.	 In	 mice	 pretreated	 with	 S4B6/IL-2	 complexes,	 enhanced	 ANA	production	was	observed	(Fig.	1E).	Four	weeks	after	disease	induction	serum	ANA	titers	were	 increased	4.5-fold	 compared	 to	 control	mice	 (mean:	 1246	 (pS4B6/IL-2	 treated);	273	 (untreated	 cGvHD).	 By	 8	weeks	 of	 cGvHD,	mean	 ANA	 titers	 in	 the	 control	 group	increased	to	levels	above	those	of	the	S4B6/IL-2	pretreated	group,	which	had	somewhat	declined	 since	 the	 previous	 time	 point.	 However,	 there	 was	 no	 significant	 statistical	difference	 in	ANA	titers	between	the	two	groups	8	weeks	after	disease	 induction.	ANA	titers	measured	after	12	weeks	of	ongoing	cGvHD	showed	that	mice	in	the	control	group	still	 had	 high	 ANA	 titers	 in	 the	 serum	 (mean:	 1251)	 whereas	 unexpectedly	 mice	pretreated	 with	 S4B6/IL-2	 complexes	 showed	 10-fold	 decreased	 mean	 ANA	 titers	
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(mean:	121).	The	decrease	in	ANA	titers	observed	at	later	time	points	likely	results	from	the	prolonged	time	of	proteinuria	in	these	mice.	It	is	known	that	mice	with	proteinuria	secrete	not	only	large	amounts	of	albumin	by	the	urine	but	also	immunoglobulins	thus	leading	to	decreased	ANA	titers	in	the	serum.	
In	the	group	of	mice	pretreated	with	S4B6/IL-2	complexes,	an	accelerated	development	and	 full	 penetrance	 of	 ICGN	was	 observed	 (Fig.	 1F).	 Already	 after	 9	weeks	 of	 cGvHD	100%	mice	in	the	S4B6/IL-2	pretreated	group	(14/14)	developed	ICGN,	whereas	in	the	control	 group	 less	 than	 60%	 (10/17)	 of	mice	 exhibited	 proteinuria	 by	 12	weeks.	 The	accelerated	 kinetics	 and	 higher	 incidence	 by	which	 ICGN	 develops	 upon	 prophylactic	S4B6/IL-2	 treatment	 reflects	 the	 more	 aggressive	 course	 of	 disease	 induced	 by	 this	treatment.	 Immunohistological	 analysis	 of	 ICGN	 kidneys	 from	 S4B6/IL-2	 pretreated	mice	 (Fig.	 2C)	 showed	 a	more	 intensive	 staining	 of	 IgG	deposition	 compared	 to	 ICGN	positive	kidneys	of	untreated	cGvHD	mice	(Fig.	2A).	Moreover,	staining	for	complement-cascade	member	C3	revealed	a	more	distinct	granular	and	sprinkled	pattern	in	kidneys	of	 S4B6/IL-2	 pretreated	 mice	 compared	 to	 the	 staining	 pattern	 observed	 in	 kidneys	from	 untreated	 cGvHD	 mice.	 This	 pattern	 of	 C3	 staining	 was	 similar	 to	 the	 staining	pattern	for	IgG	deposition.	
In	summary,	prophylactic	treatment	with	JES6/IL-2	complexes	leads	to	an	amelioration	of	 SLE-like	 symptoms	 whereas	 the	 prophylactic	 treatment	 with	 S4B6/IL-2	 has	 an	opposing	effect	and	aggravates	the	course	of	cGvHD.	
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Figure	1:	Effect	of	prophylactic	treatment	with	IL-2	complexes	on	autoimmune	symptoms	
of	mice	undergoing	cGvHD	
(A	 –	 C)	 The	 beneficial	 effect	 of	 prophylactic	 JES6/IL-2	 treatment	 on	 BDF1	 mice	undergoing	cGvHD	(pJES6/IL-2:	n=	20;	untreated	cGvHD:	n=	19).	(D	 –	 F)	The	adverse	effect	of	prophylactic	S4B6/IL-2	treatment	on	BDF1	mice	undergoing	cGvHD	(pS4B6/IL-2:	n=	14;	untreated	cGvHD:	n=	17).	(A,	D)	Cumulative	 frequencies	of	mice	positive	 for	anti-RBC	autoantibodies	determined	at	4,	8	and	12	weeks	of	cGvHD.	Numbers	above	the	bars	 indicate	 positive	 mice.	 Open	 bars:	 untreated	 cGvHD;	 Filled	 bars:	 cGvHD	prophylactically	 treated	 with	 JES6/IL-2	 (black)	 or	 S4B6/IL-2	 (grey)	 complexes.	Statistical	significance	(p<	0.05)	was	calculated	using	a	two-tailed	Fisher’s	exact	test	and	is	indicated	by	the	p-value.	(B,	E)	IgG	ANA	titer	in	the	serum	of	cGvHD	mice	determined	4,	8	and	12	weeks	after	disease	induction.	Horizontal	bars	indicate	mean	ANA	titers	in	each	group.	Titers	below	the	dotted	line	represent	mice	negative	for	IgG	ANA.	Deviations	from	initially	used	numbers	of	mice	are	indicated	at	the	respective	time	point.	Statistical	significance	(p<	0.05)	was	calculated	using	an	unpaired	student’s	t-test	and	is	indicated	by	 the	 p-value.	 Open	 circles:	 untreated	 cGvHD;	 filled	 squares:	 cGvHD	 prophylactically	treated	with	JES6/IL-2	(black)	or	S4B6/IL-2	(grey)	complexes	(C,	F)	Frequencies	of	mice	positive	 for	 proteinuria	 as	 determined	 by	 elevated	 albumin	 in	 the	 urine.	 Statistical	significance	(p<	0.05)	was	calculated	using	the	Mantel-Cox	test	and	is	indicated	by	the	p-value.	 Dotted	 line:	 untreated	 cGvHD;	 solid	 line:	 cGvHD	 prophylactically	 treated	 with	JES6/IL-2	(black)	or	S4B6/IL-2	(grey)	complexes.			 	
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Figure	 2:	 Immunohistological	 staining	 of	 IgG	 and	 C3	 deposition	 in	 glomeruli	 of	
proteinuria	positive	cGvHD	mice	Kidneys	were	 obtained	 from	mice	 positive	 for	 proteinuria	 for	 <1	week.	 Cryo	 sections	were	prepared	and	stained	for	IgG	deposition	(left	panel)	or	C3	deposition	(right	panel).	Stained	sections	were	analyzed	by	using	a	Zeiss	Axioscope	mounted	with	a	Nikon	digital	camera	DXM	1200F	in	combination	with	imaging	software	(Nikon	ACT-1).	Photos	show	representative	staining	of	kidneys	from	different	experiments.	(A)	Untreated	cGvHD	in	mice	induced	with	DBA/2	lymphocytes.	(B)	cGvHD	in	mice	as	in	(A)	but	prophylactically	treated	with	 JES6/IL-2.	 (C)	 cGvHD	 in	mice	 as	 in	 (A)	 but	 prophylactically	 treated	with	S4B6/IL-2.	 (D)	 Untreated	 cGvHD	 mice	 whose	 disease	 was	 induced	 with	 DBA/2	lymphocytes	depleted	of	CD8+	T	cells.		 	
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2. Cellular	 mechanisms	 underlying	 the	 opposing	
effects	 of	 prophylactic	 treatment	 with	 IL-2	
complexes	
To	 gain	 further	 insight	 into	 the	 cellular	 responses	 induced	 by	 the	 prophylactic	administration	 of	 IL-2	 complexes,	 multicolor	 flow	 cytometry	 was	 performed	 on	splenocytes	 of	 mice	 prophylactically	 treated	 with	 JES6/IL-2	 or	 S4B6/IL-2	 complexes,	two	weeks	 following	 induction	 of	 cGvHD.	 For	 this	 experiment	we	 used	 4	mice	 in	 the	control	 group	 and	 5	 mice	 in	 each	 of	 the	 groups	 pretreated	 with	 IL-2	 complexes.	 All	groups	were	induced	and	analyzed	in	parallel.	
Mice	pretreated	with	JES6/IL-2	complexes	had	a	total	(donor	+	host)	splenic	cellularity	comparable	to	untreated	cGvHD	mice	(Fig.	3A),	however	the	absolute	numbers	of	donor	CD4+	T	cells	recovered	from	the	spleens	of	JES6/IL-2	complex	treated	mice	were	8.8-fold	reduced	compared	to	those	of	 the	controls	(11.8	±	2.8	x106	(untreated	cGvHD);	1.34	±	0.82	x106	(pJES6/IL-2	treated)	(Fig.	3B).	Additionally,	there	were	13.4-fold	fewer	donor	CD4+	T	cells	in	the	spleens	of	pJES6/IL-2	treated	mice	displaying	an	activated	(CD44hi	/	CD62Llo)	phenotype	(9.43	±	2.89	x106	(untreated	cGvHD);	7.77	±	0.44	x105	(pJES6/IL-2	treated)	 (Fig.	 3C).	 Furthermore,	 the	 population	 of	 donor	 CD4+	 T	 cells	 with	 central	memory	(Tcm;	CD44hi	/	CD62Lhi)	phenotype	was	also	significantly	(p=	0.0076)	reduced	in	 the	 group	 prophylactically	 treated	 with	 JES6/IL-2	 complexes	 (1.27	 ±	 0.47	 x106	(untreated	 cGvHD);	 0.36	 ±	 0.27	 x106	 (pJES6/IL-2	 treated))	 (Fig.	 3D).	 There	 was	 no	significant	difference	in	the	absolute	numbers	of	donor	Tfh	cells	(CD4+	/	PD1+	/	CXCR5+)	in	pJES6/IL-2	treated	compared	to	untreated	cGvHD	mice	(Fig.	3E).	In	concordance	with	previous	 reports	 on	 JES6/IL-2	 complexes,	 the	 host	 Tregs	 (CD4+	 /	 FoxP3+)	 were	
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significantly	(p<	0.0001)	expanded	21.5-fold	in	mice	pretreated	with	JES6/IL-2	(1.88	±	0.93	 x105	 (untreated	 cGvHD);	 3.87	 ±	 0.46	 x106	 (pJES6/IL-2	 treated))	 (Fig.	 3F).	 The	reduced	engraftment	of	donor	cells	as	well	as	their	decreased	activation	status	might	be	a	consequence	of	the	expanded	host	Treg	compartment	(20-fold	increased	compared	to	control	group).	
Mice	 prophylactically	 treated	 with	 the	 S4B6/IL-2	 complexes	 showed	 significantly	(p=0.0016)	increased	total	cellularity	of	the	spleens	compared	to	untreated	cGvHD	mice	(Fig.	4A).	Spleens	of	mice	prophylactically	treated	with	S4B6/IL-2	complexes	had	a	total	cellularity	 of	 1.77	±	 0.26	 x108	cells	whereas	 spleens	 of	 control	mice	 had	 on	 average	 a	total	cellularity	of	1.07	±	0.12	x108	cells.	Although	the	numbers	of	activated	donor	CD4+	T	 cells	 in	 prophylactically	 S4B6/IL-2	 treated	 mice	 (6.17	 ±	 1.20	 x106)	 were	 reduced	compared	 to	 untreated	 cGvHD	 animals	 (9.43	 ±	 2.89	 x106),	 this	 difference	 was	 not	statistically	 significant	 (Fig.	 4B).	 In	 contrast,	 donor	 CD4+	Tcm	 cells	were	 expanded	 in	mice	 treated	 prophylactically	with	 S4B6/IL-2	 complexes	 (1.27	 ±	 0.47	 x106	 (untreated	cGvHD);	2.51±	0.42	x106	 (pS4B6/IL-2	 treated)	 (Fig.	 4D).	Moreover,	 in	 these	mice,	 the	number	of	donor	Tfh	cells	was	increased	more	than	5-fold	(0.25	±	0.12	x106	(untreated	cGvHD);	1.4	±	0.32	x106	(pS4B6/IL-2	treated)	(Fig	4E).	Unexpectedly,	the	magnitude	of	host	Treg	expansion	 in	 response	 to	prophylactic	 treatment	with	S4B6/IL-2	 complexes	was	 2-fold	 greater	 compared	 to	 the	 expansion	 induced	 by	 prophylactic	 JES6/IL-2	treatment	(3.87	±0.46	x106	(pJES6/IL-2	treated);	8.11	±	1.54	x106	(pS4B6/IL-2	treated)	(Fig.	4F).	Despite	the	expanded	host	Treg	numbers	in	mice	prophylactically	treated	with	S4B6/IL-2	complexes,	no	amelioration	of	autoimmune	symptoms	was	observed	in	these	mice.	 The	 increased	 numbers	 of	 donor	 CD4+	 Tcm	 and	 Tfh	 cells	 observed	 in	 mice	
66	
prophylactically	 treated	with	S4B6/IL-2	complexes	might	account	 for	 the	more	severe	course	of	cGvHD	in	these	animals.	
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Figure	3:	T	cell	populations	in	splenocytes	from	cGvHD	mice	prophylactically	treated	with	
JES6/IL-2	complexes	cGvHD	mice	were	analyzed	in	parallel	two	weeks	after	disease	induction.	Mean	number	of	total	cellularity	(A)	as	well	as	different	donor	(B	–	E)	and	host	(F)	T	cell	subsets	per	spleen	are	shown.	(A)	Mean	number	of	total	splenocytes	(both	donor	and	host	origin).	
(B)	Mean	number	of	engrafted	donor	CD4+	T	cells.	(C)	Mean	number	of	activated	donor	CD4+	 T	 cells	 expressing	 CD44hi.	 (D)	 Mean	 number	 of	 donor	 CD4+	T	 cells	 with	 central	memory	phenotype	co-expressing	CD44hi	and	CD62Lhi.	(E)	Mean	number	of	donor	CD4+	T	cells	with	 follicular	helper	T	cell	 (Tfh)	phenotype	co-expressing	CXCR5	and	PD1.	(F)	Mean	number	 of	 host	Tregs	 expressing	CD4	 and	FoxP3.	White	 bars:	 untreated	 cGvHD	(n=	 4);	 Black	 bars:	 cGvHD	 prophylactically	 treated	 with	 JES6/IL-2	 (n=	 5).	 Statistical	significance	(p<	0.05)	was	calculated	using	an	unpaired	student’s	t-test	and	is	indicated	by	the	p-value.	Data	are	represented	as	mean	values	±	SD.		 	
69	
		 	
70	
Figure	4:	T	cell	populations	in	splenocytes	from	cGvHD	mice	prophylactically	treated	with	
S4B6/IL-2	complexes	Mean	number	of	total	cellularity	(A)	as	well	as	different	donor	(B	–	E)	and	host	(F)	T	cell	subsets	per	 spleen	are	 shown.	(A)	Mean	number	of	 total	 splenocytes	 (donor	and	host	origin).	(B)	Mean	number	of	engrafted	donor	CD4+	T	cells.	(C)	Mean	number	of	activated	donor	 CD4+	 T	 cells	 expressing	 CD44hi.	 (D)	 Mean	 number	 of	 donor	 CD4+	T	 cells	 with	central	 memory	 phenotype	 co-expressing	 CD44hi	 and	 CD62Lhi.	 (E)	 Mean	 number	 of	donor	 CD4+	 T	 cells	with	 follicular	 helper	 T	 cell	 (Tfh)	 phenotype	 co-expressing	 CXCR5	and	 PD1.	 (F)	 Mean	 number	 of	 host	 Tregs	 expressing	 CD4	 and	 FoxP3.	 White	 bars:	untreated	cGvHD	(n=	4);	grey	bars:	cGvHD	prophylactically	treated	with	S4B6/IL-2	(n=	5);	 black	 bars:	 cGvHD	mice	 prophylactically	 treated	 with	 JES6/IL-2	 (n=	 5).	 Statistical	significance	(p<	0.05)	was	calculated	using	an	unpaired	student’s	t-test	and	is	indicated	by	the	p-value.	Data	are	represented	as	mean	values	±	SD.		 	
71	
3. Therapeutic	administration	of	IL-2	complexes	
We	also	investigated	the	effect	of	IL-2	complexes	on	SLE-like	symptoms	during	ongoing	cGvHD	disease.	To	do	so,	we	administrated	the	same	IL-2	complexes	(either	JES6/IL-2	or	S4B6/IL-2)	therapeutically	(t)	on	3	consecutive	days	starting	4	weeks	after	the	induction	of	 cGvHD.	 The	 following	 results	 represent	 pooled	 data	 of	 2	 independently	 conducted	experiments	for	each	therapeutic	administration	protocol.	Groups	contained	in	total	20	(therapy)	and	20	(untreated	cGvHD)	mice	 for	 therapeutic	 treatment	with	 JES6/IL-2	or	20	 (therapy)	 and	 17	 (untreated	 cGvHD)	 mice	 for	 the	 therapeutic	 treatment	 with	S4B6/IL-2.	
Therapeutic	treatment	with	JES6/IL-2	complexes	had	no	significant	effect	on	the	extent	of	the	measured	autoimmune	symptoms.	There	was	a	slight	reduction	of	the	frequency	of	anti-RBC	autoantibody	positive	mice	indicating	a	mild	effect	of	therapeutic	JES6/IL-2	treatment	(Fig.	 5A).	The	 frequency	of	anti-RBC	positive	mice	was	 lower	 in	 the	treated	group	throughout	the	experiment.	After	12	weeks,	45%	(9/20)	of	mice	therapeutically	treated	with	JES6/IL-2	and	60%	(12/20)	of	the	control	mice	were	positive	for	anti-RBC	autoantibodies.	 However,	 ANA	 titers	were	 not	 significantly	 different	 between	 the	 two	groups	at	any	time	point	(week	4	-	12:	740.6	±	174.9	(untreated	GvHD);	596.6	±	136.4	(tJES6/IL-2	 treated))	 (Fig.	 5B).	 The	 kinetics	 of	 ICGN	 development	 appeared	 to	 be	 a	slightly	accelerated	in	the	JES6/IL-2	therapy	group	between	week	6	and	8	but	by	the	end	of	 the	experiment	the	 frequencies	of	mice	positive	 for	proteinuria	were	comparable	 in	both	 groups	 (untreated	 cGvHD:	 55%	 (11/20);	 tJES6/IL-2	 treated:	 60%	 (12/20))	 (Fig.	
5C).	
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Upon	 therapeutic	 treatment	 with	 S4B6/IL-2	 complexes,	 all	 autoimmune	 parameters	were	reduced	compared	to	untreated	cGvHD	mice.	As	shown	in	Fig.	5D,	the	frequencies	of	 anti-RBC	positive	mice	 treated	 therapeutically	with	 S4B6/IL-2	 complexes	 remained	low	throughout	the	observation	time	and	only	22%	(4/18)	of	these	mice	had	anti-RBC	autoantibodies	 by	 12	 weeks	 following	 the	 cGvHD	 induction.	 In	 the	 untreated	 cGvHD	group,	 the	 fraction	of	mice	positive	 for	anti-RBC	autoantibodies	progressively	 increase	from	10%	(2/20)	by	4	weeks	to	70%	(14/20)	after	12	weeks	of	cGvHD.	
As	 shown	 in	 Fig.	 5E,	 therapeutic	 treatment	 with	 S4B6/IL-2	 complexes	 resulted	 in	significantly	lower	IgG	ANA	titers	by	8	weeks	(mean	titer:	853	(untreated	cGvHD);	286.7	(tS4B6/IL-2	treated);	p=	0.019)	and	12	weeks	(mean	titer:	1192	(untreated	cGvHD);	530	(tS4B6/IL-2	 treated);	 p=	 0.025).	 The	 decreased	 production	 of	 autoantibodies	 and	 the	generally	 suppressed	 autoimmunity	was	 also	 reflected	 by	 the	 significantly	 (p=	 0.019)	reduced	 incidence	 of	 ICGN	 as	 shown	 in	 Fig.	 5F.	 In	 contrast	 to	 the	 untreated	 cGvHD	group,	where	70%	(14/20)	of	mice	had	proteinuria,	 less	 than	30%	(5/17)	of	 the	mice	therapeutically	treated	with	S4B6/IL-2	complexes	were	proteinuria	positive	by	the	end	of	the	experiment.	
Taken	 together,	 therapeutic	 administration	 of	 JES6/IL-2	 complexes	 had	 no	 significant	effect	on	the	development	of	murine	lupus	although	a	mild	reduction	in	the	frequency	of	anti-RBC	 autoantibody	 positive	 mice	 was	 observed.	 On	 the	 other	 hand,	 therapeutic	administration	 of	 S4B6/IL-2	 complexes	 induced	 a	 significant	 amelioration	 in	 all	measured	autoimmune	parameters.	
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Figure	 5:	Effect	of	therapeutic	treatment	with	IL-2	complexes	on	autoimmune	symptoms	
of	mice	undergoing	cGvHD	
(A	 –	 C)	The	efficiency	of	 therapeutic	 JES6/IL-2	 treatment	of	 cGvHD	 is	 confined	 to	 the	production	 of	 anti-RBC	 (tJES6/IL-2:	 n=	 20;	 untreated	 cGvHD:	 n=	 19).	 (D	 –	 F)	 The	beneficial	 effects	 of	 therapeutic	 S4B6/IL-2	 treatment	 of	 cGvHD	 (tS4B6/IL-2:	 n=	 18;	untreated	cGvHD:	n=	20).	(A,	 D)	Cumulative	 frequencies	of	mice	positive	 for	anti-RBC	autoantibodies	 determined	 at	 4,	 8	 and	 12	 weeks	 of	 cGvHD.	 Numbers	 above	 the	 bars	indicate	positive	mice.	White	bars:	untreated	cGvHD;	filled	bars:	cGvHD	therapeutically	treated	 with	 JES6/IL-2	 (black)	 or	 S4B6/IL-2	 (grey)	 complexes.	 Statistical	 significance	(p<	0.05)	was	calculated	using	a	two-tailed	Fisher’s	exact	test	and	is	indicated	by	the	p-value.	(B,	 E)	 IgG	ANA	titer	 in	the	serum	of	cGvHD	mice	determined	4,	8	and	12	weeks	after	disease	 induction.	Horizontal	bars	 indicate	mean	ANA	titers	 in	each	group.	Titers	below	 the	 dotted	 line	 represent	 mice	 negative	 for	 IgG	 ANA.	 Deviations	 from	 initially	used	numbers	of	mice	are	indicated	at	the	respective	time	point.	Statistical	significance	(p<	 0.05)	was	 calculated	 using	 an	 unpaired	 student’s	 t-test	 and	 is	 indicated	 by	 the	 p-value.	Open	circles:	untreated	cGvHD;	filled	squares:	cGvHD	therapeutically	treated	with	JES6/IL-2	(black)	or	S4B6/IL-2	(grey)	complexes.	(C,	F)	Frequencies	of	mice	positive	for	proteinuria	as	determined	by	elevated	albumin	in	the	urine.	Statistical	significance	(p<	0.05)	was	calculated	using	 the	Mantel-Cox	 test	and	 is	 indicated	by	 the	p-value.	Dotted	line:	untreated	cGvHD;	solid	line:	cGvHD	prophylactically	treated	with	JES6/IL-2	(black)	or	S4B6/IL-2	(grey)	complexes.		 	
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4. The	 contribution	 of	 donor	 CD8+	 T	 cells	 to	 the	
pathogenesis	of	murine	cGvHD	
CD8+	 T	 cells	 are	 suggested	 to	 play	 an	 important	 role	 in	 the	 development	 of	 SLE	 and	murine	 cGvHD	 [142].	 The	 potent	 capacity	 of	 S4B6/IL-2	 complexes	 to	 expand	 CD8+	 T	cells	 and	 the	 observation	 of	 a	 beneficial	 clinical	 effect	 of	 therapeutic	 S4B6/IL-2	treatment	 prompted	 us	 to	 further	 examine	 the	 involvement	 of	 the	 CD8+	 T	 cell	compartment	in	mice	undergoing	cGvHD.	
Analysis	of	IFN-γ	production	showed	that	CD8+	T	cells	from	both,	donor	and	host	were	highly	activated	irrespective	of	the	time	point	of	the	analysis	after	cGvHD	induction	(Fig	
6A).	On	average	more	than	80%	(82.7	±	11.5%)	of	donor	CD8+	T	cells	produced	IFN-γ	after	 in	 vitro	 stimulation	 with	 PMA/ionomycin,	 whereas	 the	 frequency	 of	 IFN-γ	producing	 cells	 in	 the	 host	 population	was	 around	 40%	 (41.2	 ±	 9.6%).	 These	 results	further	support	a	contribution	of	CD8+	T	cells	in	the	course	of	cGvHD.	To	demonstrate	a	mechanistic	involvement	of	CD8+	T	cells	and	to	test	the	particular	contribution	of	donor	and	host	CD8+	T	cells	 in	 the	pathogenesis	of	cGvHD	we	monitored	the	development	of	SLE-like	 symptoms	 in	 the	 absence	 of	 donor	 CD8+	 T	 cells.	 For	 this,	 CD8+	 T	 cells	 were	depleted	from	donor	DBA/2	mice	by	i.v.	 injection	of	200	µg	YTS-156	(a	rat	anti-mouse	CD8β	mAb)	four	days	in	advance	of	harvesting	DBA/2	(donor)	lymphocytes	for	cGvHD	induction.	The	high	efficiency	of	 in	vivo	CD8+	T	cell	depletion	 (>99%)	of	donor	DBA/2	mice	was	confirmed	by	flow	cytometry	analysis	of	the	lymphocyte	preparations	used	to	induce	the	disease	(data	not	shown).	
The	results	shown	in	Fig.	6B	-	D	represent	pooled	data	from	2	independently	conducted	experiments.	 Twenty	 mice	 per	 group	 were	 used	 to	 induce	 the	 disease	 as	 previously	
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described	 with	 either	 CD8+	 T	 cell	 depleted	 (dCD8-)	 or	 containing	 (dCD8+)	 DBA/2	lymphocytes.	The	data	demonstrate	that	donor	CD8+	T	cells	have	substantial	effects	on	the	disease	symptoms	and	that	a	much	more	severe	and	accelerated	disease	develops	in	the	absence	of	this	population.	90%	(18/20)	of	the	BDF1	mice	induced	with	CD8+	T	cell	depleted	donor	lymphocytes	(dCD8-	group)	developed	anti-RBC	antibodies	already	by	3	weeks	of	cGvHD	whereas	 in	 the	control	 cGvHD	group	(dCD8+	group),	70%	(14/20)	of	mice	developed	anti-RBC	antibodies	but	only	by	12	weeks	after	disease	induction	(Fig.	
6B).	
ANA	titers	in	the	two	groups	were	not	significantly	different	during	the	first	6	weeks	of	cGvHD	(week	3	–	6:	144.2	±	96.38	 (dCD8+);	137.6	±	22.98	 (dCD8-)).	Between	week	6	and	9,	ANA	titers	in	mice	induced	with	DBA/2	cells	depleted	of	CD8+	T	cells	decreased	whereas	the	titers	of	the	control	group	(DBA/2	cells	containing	CD8+	T	cells)	increased	progressively	 (Fig.	 6C).	After	9	weeks	of	cGvHD,	ANA	titers	of	 the	control	group	were	more	than	10-fold	higher	compared	to	 the	group	 induced	with	donor	cells	depleted	of	CD8+	T	cells.	The	decrease	 in	ANA	titers	among	cGvHD	mice	 induced	with	DBA/2	cells	lacking	CD8+	T	cells	might	be	the	consequence	of	the	prolonged	time	and	high	incidence	of	proteinuria	and	the	significant	amount	of	immunoglobulin	secreted	into	the	urine.	
As	 shown	 in	 Fig.	 6D,	 mice	 in	 the	 donor	 CD8+	 T	 cell	 depleted	 group	 (dCD8-)	 showed	accelerated	development	of	ICGN	with	full	penetrance	after	9	weeks.	The	development	of	proteinuria	 in	 the	 control	 group	 (CD8+)	was	 limited	with	only	20%	(4/20)	of	mice	exhibiting	proteinuria	by	the	end	of	the	experiment.	It	should	be	pointed	out	that	control	groups	of	other	experiments	(induced	with	DBA/2	lymphocytes	containing	CD8+	T	cells)	had	 on	 average	 30	 -	 40%	 proteinuria	 positive	 mice	 after	 9	 weeks.	 Nevertheless,	depleting	CD8+	T	cells	 from	the	donor	population	accelerates	proteinuria.	The	kinetics	
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by	which	ICGN	(proteinuria)	develops	in	cGvHD	induced	in	absence	of	donor	CD8+	T	cell	resembles	 those	 observed	 in	 cGvHD	 mice	 prophylactically	 treated	 with	 S4B6/IL-2	complexes.	 Consistent	 with	 this	 observation,	 the	 analysis	 of	 kidneys	 of	 ICGN	 positive	mice	from	the	dCD8-	group	(Fig.	2D)	showed	enhanced	deposition	of	IgG	antibodies	and	complement-component	C3	compared	to	controls.	
Taken	 together,	 donor	 CD8+	 T	 cells	 are	 important	 modulators	 of	 cGvHD	 with	 the	capacity	to	slow	the	development	of	SLE-like	symptoms	of	cGvHD.	
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5. The	 beneficial	 effect	 of	 therapeutic	 S4B6/IL-2	
treatment	depends	on	donor	CD8+	T	cells	
The	 recognition	 of	 the	 role	 of	 donor	 CD8+	 T	 cells	 in	 limiting	 the	 severity	 of	 cGvHD	symptoms	 leads	 to	 the	question	whether	 the	observed	effect	of	 therapeutic	S4B6/IL-2	administration	depends	on	the	presence	of	donor	CD8+	T	cells.	To	test	this,	cGvHD	was	induced	 by	 transfer	 of	 donor	 CD8+	 T	 cell	 depleted	 DBA/2	 lymphocytes	 into	 parental	BDF1	 mice.	 After	 4	 weeks	 of	 ongoing	 disease,	 one	 group	 of	 mice	 was	 treated	 with	S4B6/IL-2	 complexes	 on	 three	 consecutive	 days.	 The	 experiment	was	 repeated	 twice	with	 a	 total	 of	 19	 mice	 treated	 with	 S4B6/IL-2	 complexes	 and	 19	 control	 mice	 left	untreated.	
The	 therapeutic	 effect	 of	 S4B6/IL-2	 complexes	 on	 the	 development	 of	 proteinuria	clearly	depends	on	the	presence	of	donor	CD8+	T	cells	(compare	Fig.	 6D	and	Fig.	 6G).	However,	 the	 depletion	 of	 donor	 CD8+	 T	 cells	 in	 this	 cGvHD	model	 did	 not	markedly	affect	 production	 of	 autoantibodies.	 As	 shown	 in	Fig.	 6E,	 the	 frequencies	 of	 anti-RBC	positive	 mice	 were	 comparably	 high	 in	 both	 groups	 before	 and	 after	 the	 treatment.	Moreover,	ANA	titers	did	not	change	significantly	over	time	in	both	groups	before	and	after	the	treatment	(Fig.	6F).	
Proteinuria	 measurements	 might	 indicate	 a	 mild	 effect	 of	 therapeutic	 S4B6/IL-2	treatment	on	 the	kinetics	of	 ICGN	development	but	 the	difference	was	not	statistically	significant.	 After	 9	 weeks	 79%	 (15/19)	 of	 S4B6/IL-2	 treated	 mice	 and	 all	 (19/19)	control	mice	were	positive	for	proteinuria	(Fig.	6G).	
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These	 results	 provide	 strong	 evidence	 that	 donor	 CD8+	 T	 cells	 are	 an	 important	population	mediating	the	therapeutic	effect	of	S4B6/IL-2	complexes	on	the	development	of	SLE-like	symptoms	in	cGvHD	mice.	
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Figure	 6:	 Donor	 CD8+	 T	 cells	 are	 important	 modulators	 of	 cGvHD	 and	 mediate	 the	
beneficial	effect	of	therapeutic	S4B6/IL-2	therapy	
(A)	 Frequencies	of	 IFN-γ	producing	CD8+	T	 cells	 of	donor	 (circles)	 and	host	 (squares)	origin	in	splenocytes	of	untreated	cGvHD	mice	analyzed	at	various	time	points	between	2	and	12	weeks	after	disease	 induction.	(B	 -	 D)	A	more	severe	cGvHD	develops	when	induced	with	DBA/2	lymphocytes	depleted	of	CD8+	T	cells	(DBA/2	CD8-)	(DBA/2:	n=	20;	DBA/2	CD8-:	n=	20).	(E	–	G)	No	effect	on	cGvHD	severity	with	S4B6/IL-2	therapy	in	the	absence	 of	 donor	 CD8+	T	 cells	 (untreated	 cGvHD:	 n=	 19;	 tS4B6/IL-2:	 n=	 19).	 (B,	 E)	Cumulative	frequencies	of	mice	positive	for	anti-RBC	autoantibodies	determined	at	3,	6	and	 9	 weeks	 of	 cGvHD.	 Numbers	 above	 the	 bars	 indicate	 positive	 mice.	 Statistical	significance	 (p<	 0.05)	 was	 calculated	 using	 a	 two-tailed	 Fisher’s	 exact	 test	 and	 is	indicated	by	the	p-value.	(B)	White	bars:	cGvHD	mice	induced	with	DBA/2	lymphocytes;	Black	bars:	cGvHD	induced	with	DBA/2	lymphocytes	depleted	of	CD8+	T	cells.	(e)	White	bars:	cGvHD	induced	with	DBA/2	lymphocytes	depleted	of	CD8+	T	cells.	(C,	F)	IgG	ANA	titer	in	the	serum	of	cGvHD	mice	determined	3,	6	and	9	weeks	after	disease	induction.	Horizontal	bars	indicate	mean	of	ANA	titers	in	each	group.	Titers	below	the	dotted	line	represent	mice	negative	for	IgG	ANA.	Deviations	from	initially	used	numbers	of	mice	are	indicated	at	 the	 respective	 time	point.	 Statistical	 significance	 (p<	0.05)	was	 calculated	using	 an	 unpaired	 student’s	 t-test	 and	 is	 indicated	 by	 the	 p-value.	 (C)	 Open	 circles:	cGvHD	 induced	with	 DBA/2	 lymphocytes;	 filled	 squares:	 cGvHD	 induced	with	 DBA/2	lymphocytes	depleted	of	CD8+	T	cells.	(F)	Open	circles:	Untreated	cGvHD	mice	induced	with	DBA/2	 lymphocytes	depleted	of	CD8+	T	cells;	 filled	squares:	cGvHD	mice	 induced	with	 DBA/2	 lymphocytes	 depleted	 of	 CD8+	 T	 cells	 and	 therapeutically	 treated	 with	S4B6/IL-2	complexes.	(D,	G)	Frequencies	of	mice	positive	for	proteinuria	as	determined	by	elevated	albumin	in	the	urine.	Statistical	significance	(p<	0.05)	was	calculated	using	the	Mantel-Cox	test	and	is	indicated	by	the	p-value.	(D)	Dotted	line:	cGvHD	induced	with	DBA/2	 lymphocytes;	 solid	 line:	 cGvHD	 induced	 with	 DBA/2	 lymphocytes	 depleted	 of	CD8+	T	cells.	(G)	Dotted	line:	cGvHD	induced	with	DBA/2	lymphocytes	depleted	of	CD8+	T	cells;	solid	line:	cGvHD	induced	with	DBA/2	lymphocytes	depleted	of	CD8+	T	cells	and	therapeutically	treated	with	S4B6/IL-2	complexes.		 	
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6. GvHD	in	TCR	transgenic	BDF1	mice	
The	contribution	of	host	T	cells	to	the	pathogenesis	of	GvHD	is	still	obscure	[143,	144].	The	 finding	 that	 prophylactic	 treatment	 with	 IL-2	 complexes,	 as	 described	 above,	markedly	influences	the	development	of	cGvHD	is	consistent	with	the	idea	that	the	host	T	 cell	 compartment	 plays	 a	 role	 in	 the	 pathogenesis	 of	 this	 disease.	 In	 order	 to	investigate	this,	we	generated	BDF1	mice	with	a	restricted	T	cell	repertoire	by	crossing	B6	 mice	 expressing	 the	 MHC-I	 (Kb)	 restricted	 OT-I	 TCR	 transgene	 to	 DBA/2	 mice	 to	generate	OT1-BDF1	animals.	Similarly,	B6	mice	expressing	the	MHC-II	(I-Ab)	restricted	OT-II	TCR	transgene	were	crossed	with	DBA/2	animals	to	generate	OT2-BDF1	mice.	Due	to	 the	dominant	expression	of	 the	 transgenic	TCR	and	 the	extensive	but	not	 complete	suppression	 of	 host	 TCR	 gene	 rearrangement,	 these	 animals	 have	 a	 reduced	 T	 cell	receptor	repertoire.	
As	shown	in	Fig.	7A,	the	total	absolute	cellularity	of	spleens	from	normal	non-transgenic	BDF1	mice	and	OT1-BDF1	mice	was	comparable	(81.1	±23.1	x106	(BDF1);	70.2	±	7.40	x106	(OT1-BDF1))	whereas	spleens	from	OT2-BDF1	mice	exhibited	a	modest	increase	in	cellularity	and	contained	108.5	±	9.0	x106	cells.	However,	the	T	cell	compartment	of	both	TCR	 transgenic	BDF1	strains	was	heavily	comprised	 in	CD4+	and	CD8+	T	cell	numbers	compared	to	non-transgenic	BDF1	mice	(Fig.	7B,	C).	In	spleens	of	OT1-BDF1	mice,	CD4+	(1.17	±	0.17	x106)	and	CD8+	(1.58	±	0.06	x106)	T	cells	represented	only	10%	and	23%	of	absolute	 CD4+	 and	 CD8+	 T	 cells	 normally	 found	 in	 BDF1	 spleens	 (11.71	 ±	 2.54	 x106	(CD4+);	6.80	±	1.02	x106	(CD8+)).	In	OT2-BDF1	mice,	numbers	of	CD4+	(4.18	±	0.31	x106)	and	CD8+	(4.62	±	0.56	x106)	T	cells	were	less	compromised	compared	to	OT1-BDF1	mice	and	 represented	 36%	 of	 CD4+	 and	 68%	 of	 CD8+	 T	 cells	 usually	 found	 in	 spleens	 of	normal	 BDF1	mice.	 Additionally,	 the	 Treg	 compartment	 in	 OT1-BDF1	 spleens	 (0.53	 ±	
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0.12	 x106)	 was	 only	 39%	 of	 that	 in	 normal	 BDF1	mice	 (1.35	 ±	 0.45	 x106)	 (Fig.	 7D).	Absolute	 numbers	 of	 CD4+	 FoxP3+	 Tregs	 in	 OT2-BDF1	 spleens	 (1.3	 ±	 0.5	 x106)	 were	slightly	 increased	 compared	 to	 normal	 BDF1	 mice,	 however	 this	 difference	 was	 not	statistically	 significant	 (Fig.	 7D).	 Analysis	 of	 the	 TCR	 repertoire	 for	 expression	 of	transgenic	receptors	(Vα2	and	Vβ5)	or	TCRs	with	endogenously	encoded	Vβ-families,	as	shown	in	Fig.	8,	revealed	a	highly	restricted	TCR	repertoire	in	CD4+	and	CD8+	T	cells	of	both	TCR	transgenic	BDF1	strains.	A	considerable	fraction	of	splenic	CD4+	T	cells	(41.4	±	3.0%)	 and	 virtually	 all	 CD8+	T	 cells	 (98.8	 ±	 0.1%)	 in	 OT1-BDF1	mice	 expressed	 TCRs	composed	of	Vβ5	on	the	surface.	The	frequency	of	T	cells	expressing	other	Vβ-families	expressed	in	the	CD8+	T	cell	compartment	was	on	average	less	than	1%.	In	contrast,	the	CD4+	 T	 cell	 compartment	 of	 OT1-BDF1	 mice	 showed	 a	 higher	 proportion	 of	 cells	expressing	endogenous	Vβ-families	(Fig.	8A).	Furthermore,	28.2	±	2.4%	of	CD4+	T	cells	and	94.0	±	1.2%	of	CD8+	T	cells	expressed	both	transgenic	TCR	chains	(Vα2+/Vβ5+)	 in	OT1-BDF1	mice	 (Fig.	 8C).	 In	normal	BDF1	mice,	only	a	minor	 fraction	of	CD4+	T	 cells	(0.15	 ±	 0.05%)	 and	 CD8+	T	 cells	 (1.1	 ±	 0.22%)	 was	 positive	 for	 Vβ5	 expression	 and	Vα2+/Vβ5+	 T	 cells	 are	 virtually	 absent.	 Taken	 together,	 these	 data	 show	 that	 the	 TCR	repertoire	in	TCR	transgenic	BDF1	mice	expresses	a	limited	diversity	of	TCRs.	
As	 shown	 in	Fig.	 8A,	 a	 higher	 fraction	 of	OT2-BDF1	CD4+	T	 cells	 express	 a	 Vβ5+	TCR	(54.2	±	3.0%)	compared	to	CD4+	T	cells	in	OT1-BDF1	mice	(41.4	±	3.0%).	In	CD8+	T	cells	of	OT2-BDF1	mice,	the	most	frequently	used	Vβ-family	was	again	Vβ5	(55.5	±	3.0%),	but	additionally	other	Vβ-families	were	well	 represented	 (Fig.	 8B).	The	 frequency	of	 cells	expressing	both	Vα2+	and	Vβ5+	TCR	chains	among	CD4+	and	CD8+	T	cells	 in	OT2-BDF1	mice	was	44.8	±	4.7%	and	48.4	±	3.7%,	respectively.	
84	
In	 summary,	 OT1-BDF1	 und	 OT2-BDF1	 represent	 two	 TCR	 transgenic	 mouse	 strains	exhibiting	a	variable	degree	of	T	cell	deficiency	and	TCR	repertoire	restriction	in	both,	the	CD4+	and	the	CD8+	T	cell	compartments.	Moreover,	 the	Treg	compartment	 in	OT1-BDF1	mice	is	both,	severely	reduced	in	numbers	and	highly	restricted	in	TCR	repertoire	diversity,	whereas	the	Treg	compartment	in	OT2-BDF1	mice	is	not	reduced	in	numbers	compared	 to	 normal	 BDF1	mice	 but	 it	 nevertheless	 expresses	 a	 highly	 restricted	TCR	repertoire.	
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Figure	 7:	 Altered	 T	 cell	 compartments	 in	 OT1-BDF1	 and	 OT2-BDF1	mice	 compared	 to	
normal	BDF1	mice	
(A)	Absolute	cellularity	of	spleens.	(B)	Absolute	numbers	of	CD4+	T	cells.	(C)	Absolute	numbers	 of	 CD8+	 T	 cells.	 (D)	 Absolute	 numbers	 of	 Tregs	 expressing	 CD4	 and	 FoxP3.	BDF1:	white	bars,	n=	4;	OT1-BDF1:	black	bars,	n=	4;	OT2-BDF1:	grey	bars,	n=	4.	Data	are	presented	as	mean	values	±	SD.		 	
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Figure	8:	Highly	restricted	TCR	repertoire	in	OT1-BDF1	and	OT2-BDF1	mice	
(A)	Frequencies	of	various	Vβ-families	expressed	by	splenic	CD4+	T	cell.	(B)	Frequencies	of	 various	 Vβ-families	 expressed	 by	 splenic	 CD8+	 T	 cell.	 (C)	 Frequencies	 of	 CD4+	 and	CD8+	 T	 cells	 expressing	 both	 transgene-encoded	 TCR	 α-	 and	 β-chains	 (Vβ5+/V	 α2+).	BDF1:	white	bars,	n=	4;	OT1-BDF1:	black	bars,	n=	4;	OT2-BDF1:	grey	bars,	n=	4.	Data	are	presented	as	mean	values	±	SD.		 	
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7. 	DBA/2	 lymphocytes	 induce	 acute	 GvHD	 in	 TCR	
transgenic	BDF1	mice	
To	 examine	 the	 influence	 of	 a	TCR	 restricted	host	T	 cell	 repertoire	 on	 the	developing	symptoms	of	GvHD,	OT1-BDF1	(n=	13)	and	OT2-BDF1	(n=	7)	mice	were	injected	i.v.	with	70x106	DBA/2	lymphocytes.	
Instead	of	the	anticipated	chronic	course	of	GvHD	(cGvHD)	that	usually	results	from	the	transfer	of	DBA/2	 lymphocytes	 into	normal	BDF1	mice,	we	observed	an	acute	 form	of	GvHD	 (aGvHD)	 in	 TCR	 transgenic	 BDF1	 host	 mice.	 This	 was	 accompanied	 by	 the	characteristic	 disease	 symptoms	 including	 progressive	 loss	 of	 body	 weight	 and	 the	destruction	 of	 the	 host	 lympho-hematopoietic	 system	 by	 donor	 CD8+	 CTLs.	 The	symptoms	were	 severe	 enough	 that	 the	mice	 were	 sacrificed	 within	 weeks	 following	disease	induction.	
Fig.	9	shows	the	relative	body	weights	(body	weight	compared	to	the	weight	at	day	0	of	disease	induction)	of	OT1-BDF1	(Fig.	9A)	and	OT2-BDF1	mice	(Fig.	9B)	over	a	period	of	30	and	40	days,	 respectively.	The	majority	of	OT1-BDF1	mice	 (10/13)	were	sacrificed	after	2	to	3	weeks	(Fig.	9A;	filled	circles;	mean	survival:	16.3	days)	due	to	a	reduction	of	initial	body	weight	of	more	than	20%.	Spleens	(Fig.	9E	–	G)	and	bone	marrow	(Fig.	9H)	of	 long-term	survivors	that	survived	the	phase	of	 lympho-hematopoietic	depletion	and	almost	 regained	 their	 initial	 body	weight	 (Fig.	 9A;	 filled	 triangles)	 were	 analyzed	 by	flow	cytometry	in	order	to	determine	the	extent	of	reconstitution	by	donor	DBA/2	(H-2d/d)	cells.	Whereas	more	than	99%	of	all	CD4+,	CD8+	and	CD19+	cells	in	the	spleens	and	bone	marrow	expressed	Kd	on	 their	 surface,	only	about	4	 -	9%	were	positive	 for	host	derived	Kb	molecules.	These	results	show	that	in	these	OT1-BDF1	mice	almost	complete	
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reconstitution	by	donor	hematopoietic	stem	cells	had	occurred.	It	was	previously	shown	that	reconstitution	by	donor-derived	splenic	hematopoietic	stem	cells,	contained	in	the	donor	 inoculum	 used	 for	 disease	 induction,	 can	 rescue	mice	 from	 developing	 a	 lethal	form	of	aGvHD	[145].	
The	transfer	of	DBA/2	lymphocytes	into	OT2-BDF1	mice	(Fig.	9B)	induced	the	same	but	milder	aGvHD	symptoms	observed	 from	the	 transfer	of	DBA/2	 lymphocytes	 into	OT1-BDF1	mice.	The	mice	 rapidly	 lost	body	weight	 and	57%	(4/7;	 filled	 circles)	had	 to	be	sacrificed	within	3	to	4	weeks	after	disease	 induction.	The	mean	survival	time	of	OT2-BDF1	(24.5	days)	was	longer	compared	to	OT1-BDF1	mice	(16.3	days)	(Fig.9C).	A	small	number	of	OT1-BDF1	mice	surviving	the	initial	phase	of	aGvHD	and	the	accompanying	depletion	of	host	lympho-hematopoietic	system	(43%	(3/7);	filled	triangles)	recovered	from	 their	 weight	 loss	 and	 showed	 reconstitution	 by	 donor	 hematopoietic	 stem	 cells	(data	not	shown).	This	is	similar	to	what	is	observed	in	long-term	survivors	of	aGvHD	in	OT1-BDF1	mice.	
These	 results	 show	 that	 kinetics	 and	 symptoms	 resulting	 from	 GvHD	 are	 strongly	influenced	by	host	T	cells	and	the	diversity	of	 the	host	TCR	repertoire.	The	severity	of	the	 developing	 aGvHD	 symptoms	 correlates	 with	 a	 limited	 diversity	 of	 the	 TCR	repertoire	 and	 the	 reduced	 size	 of	 the	 Treg	 compartment	 resulting	 in	 a	more	 severe	disease	in	OT1-BDF1	compared	to	OT2-BDF1	mice	(Fig.	9C).	
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Figure	9:	 Injection	of	full	DBA/2	lymphocytes	into	OT1-BDF1	and	OT2-BDF1	mice	induces	
acute	GvHD	
(A)	 Relative	 body	 weight	 of	 OT1-BDF1	 mice	 (n=13)	 over	 a	 period	 of	 30	 days.	 Black	circles	 (n=	10):	mice	developing	 lethal	aGvHD	had	 to	be	sacrificed	due	 to	reduction	of	initial	 body	weight	 of	more	 than	 20%.	 Black	 triangles	 (n=	 3):	 Long-term	 survivors	 of	aGvHD	 showing	 reconstitution	by	DBA/2	HSC.	 (B)	 Relative	 body	weight	 of	OT2-BDF1	(n=7)	mice	over	a	period	of	40	days.	Grey	circles	(n=	4):	mice	developing	lethal	aGvHD	had	 to	 be	 sacrificed	 due	 to	 reduction	 of	 initial	 body	 weight	 of	 more	 than	 20%.	 Grey	triangles	(n=	3):	Survivors	of	aGvHD	showing	reconstitution	by	DBA/2	HSC.	(C)	Survival	of	OT1-BDF1	(solid	line),	OT2-BDF1	(dashed	line)	and	BDF1	mice	(dotted	line)	after	the	injection	of	 full	DBA/2	 lymphocytes.	 (D	 –	 G)	Analysis	 of	 spleens	 and	bone	marrow	of	OT1-BDF1	mice	surviving	the	phase	of	aGvHD	for	the	expression	of	H-2Kb	(y-axis,	upper	panel)	and	H-2Kd	(y-axis,	lower	panel)	and	CD4,	CD8	and	CD19	(x-axis).		 	
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8. DBA/2	 lymphocytes	 depleted	 of	 CD8+	 T	 cells	
induce	chronic	GvHD	in	TCR	transgenic	BDF1	mice	
It	 was	 shown	 previously	 that	 donor	 CD8+	 T	 cells	 are	 required	 for	 the	 induction	 of	aGvHD,	 In	 order	 to	 test	 whether	 depletion	 of	 CD8+	 T	 cells	 prevents	 the	 induction	 of	aGvHD	 in	 TCR	 transgenic	 hosts,	 OT1-BDF1	 and	 OT2-BDF1	 mice	 were	 induced	 with	DBA/2	 donor	 cells	 depleted	 of	 CD8+	 T	 cells.	 Injection	 of	 CD8+	 T	 cell	 depleted	 donor	lymphocytes	 into	 OT1-BDF1	 (n=	 13)	 or	 OT2-BDF1	 (n=	 6)	 transgenic	 hosts	 induced	cGvHD	 with	 characteristic	 production	 of	 autoantibodies	 and	 the	 occurrence	 of	proteinuria	 (Fig.	 10A	 -	 C).	Three	weeks	 following	disease	 induction,	 all	 (13/13)	OT1-BDF1	mice	produced	significant	amounts	of	anti-RBC	autoantibodies	 (Fig.	 10A).	Mean	IgG	ANA	titers	in	the	serum	of	OT1-BDF1	mice	undergoing	cGvHD	(week	3	–	6:	122.8	±	26.54)	were	comparable	to	those	of	normal	BDF1	mice	when	disease	was	induced	with	CD8+	T	cell	depleted	DBA/2	lymphocytes	(Fig.	 10B	 (compare	to	Fig.	 6C	and	Fig.	 6F)).	The	most	striking	observation	in	cGvHD	OT1-BDF1	mice	was	the	fast	kinetics	and	early	onset	 by	 which	 proteinuria	 emerged	 (Fig.	 10C).	 By	 7	 days	 of	 cGvHD,	 significantly	elevated	 concentrations	 of	 albumin	 could	 be	 detected	 in	 the	 urine	 of	 almost	 all	 OT1-BDF1	mice	 (7/8);	 after	 2	weeks	 all	mice	were	 proteinuria	 positive	 in	 this	 group.	 The	extremely	 early	 disease	 onset	 suggests	 that	 proteinuria	 in	 these	 mice	 may	 not	 be	mediated	 by	 the	 typical	 deposition	 of	 immune	 complexes	 in	 the	 kidney.	 This	 was	confirmed	by	staining	 for	 IgG	deposition	 in	kidney	sections	prepared	 from	proteinuria	positive	OT1-BDF1	mice.	There	was	no	detectable	deposition	of	IgG	immune	complex	in	the	glomeruli	of	those	mice	(data	not	shown).	Thus,	other	mechanisms	apart	from	renal	deposition	 of	 immune	 complex	 causing	 SLE-like	 glomerulonephritis	might	 have	 to	 be	
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considered	 for	 the	 failure	 of	 kidney	 function	 in	 these	mice.	 Due	 to	 the	 early	 onset	 of	proteinuria	in	OT1-BDF1	mice,	the	experiments	were	terminated	after	6	weeks.	
When	DBA/2	 lymphocytes	depleted	of	CD8+	T	 cells	were	 injected	 into	OT2-BDF1	host	mice,	cGvHD	developed	that	was	comparable	to	the	disease	in	OT1-BDF1	mice	in	terms	of	anti-RBC	and	ANA	production	(Fig.	10C	-	E).	All	OT2-BDF1	mice	(6/6)	produced	anti-RBC	autoantibodies	within	3	weeks	after	disease	induction	(Fig.	10D).	IgG	ANA	titers	in	OT2-BDF1	mice	during	 the	 first	6	weeks	of	 cGvHD	 (220	±	28.28)	were	 comparable	 to	those	in	OT1-BDF1	(122.8	±	26.54).	After	9	weeks,	ANA	titers	in	OT2-BDF1	mice	again	declined,	likely	due	to	the	prolonged	time	of	proteinuria.	In	contrast	to	the	proteinuria	in	OT1-BDF1	mice,	 proteinuria	 in	OT2-BDF1	was	delayed.	The	proportion	of	 proteinuria	positive	 OT2-BDF1	 mice	 progressively	 increased	 starting	 3	 weeks	 after	 disease	induction	and	reached	full	penetrance	after	6	weeks	of	cGvHD	(Fig.	10C).	The	time	point	of	 proteinuria	 onset	 in	 cGvHD	 OT2-BDF1	 mice	 is	 similar	 to	 that	 observed	 in	 normal	BDF1	 mice	 induced	 with	 CD8+	 T	 cell	 depleted	 donor	 lymphocytes.	 However,	 the	accelerated	kinetics	that	lead	to	full	penetrance	of	ICGN	almost	3	weeks	earlier	indicate	that	DBA/2	donor	lymphocytes	depleted	of	CD8+	T	cells	induce	a	more	severe	cGvHD	in	hosts	with	a	restricted	TCR	repertoire	compared	to	normal	hosts.	
Corresponding	 to	 the	 development	 of	 aGvHD	 in	 these	 mice,	 we	 observed	 that	 also	cGvHD	in	these	TCR	repertoire	restricted	mice	evolves	with	variable	degrees	of	severity.	Using	 kidney	 involvement	 as	 major	 criteria	 for	 the	 severity	 of	 SLE-like	 cGvHD,	 a	markedly	 more	 severe	 disease	 develops	 in	 OT1-BDF1	 compared	 to	 OT2-BDF1	 mice	following	transfer	of	DBA/2	cells	depleted	of	CD8+	T	cells.	
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The	 fact	 that	 OT1-BDF1	 and	 OT2-BDF1	 mice	 differ	 in	 their	 number	 of	 Tregs,	 is	consistent	with	the	idea	that	Tregs	with	the	capacity	to	control	the	activation	of	donor	CD8+	T	cells	may	play	a	role	in	this	model.	The	fact	that	fairly	normal	numbers	of	Tregs	in	 OT2-BDF1	 mice	 could	 not	 prevent	 the	 induction	 of	 acute	 GvHD	 upon	 injection	 of	DBA/2	lymphocytes	containing	all	T	cell	subsets	indicates	that	Tregs	with	a	reduced	TCR	diversity	might	 fail	 to	 control	 the	 activation	 of	 donor	CD8+	T	 cells.	How	 the	 host	 TCR	repertoire	 influences	 the	 suppression	 of	 donor	 CD8+	 T	 cells	 requires	 further	investigation.	
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Figure	 10:	 Injection	of	DBA/2	 lymphocytes	depleted	of	CD8+	T	 cells	 into	OT1-BDF1	and	
OT2-BDF1	mice	induces	chronic	GvHD 
(A,	D)	Frequencies	of	mice	positive	for	anti-RBC	autoantibodies	determined	at	3,	6	(and	9)	weeks	of	cGvHD	(cumulative).	Black	bars:	OT1-BDF1	(n=	13);	grey	bars:	OT2-BDF1	(n=	6).	(B,	 E)	 IgG	ANA	 titers	 in	 the	 serum	of	OT1-BDF1	 (black	circles)	and	OT2-BDF1	mice	 (grey	 circles)	 determined	 3,	 6	 (and	 9)	weeks	 after	 disease	 induction.	Horizontal	bars	 indicate	 the	 mean	 of	 ANA	 titers.	 Titers	 below	 the	 dotted	 line	 represent	 mice	negative	for	IgG	ANA.	Deviations	from	initially	used	numbers	of	mice	are	indicated	at	the	respective	time	point.	(C)	Frequencies	of	mice	positive	for	proteinuria	as	determined	by	elevated	 albumin	 concentrations	 in	 the	 urine.	 Statistical	 significance	 (p<	 0.05)	 was	calculated	 using	 the	Mantel-Cox	 test	 and	 is	 indicated	 by	 the	 p-value.	 Solid	 line:	 OT1-BDF1;	dashed	line:	OT2-BDF1;	dotted	line:	BDF1.		 	
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Discussion	
Murine	 cGvHD	 results	 from	 the	 injection	 of	 DBA/2	 lymphocytes	 into	 BDF1	 mice,	generating	 autoimmune	 symptoms,	 which	 closely	 resemble	 those	 present	 in	 SLE	patients.	 There	 is	 still	 no	 universally	 effective	 therapy	 for	 this	 class	 of	 systemic	autoimmune	 diseases.	 Previously,	 it	 was	 shown	 that	 IL-2	 could	 ameliorate	autoimmunity	in	MRL	mice	[131].	However,	due	to	the	severe	side	effects	IL-2	was	not	considered	for	therapeutic	purposes.	Some	years	ago	it	was	demonstrated	that	adverse	side	effects	of	this	cytokine	could	be	prevented	when	IL-2	is	administered	together	with	an	anti-IL-2	mAb,	in	the	form	of	an	immune	complex	[133].	Moreover,	it	was	shown	that	depending	on	the	anti-IL-2	mAb	used	for	the	formation	of	such	IL-2	complexes	different	T	cell	subsets	could	be	stimulated.	Thus,	administration	of	JES6/IL-2	complexes	results	in	 the	 expansion	 of	 IL-2Rαβγc+	 regulatory	 T	 cells	 whereas	 S4B6/IL-2	 complexes	preferentially	 induce	 the	expansion	of	CD8+	T	cells	with	high	 levels	of	 IL-2Rβγc	on	 the	surface	[122].	
Recently,	 the	 potency	 of	 these	 immune	 complexes	 in	 immunotherapy	 was	 shown	 in	several	mouse	models.	Thus,	JES6/IL-2	complexes	induced	resistance	to	EAE,	a	murine	model	 for	 multiple	 sclerosis,	 and	 induced	 long-term	 tolerance	 to	 pancreatic	 islet	allografts	 in	 transplantation	 settings	 [137].	 On	 the	 other	 hand,	 S4B6/IL-2	 complexes	were	 shown	 to	 be	 highly	 efficient	 in	 cancer	 immunotherapy	 in	 a	 murine	 model	 of	melanoma	 [130].	 However,	 studies	 are	 lacking	 which	 examine	 on	 the	 use	 of	 IL-2	complexes	in	an	autoimmune	disease	like	SLE,	which	is	characterized	by	a	particularly	strong	autoantibody	response	and	consequent	pathology.	
101	
Thus,	 we	 investigated	 the	 prophylactic	 and	 therapeutic	 potential	 of	 JES6/IL-2	 and	S4B6/IL-2	complexes	on	the	development	of	a	SLE–like	cGvHD	in	BDF1	mice	induced	by	the	transfer	of	DBA/2	lymphocytes.	
Prophylactic	 treatment	with	 the	 different	 IL-2	 complexes	 showed	 opposing	 effects	 on	the	 symptoms	 of	 developing	 cGvHD.	 The	 amelioration	 of	 disease	 upon	 JES6/IL-2	treatment	was	accompanied	by	significantly	decreased	numbers	of	donor	CD4+	T	cells	that	had	engrafted	in	the	spleens	of	recipient	mice	2	weeks	after	transfer.	Donor	CD4+	T	cells	 are	 central	 to	 the	 pathogenesis	 of	 murine	 cGvHD	 since	 they	 provide	 help	 to	autoreactive	 B	 cells	 in	 order	 to	 produce	 disease	 driving	 autoantibodies.	 Most	 likely,	disease	 amelioration	 is	 a	 consequence	 of	 the	 expanded	 host	 Treg	 compartment	 with	increased	 suppressive	 capacity	 at	 the	 time	 of	 disease	 induction.	 It	 is	well	 established	that	 Tregs	 are	 capable	 to	 regulate	 various	 immune	 responses	 and	 prevent	autoimmunity.	 Host	 Treg	 numbers	 in	 JES6/IL-2	 pretreated	 cGvHD	 mice	 were	 still	elevated	2	weeks	after	the	last	injection	of	IL-2	complexes.	The	fact	that	Treg	numbers	in	healthy	 mice	 usually	 return	 to	 baseline	 within	 approximately	 10	 days	 after	 the	treatment	with	 IL-2	 complexes	 [137]	 supports	 the	 idea	 that	 cGvHD	 associated	 events	(e.g.	elevated	endogenous	IL-2	levels)	maintain	the	increase	Treg	numbers	in	these	mice.	
In	contrast,	prophylactic	treatment	with	S4B6/IL-2	complexes	resulted	in	a	more	severe	form	of	cGvHD.	In	these	mice,	we	found	significantly	increased	numbers	of	donor	CD4+	T	cells	with	a	central	memory	phenotype,	identified	by	their	high	expression	of	CD44	and	CD62L	 on	 the	 surface	 (CD44hi	 /	 CD62Lhi).	 Memory	 T	 cells	 have	 a	 lower	 activation	threshold	and	exhibit	enhanced	effector	function	upon	re-stimulation	compared	to	their	less	differentiated	counterparts.	Besides	the	increased	numbers	of	memory	CD4+	T	cells,	S4B6/IL-2	pretreated	mice	also	contain	significantly	more	CD4+	Tfh	cells	of	donor	origin,	
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expressing	PD1	 and	CXCR5	 two	weeks	 after	 disease	 induction	 compared	 to	 untreated	cGvHD	 mice.	 Tfh	 cells	 are	 involved	 in	 germinal	 center	 reaction	 and	 promote	 the	differentiation	 of	 antibody	 secreting	 cells	 through	 IL-21	 secretion	 along	 with	 co-stimulatory	 signaling.	 These	 findings	 suggest	 that	 the	 exacerbated	 disease	 in	 mice	pretreated	 with	 S4B6/IL-2	 complexes	 might	 be	 primarily	 driven	 by	 the	 markedly	expanded	numbers	of	differentiated	donor	CD4+	T	cells	providing	enhanced	stimulation	to	host	B	cells	resulting	in	elevated	production	of	pathogenic	autoantibodies.	
The	 finding	of	a	more	severe	autoimmunity	 in	cGvHD	mice	pretreated	with	S4B6/IL-2	complexes	despite	a	significantly	increased	Treg	compartment	after	2	weeks	of	ongoing	disease	 is	 intriguing.	 The	 literature	 about	 S4B6/IL-2	 complexes	 and	 the	 underlying	mechanism	usually	describes	a	potent	expansion	of	CD8+	T	cell	populations	as	well	as	NK	cells.	The	mechanism	is	explained	by	the	binding	of	S4B6	mAb	to	the	epitope	of	the	IL-2	 molecule	 required	 for	 the	 interaction	 with	 high	 affinity	 component	 of	 the	 IL-2	receptor,	 CD25	 [134,	 135].	 Thereby,	 more	 IL-2	 is	 available	 for	 cells	 expressing	 low-affinity	receptors	for	IL-2	(IL-2Rβγc).	Nevertheless,	S4B6/IL-2	complexes	obviously	have	a	considerable	effect	on	CD4+	/	CD25+	T	cells	as	shown	by	Boyman	at	el.	in	the	original	description	 of	 these	 IL-2	 complexes	 [122].	 There,	 S4B6/IL-2	 complexes	 were	 at	 least	equally	 efficient	 in	 the	 expansion	 of	 the	 CD4+	 /	 CD25+	 (assumed	 to	 be	 Tregs)	compartment	 compared	 to	 JES6/IL-2	 complexes.	 Considering	 these	 results,	 it	 seems	plausible	that,	at	the	time	of	disease	induction,	the	Treg	compartment	in	recipient	mice	was	 similarly	 expanded	 in	 terms	 of	 absolute	 numbers	 in	 response	 to	 S4B6/IL-2	 and	JES6/IL-2	 treatment.	 However,	 only	 the	 Treg	 compartment	 expanded	 upon	 JES6/IL-2	treatment	efficiently	suppressed	the	activation	and	differentiation	of	donor	CD4+	T	cells	resulting	 in	 reduced	 autoimmunity.	 This	 suggests	 a	 qualitative	 difference	 in	 the	
103	
suppressive	capacity	of	Tregs	expanded	by	S4B6/IL-2	or	JES6/IL-2	complexes.	Possibly,	this	 might	 result	 from	 differences	 in	 IL-2R	 signaling	 and	 activation	 of	 downstream	pathways.	Whether	 the	Treg	TCR	 repertoire	differs	between	 JES6/IL-2	 and	S4B6/IL-2	treated	mice	and	whether	these	differences	might	impact	the	suppressive	capacity	needs	to	be	further	investigated.	
Another	 open	 question	 regarding	 the	 exacerbated	 disease	 induced	 in	 S4B6/IL-2	pretreated	mice	 is	 the	pronounced	differentiation	of	donor	CD4+	T	 cells	 into	Tfh	 cells.	We	 found	 this	 subset	 significantly	 increased	 only	 in	 mice	 pretreated	 with	 S4B6/IL-2	complexes.	These	findings	might	suggest	a	direct	effect	of	S4B6/IL-2	complexes	on	the	differentiation	of	activated	donor	CD4+	T	cells	into	various	effector	subsets.	However,	it	was	shown	previously	that	already	4	hours	after	administration,	the	biological	activity	of	S4B6/IL-2	 complexes	 to	 stimulate	 CD8+	T	 cells	 is	 substantially	 reduced	 and	 after	 24	hours	the	stimulatory	effect	was	essentially	gone	[122].	Whether	this	also	applies	for	the	stimulation	of	CD4+	T	cells	has	not	been	reported.	In	addition,	naïve	CD4+	T	cells	express	relatively	 low	 levels	 of	 IL-2	 receptor	 on	 their	 surface	 and	 are	 less	 responsive	 to	 IL-2	compared	 to	 their	 CD8+	 counterparts.	 Taken	 together,	 these	 findings	 rather	 point	towards	an	indirect	effect	of	S4B6/IL-2	complexes	on	the	differentiation	of	donor	CD4+	T	cells	into	cells	of	the	follicular	helper	subset.	Perhaps,	the	differentiation	of	donor	cells	into	follicular	helper	T	cells	is	a	secondary	effect	of	prophylactic	S4B6/IL-2	treatment	on	other	cells	of	the	host	immune	system	(e.g.	DCs).	
We	also	examined	the	effect	of	these	two	IL-2	complexes	in	treating	ongoing	cGvHD.	The	therapeutic	administration	of	JES6/IL-2	showed	no	significant	effect	on	the	symptoms	of	cGvHD.	Probably,	after	4	weeks,	the	cGvHD	has	already	progressed	for	too	long	so	that	the	 established	 effector	 mechanisms	 were	 no	 longer	 suppressible	 by	 JES6/IL-2	
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stimulated	Tregs.	 It	might	also	well	be	envisaged	that	a	stimulatory	effect	of	 JES6/IL-2	complexes	on	previously	activated	donor	CD4+	T	cells	exceeds	the	suppressive	capacity	of	the	expanded	host	Treg	compartment.	
CD8+	T	cells	from	donor	DBA/2	mice	are	most	likely	the	population	accountable	for	the	positive	effect	of	therapeutic	administration	of	S4B6/IL-2	complexes.	This	assumption	is	supported	by	 the	 following	observations:	First,	 in	 the	absence	of	donor	CD8+	T	 cells	 a	more	 severe	 cGvHD	 develops,	 and	 second,	 host	 CD8+	 T	 cells	 alone	 are	 unable	 to	ameliorate	disease	symptoms	after	stimulation	with	S4B6/IL-2	complexes.	
Our	 findings	 confirm	 the	 important	 influence	 of	 donor	 CD8+	 T	 cells	 and	 emphasize	paradoxical	features	for	this	population	in	the	development	of	cGvHD	in	BDF1	mice.	On	one	hand,	in	our	cGvHD	model,	donor	CD8+	T	cells	seem	to	be	insufficiently	stimulated	to	mount	a	strong	anti-host	response	that	would	result	in	aGvHD.	On	the	other	hand,	they	are	 critical	 for	 mechanisms	 leading	 to	 an	 amelioration	 of	 cGvHD	 symptoms	 upon	S4B6/IL-2	therapy.	Possibly,	therapeutic	S4B6/IL-2	treatment	promotes	the	stimulation	of	 donor	 CD8+	 T	 cells	 above	 a	 threshold	 sufficient	 to	 induce	 low-level	 anti-host	responses.	This	would	resemble	a	mild	form	of	aGvHD	where	host	cells	(e.g.	autoreactive	B	cells)	expressing	H-2b	antigens	are	targeted	by	S4B6/IL-2	activated	donor	CD8+	T	cells,	leading	 to	 an	 amelioration	 of	 disease	 symptoms.	 Data	 supporting	 this	 hypothesis	 is	provided	by	Nguyen	et	al.,	showing	that	stimulation	of	donor	or	host	CD8+	T	cells	with	IL-21	 results	 in	anti-host	 responses	 that	 lead	 to	an	amelioration	of	 cGvHD	 induced	by	DBA/2	 lymphocytes	 in	 BDF1	mice	 [107].	 Since	 there	 is	 no	 disparity	 in	MHC	 antigens	expressed	by	CD8	+	T	cells	and	B	cell	of	the	host,	other	antigenic	determinants	would	be	required	 to	 make	 autoreactive	 B	 cell	 a	 potential	 target	 of	 S4B6/IL-2	 stimulated	 host	CD8+	T	cells	[146].	
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In	conclusion,	the	use	of	IL-2	complexes	for	the	treatment	of	autoimmune	disease	seems	to	 be	 critically	 dependent	 on	 the	 stage	 of	 disease.	 While	 JES6/IL-2	 complexes	 could	mediate	 disease	 amelioration	 only	 when	 administrated	 prophylactically,	 their	therapeutic	potential	might	be	critically	limited	to	patients	with	a	very	early	diagnosis	of	SLE	in	the	clinics.	Thus,	together	with	improved	diagnostic	tools,	 the	administration	of	JES6/IL-2	 complexes	 might	 represent	 a	 more	 specific	 approach	 to	 prevent	 the	development	 of	 severe	 lupus	 with	 fatal	 organ	 damage.	 On	 the	 other	 hand,	 the	therapeutic	administration	of	JES6/IL-2	complexes	showed	no	positive	clinical	effect	on	the	 cGvHD	 symptoms	 in	 our	 experimental	 model.	 Due	 to	 the	 strong	 alloresponses	driving	 the	 pathology	 of	 cGvHD	 it	 can’t	 be	 excluded	 that	 therapeutic	 approaches	with	JES6/IL-2	 complex	might	 be	 efficient	 in	 other	 lupus	model	 or	 even	 human	 SLE.	 From	experiments	examining	the	therapeutic	treatment	with	S4B6/IL-2	complexes	as	well	as	from	 the	 depletion	 experiments	we	 can	 conclude	 that,	mechanisms	 leading	 to	 disease	amelioration	critically	depend	on	alloresponses	mediated	by	donor	CD8+	T	cells.	Since	no	donor	CD8+	T	cells	exist	in	human	SLE	and	activation	of	host	CD8+	T	cells	correlates	with	 disease	 severity	 due	 to	 increased	 production	 and	 availability	 of	 self-antigens,	 a	clinical	application	of	S4B6/IL-2	complexes	as	a	therapeutic	approach	for	SLE	might	be	questionable.	Based	on	our	results,	 it	seems	 likely	 that	S4B6/IL-2	complexes	 impose	a	risk	to	augment	autoimmune	diseases	through	enhanced	stimulation	of	CD8+	T	cells	in	the	host.	
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GvHD	results	from	the	injection	of	parental	lymphocytes	into	F1	mice.	Moreover,	DBA/2	lymphocytes	 injected	 into	 BDF1	mice	 induce	 cGvHD	 that	 resembles	 SLE	 in	 man.	 Our	findings	 from	 the	 prophylactic	 treatment	 of	 cGvHD	with	 IL-2	 complexes	 indicate	 that	host	T	cells	have	an	influence	on	the	development	on	this	disease.	To	further	establish	the	 role	played	by	host	T	 cells	 on	developing	 symptoms	we	generated	OT1-BDF1	and	OT2-BDF1	mice.	These	mice	have	a	highly	restricted	TCR	repertoire	in	both,	their	CD4+	and	CD8+	T	cell	compartments.	Additionally,	Treg	numbers	are	substantially	reduced	in	OT1-BDF1	 mice	 compared	 to	 OT2-BDF1	 and	 normal	 BDF1	 mice.	 Thus,	 these	 mice	represent	 a	 good	 model	 system	 to	 demonstrate	 the	 impact	 of	 altered	 host	 T	 cell	compartments	on	the	development	of	GvHD.	
In	the	second	part	of	this	thesis	it	was	investigated	whether	alterations	in	the	diversity	of	 the	 host	 TCR	 repertoire	 has	 an	 impact	 on	 GvHD	 resulting	 from	 injection	 of	 DBA/2	lymphocytes	into	OT1-BDF1	and	OT2-BDF1.	
The	induction	of	acute	GvHD	in	T	cell	repertoire	limited,	TCR	transgenic	BDF1	mice	was	a	rather	unexpected	event	that	has	not	been	previously	described	in	the	GvHD	literature.	These	findings	suggest	a	critical	role	of	host	T	cells	in	the	inhibition	of	aGvHD	in	normal	BDF1	 mice.	 In	 normal	 BDF1	 host	 mice,	 donor	 CD8+	 T	 cells	 are	 efficiently	 controlled	leading	to	cGvHD	instead	of	aGvHD.	It	seems	likely	that	“full”	Treg	compartment	in	the	BDF1	 host	 mediates	 the	 suppression	 of	 donor	 CD8+	 T	 cells	 and	 prevents	 the	development	of	aGvHD.	The	observation	that	a	milder	form	of	aGvHD	develops	in	OT2-BDF1	mice	provides	further	evidence	for	the	control	of	donor	CD8+	T	cells	by	host	Tregs.	The	Treg	compartment	in	OT2-BDF1	is	significantly	larger	compared	to	OT1-BDF1	mice.	It’s	 conceivable	 that	 this	 larger	Treg	compartment	protected	OT2-BDF1	mice	 from	the	more	severe	form	of	aGvHD	observed	in	OT1-BDF1	animals.	However,	although	the	Treg	
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compartment	 in	 OT2-BDF1	mice	 is	 comparable	 to	 normal	 BDF1	mice	 in	 terms	 of	 cell	numbers	 the	OT2-BDF1	Tregs	are	unable	 to	efficiently	 control	donor	CD8+	T	cells	and	completely	 inhibit	 the	 development	 of	 aGvHD.	 It	 might	 be	 envisaged	 that	 is	 a	consequence	of	the	restricted	TCR	repertoire	of	CD4+	T	cells	in	OT2-BDF1	mice.	
Another	reason	for	the	stronger	aGvHD	in	OT1-BDF1	mice	might	be	elevated	levels	of	IL-2	 resulting	 from	 the	 lack	 of	 IL-2	 consumption	by	Tregs.	 It	was	previously	 shown	 that	deprivation	of	IL-2	by	Tregs	is	an	important	mechanism	to	promote	the	suppression	of	CD8+	T	cells	[147].	
The	 chronic	 form	of	GvHD	 resulting	 from	 the	 injection	of	CD8+	T	 cell-depleted	DBA/2	lymphocytes	 into	 TCR	 repertoire	 restricted	 (i.e.	 TCR	 transgenic)	 BDF1	 mice	 further	confirms	 the	 requirement	 for	 CD8+	 T	 cells	 in	 the	 donor	 inoculum	 for	 the	 induction	aGvHD.	When	cGvHD	was	induced	in	the	absence	of	donor	CD8+	T	cells,	OT1-BDF1	and	OT2-BDF1	mice	 developed	 stronger	 disease	 symptoms	 especially	 in	 regard	 to	 kidney	pathology	 compared	 to	 normal	 BDF1	 mice.	 Interestingly,	 similar	 to	 the	 situation	 in	aGvHD,	 the	 cGvHD	 in	 OT1-BDF1	 mice	 was	 also	 associated	 with	 stronger	 disease	symptoms	compared	 to	OT2-BDF1.	The	strikingly	rapid	development	of	proteinuria	 in	OT1-BDF1	 mice	 undergoing	 cGvHD	 likely	 reflects	 their	 severely	 impaired	 Treg	compartment.	Besides	the	highly	restricted	TCR	repertoire	in	OT1-BDF1	mice,	the	Treg	compartment	is	considerably	reduced	in	absolute	numbers	in	comparison	to	OT2-BDF1	and	normal	BDF1	mice.	
Injection	of	10	x106	DBA/2	 lymphocytes	depleted	of	CD8+	T	cells	 (suboptimal	dose	 for	the	 induction	 of	 cGvHD	 in	 normal	 recipients)	 induce	 low-level	 cGvHD	 without	 the	abnormal	fast	development	of	proteinuria	in	OT1-BDF1	mice	whereas	in	OT2-BDF1	and	
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normal	 BDF1	 mice	 this	 dose	 is	 not	 sufficient	 to	 induce	 autoimmune	 symptoms	(preliminary	 results).	 These	 findings	 further	 support	 the	 notion	 that	 the	 Treg	compartment	in	OT1-BDF1	and	OT2-BDF1	mice	varies	in	the	capacity	to	suppress	graft-versus-host	reactions.	
In	conclusion,	the	presented	results	strongly	argue	for	an	important	role	of	host	T	cells,	especially	Tregs,	 in	 the	 control	of	 the	alloresponses,	which	 induce	 the	development	of	GvHD.	
In	summary	Graft-versus-Host	Diseases	are	caused	by	a	complex	interplay	of	donor	and	host	cell	populations.	Which	populations	dominate	and	drive	these	cellular	interactions	determine	the	pathology,	symptoms	and	outcome	of	the	disease	in	an	individual	patient.	Immunologists	working	on	therapies	for	this	set	of	systemic	diseases	need	to	keep	these	interactions	and	population	dynamics	in	mind.	
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The	impact	of	host	Tregs	and	donor	CD8+	T	cells	on	the	developing	GvHD	is	depicted	in	the	following	graphical	summary:	
	
a)	DBA/2	!	tg-BDF1	The	 injection	of	DBA/2	 lymphocytes	 into	TCR	restricted	BDF1	(tg-BDF1)	mice	 induces	aGvHD.	The	disease	is	ameliorated	in	OT2-BDF1	mice	having	increased	numbers	of	TCR	restricted	Tregs.	Normal	numbers	(wt)	of	TCR	restricted	Tregs	do	not	prevent	aGvHD.		
b)	DBA/2	(CD8-)	!	tg-BDF1	or	BDF1	The	 injection	 of	 DBA/2	 lymphocytes	 depleted	 of	 CD8+	 T	 cells	 (DBA/2(CD8-))	 induces	exacerbated	 cGvHD	 in	 tg-BDF1	 and	 normal	 BDF1	mice.	 The	 disease	 is	 ameliorated	 in	OT2-BDF1	mice	that	have	increased	numbers	of	tg-Tregs.	The	presence	of	normal	Tregs	further	ameliorates	disease	symptoms.	GvHD	in	b)	is	characterized	by	full	penetrance	of	proteinuria	within	9	weeks.	
c)	DBA/2	!	BDF1	+	pJES6/IL-2	or	tS4B6/IL-2	In	 normal	 BDF1	mice,	 the	 presence	 of	 donor	 CD8+	 T	 cells	 leads	 to	 an	 amelioration	 of	cGvHD.	Disease	symptoms	resulting	from	this	GvHD	can	be	ameliorated	by	prophylactic	JES6/IL-2	treatment	(+	pJES6/IL-2)	or	by	therapeutic	S4B6/IL-2	treatment	(+	tS4B6/IL-2).	 GvHD	 in	 c)	 is	 characterized	 by	 30	 -	 40%	 proteinuria	 positive	mice	 after	 9	weeks.	Indicated	IL-2	complexes	ameliorate	GvHD	by	expansion	of	the	indicated	T	cell	subsets.			
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*	 Level	 of	 disease	 severity	 resulting	 from	 GvHD	 in	 OT1-BDF1,	 OT2-BDF1	 and	 normal	BDF1	is	indicated	on	top	of	each	section.	**	Double-headed	 arrows	 indicate	 size	 of	 the	 depicted	T	 cell	 populations	 in	wild-type	(wt),	untreated	BDF1	or	DBA/2	mice.			 	
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Two Distinct Pathways in Mice 
Generate Antinuclear Antigen-
Reactive B Cell Repertoires
Martin Faderl†‡, Fabian Klein‡, Oliver F. Wirz†‡, Stefan Heiler, Llucia Albertí-Servera,  
Corinne Engdahl, Jan Andersson* and Antonius Rolink
Developmental and Molecular Immunology, Department of Biomedicine, University of Basel, Basel, Switzerland
The escape of anti-self B cells from tolerance mechanisms like clonal deletion, receptor 
editing, and anergy results in the production of autoantibodies, which is a hallmark 
of many autoimmune disorders. In this study, we demonstrate that both germline 
sequences and somatic mutations contribute to autospecificity of B cell clones. For this 
issue, we investigated the development of antinuclear autoantibodies (ANAs) and their 
repertoire in two different mouse models. First, in aging mice that were shown to gain 
several autoimmune features over time including ANAs. Second, in mice undergoing a 
chronic graft-versus-host disease (GVHD), thereby developing systemic lupus erythema-
tosus-like symptoms. Detailed repertoire analysis revealed that somatic hypermutations 
(SHM) were present in all Vh and practically all Vl regions of ANAs generated in these 
two models. The ANA B  cell repertoire in aging mice was restricted, dominated by 
clonally related Vh1-26/Vk4-74 antibodies. In the collection of GVHD-derived ANAs, the 
repertoire was less restricted, but the usage of the Vh1-26/Vk4-74 combination was 
still apparent. Germline conversion showed that the SHM in the 4-74 light chain are 
deterministic for autoreactivity. Detailed analysis revealed that antinuclear reactivity of 
these antibodies could be induced by a single amino acid substitution in the CDR1 of the 
Vk4-74. In both aging B6 and young GVHD mice, conversion of the somatic mutations in 
the Vh and Vl regions of non Vh1-26/Vk4-74 using antibodies showed that B cells with 
a germline-encoded V gene could also contribute to the ANA-reactive B cell repertoire. 
These findings indicate that two distinct pathways generate ANA-producing B cells in 
both model systems. In one pathway, they are generated by Vh1-26/Vk4-74 expressing 
B cells in the course of immune responses to an antigen that is neither a nuclear antigen 
nor any other self-antigen. In the other pathway, ANA-producing B cells are derived from 
progenitors in the bone marrow that express B cell receptors (BCRs), which bind to 
nuclear antigens and that escape tolerance induction, possibly as a result of crosslinking 
of their BCRs by multivalent determinants of nuclear antigens.
Keywords: antinuclear antibodies, autoantibodies, monoclonal antibodies, mouse model, systemic lupus 
erythematosus-like disease, somatic hypermutation
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INTRODUCTION
A hallmark of the autoimmune disease systemic lupus erythema-
tosus (SLE) is the presence of antinuclear autoantibodies (ANAs) 
in the serum (1–6). These antibodies are directed against histones, 
DNA, histone–DNA complexes, and various ribonuclear com-
plexes (anti-SM, anti-Ro, and anti-La) (3–6) and may be found in 
immune complexes that play an important role in the pathogen-
esis of SLE. The disease occurs more frequently in females than 
males (ratio 10:1) with a peak incidence at 45–65 years. Based 
on the findings that ANA producing B cells have undergone Ig 
class switching and carry large numbers of somatic mutations, it 
is very likely that ANAs arise from B cells participating in T cell 
dependent antigen responses (3–6).
Studies using mouse models spontaneously developing an 
SLE-like disease have improved our knowledge of the etiology of 
this disease (7–9). In particular, these studies have highlighted the 
complex genetic contribution to the development of the disease as 
well as the important role of somatic mutations of antibody genes 
in the formation of autoantibodies (7–13).
The generation of a self-tolerant B cell repertoire is critically 
dependent upon the processes of clonal deletion, receptor editing, 
and anergy (14–19). Exactly how B cells escape central tolerance 
is, however, still not completely understood. Ample evidence 
has been provided indicating that non-autoreactive B cells can 
become autoreactive through somatic mutations in their variable 
heavy (Vh) and light (Vl) chain regions (6, 10, 13, 20). Equally, 
B cells using germline-encoded Vh and Vl regions escaping cen-
tral tolerance induction in the bone marrow could also generate 
autoreactive B cells (21).
Recently we showed that almost all aging (8–12 months old) 
C57BL/6 (B6) mice develop several features characteristic of 
autoimmunity. This included germinal center formations in the 
spleen, kidney depositions of IgM, lymphocyte infiltrates in the 
salivary glands, as well as the production of high titers of IgG 
ANAs. Furthermore, this IgG ANA generation was shown to be 
T cell dependent (22). However, aging B6 mice do not develop 
real signs of disease. Here, we compare the ANA B cell repertoire 
of such aging B6 mice with that of (B6 × B6.H-2bm12)F1 mice 
undergoing a chronic graft-versus-host disease (cGVHD) and 
thus developing an SLE-like disease and death (23). Results 
indicate that the ANA B cell repertoire of aging B6 mice is more 
restricted than that of mice undergoing GVHD and is only 
partially overlapping. Moreover, we show that the ANA produc-
ing B cells in aging mice and in GVHD mice are derived from 
progenitors expressing B cell receptors (BCRs) either recognizing 
or not recognizing nuclear antigens. These findings indicate that 
ANA producing B cells in both aging mice and in GVHD mice are 
generated by two pathways: by defective tolerance induction in 
the bone marrow or by hypermutation in the V-regions of B cells 
responding to a foreign antigen.
MATERIALS AND METHODS
Mice and Induction of cGVHD
C57BL/6 and (C57BL/6 × B6(C)-H2-Abbm12/KhEgJ)F1 mice were 
bred under specific pathogen free conditions in our animal unit. 
A cGVHD was induced by i.v. injection of 8 × 107 spleen plus 
lymph node cells from B6 mice into 8–10 weeks old B6 × bm12 
mice, following established protocols (23).
Generation of Hybridomas
Spleen cells derived from aging B6 mice (aged 8–12 months) 
or B6 × bm12 mice undergoing a cGVHD were fused to the 
Sp2/0-Ag14 fusion partner following standard protocols. In 
brief, 2 ×  107 Sp2/0 cells were used for the PEG1500 (Roche 
Diagnostics)-mediated fusion of all lymphoid cells prepared 
from an entire spleen. The fused cells were plated into 25 flat-
bottom 96-well plates containing 200 µl HAT-medium (2%FBS; 
GIBCO, 2% IL6, in house, 1× HAT supplement, Sigma) per 
well and incubated at 37°C in 10% CO2 in air. After 10–12 days, 
supernatants were tested for IgG production by ELISA and for 
antinuclear reactivity by immunofluorescence (see below). Cells 
from IgG ANA positive wells were thereafter sub-cloned at limit-
ing dilution. We routinely obtained fusion frequencies between 
10−3 and 5  ×  10−3. Thus, for each mouse, we have screened 
between 5,000 and 20,000 hybrids for IgG ANA production. 
Since the vast majority of B cell hybrids produce IgM, we tested 
for the success of sub-cloning by performing simultaneous 
ELISA for IgM and IgG (see below) in supernatants of growing 
clones. The IgG containing supernatants were re-tested for ANA 
reactivity, before being further processed for Ig V-gene analyses 
(see below).
Determination of IgG Sub-Class and Anti-
Histone/DNA/Sm/SS-B/La Reactivity
Determination of IgG sub-class, l-chain, and detection of anti-
DNA antibodies was done by standard ELISA. For determination 
of anti-histone, anti-Sm or anti-SS-B/La ELISA plates were coated 
with 2.5 μg/ml of the respective antigens in PBS (all purchased 
from Immunovision). Alkaline phosphatase labeled goat anti-
mouse IgG, goat anti-mouse l-chain or goat anti-human IgG 
(Southern Biotech) was used for detection. The ELISA was 
performed as previously described (24–26).
Antinuclear Autoantibody Determination
Kidney cryosections from Rag2−/− mice of homozygous mat-
ings were incubated with supernatants or purified antibodies 
as described in Ref. (27). For detection, either FITC labeled 
goat anti-mouse IgG (Jackson ImmunoResearch) or FITC 
labeled rabbit anti-human IgG (Jackson ImmunoResearch) 
were used.
Vh and Vl Sequencing Analysis
RNA from ANA positive hybridomas was extracted using TRI 
Reagent (Sigma) followed by cDNA synthesis (GoScript Reverse 
Transcriptase) according to the manufacturer’s protocol and 
using primers as specified in Table S5 in Supplementary Material. 
Amplification of the heavy and light chain V-regions was per-
formed using Vent polymerase (New England Biolabs) and, 
subsequently, the Vh and Vl regions were ligated into the pJet1.2 
blunt end cloning vector (Thermo Fisher Scientific). For sequenc-
ing, plasmids were sent to Microsynth (Balgach, Switzerland). 
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TABLE 1 | Characteristics of ANA-reactive mAbs derived from aging B6 mice.a,b
Mouse number Hybridoma number IgG isotype Ig-heavy chain v-region Ig-light chain v-region
Aging B6 # 1 5.D3.D10 IgG2b Vh1-26 D1-1 J4 Vk4-74 Jk4
5.D3. E12 IgG2b Vh1-26 D1-1 J4 Vk4-74 Jk4
7.E8.B11 IgG2b Vh1-26 D1-1 J4 Vk4-74 Jk4
7.F9.F1 IgG2b Vh1-75 D2-4 J2 Vk?
8G3.E6 IgG2a Vh1-26 D1-1 J4 Vk4-74 Jk4
8.H7.D3 IgG2b Vh1-26 D1-1 J4 Vk4-74 Jk4
15.G10.F10 IgG2b Vh1-26 D1-1 J4 Vk4-74 Jk4
15.H12.E4 IgG2b Vh1-26 D1-1 J4 Vk4-74 Jk4
16.B9.C9 IgG2b Vh1-26 D1-1 J4 Vk4-74 Jk4
16.D7.A9 IgG2a Vh1-26 D1-1 J4 Vk4-74 Jk4
17.A9.E6 IgG2b Vh1-26 D1-1 J4 Vk4-74 Jk4
22.C9.G7 IgG2b Vh1-26 D1-1 J4 Vk4-74 Jk4
Aging B6 # 2 1.G5.B8 IgG1 Vh1-39 D4-1 J1 Vk4-57 Jk5
8.G9.G4 IgG2b Vh1-26 D1-1 J4 Vk6-32 Jk2
Aging B6 # 3 13.4.5.A IgG2a Vh1-26 D2-4 J3 Vk4-74 Jk2
13.18.A IgG2a Vh1-26 D2-4 J3 Vk4-74 Jk2
13.27.B IgG2a Vh1-26 D2-4 J3 Vk4-74 Jk2
13.31A IgG2a Vh1-26 D2-4 J3 Vk4-74 Jk2
13.69.B IgG2a Vh1-26 D2-4 J3 Vk4-74 Jk2
13.85B IgG2a Vh1-26 D2-4 J3 Vk4-74 Jk2
Aging B6 # 4 1A2.1 IgG2a Vh1-26 D2-2 J4 Vk4-74 Jk2
2F8.1 IgG2b Vh1-26 D1-1 J4 Vk4-74 Jk2
Aging B6 # 5 12.G3.G7 IgG2a Vh1-26 D1-1 J4 Vk5-43 Jk2
15.D10B3 IgG2a Vh1-26 D1-1 J4 Vk5-43 Jk2
Aging B6 # 6 3.2.2A IgG2b Vh1-74 D2-4 J3 Vk6-23 Jk5
3.10.1A IgG2b Vh1-26 D1-1 J2 Vk4-61 Jk1
5.13.1A IgG2b Vh1-26 D1-1 J2 Vk4-74 Jk2
6.15.1A IgG2a Vh8-12 D3-1 J1 Vk4-91 Jk2
7.7.3A IgG2b Vh1-22 D2-2 J1 Vk10-96 Jk2
20.15.1A IgG2a Vh1-50 D4-1 J2 Vk4-74 Jk2
23.6.1A IgG2a Vh1-22 D2-2 J1 Vk10-96 Jk2
24.18.1A IgG2b Vh1-22 D2-2 J1 Vk10-96 Jk2
25.8.1A IgG2b Vh3-6 D3-3 J3 Vk4-74 Jk2 
Aging B6 # 7 3.25A IgG2b Vh1-50 D2-4 J2 Vk?
3.36A IgG2a Vh1-80 D2-4 J3 Vk4-58 Jk2
3.73A IgG2a Vh1-26 D1-1 J4 Vk4-74 Jk2
aAll the mAbs converted into germline sequences are boxed in orange.
bAll the mAbs using Vh1-26 have been boxed in yellow and those using Vk4-74 in red.
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Resulting sequences were inspected using DNASTAR and 
aligned to the germline heavy and light chain sequences of the 
international ImMunoGeneTics information system® (http://
imgt.org).
Reversion of Somatic Mutations Back into 
Germline Configuration
Double-stranded DNA encoding the variable regions of heavy and 
light chains obtained from ANA positive hybridomas as well as 
their germline and mutated versions were ordered as gBlock gene 
fragments from IDT (Integrated DNA Technologies). These frag-
ments were cloned into heavy and light chain expression vectors 
driven by the human cytomegalovirus promoter and containing 
the human IgG1 constant region for the heavy chain and the human 
kappa constant region for the light chain (28) (a kind gift from 
Dr. Hedda Wardemann, Deutsches Krebsforschungszentrum, 
Heidelberg, Germany). Subsequently, antibodies were produced 
in HEK 293 cells (ATCC, No. CRL-1573) and purified by affinity 
chromatography on Protein A Sepharose® (GE Health Care, 
Uppsala, Sweden) as described (28, 29).
RESULTS
IgG ANA Producing Hybridomas from 
Aging B6 Mice
Hybridomas were generated independently from spleen cells of 
seven individual aging B6 mice, which had high titers of serum 
ANA. The resulting IgG producing hybridomas were then tested 
for ANA reactivity by immunofluorescence, and positive cultures 
were sub-cloned. In total, 36 hybridomas producing IgG ANA 
were generated (Table 1). Of these, 16 were IgG2a, 19 were IgG2b, 
and only one was IgG1. This heavy chain selection suggests 
that IgG ANA formation in aging B6 mice is mainly driven by 
a Th1 response (30). All ANAs contained a kappa light chain. 
Sequence analysis of the corresponding Vh and Vk regions used 
by these hybridomas revealed a restricted repertoire (V, D, and 
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FIGURE 1 | ANA reactivity is directed against histones. Histone, dsDNA, ssDNA, Sm, or SS-B/La binding of ANA-reactive mAbs derived from (A) aging B6 (Table 1) 
or (B) young B6 × bm12 mice undergoing a cGVH reaction (Table 2). Significant binding was defined as an O.D. of five times over background in ELISA. (−), no 
significant binding at 5 μg/ml; (+), binding at 5 μg/ml; (++), binding at 1.7 µg/ml; (+++), binding at 0.55 µg/ml; and (++++), binding at 0.19 µg/ml or lower.
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J annotations are according to the IMGT data base). Thus, 25 
(69.4%) hybridomas used the Vh1-26 gene and this usage was 
found among hybridomas of all seven individual mice. Moreover, 
a very high frequency of Vk4-74 gene usage was also found. Thus, 
23 (63.9%) hybridomas, derived from 5 of 7 individual mice, used 
this particular Vk light chain gene. Strikingly, 21 of the 23 Vk4-74 
expressing hybridomas expressed the Vh1-26 heavy chain. Thus, 
the IgG ANA B cell repertoire of aging B6 mice is dominated by 
those expressing a Vh1-26 heavy chain gene in combination with 
a Vk4-74 light chain gene.
We also tested these ANAs for their capacity to bind to 
histones, Sm antigens, SS-B/La antigens, and DNA. By ELISA, 
26 of the 36 showed strong and 5 showed weak histone binding, 
whereas binding to the other nuclear antigens was undetectable 
(Figure 1A).
In Individual Mice, Hybridomas Using 
Vh1-26/Vk4-74 Were Clonally Related
The fact that we obtained 11 hybridomas from mouse 1, and 6 
hybridomas from mouse 3 using the Vh1-26/Vk4-74 combination 
with the same D, Jh, and Jk elements already strongly suggested 
a clonal relationship among the B cells that had fused to gener-
ate these hybridomas (Table 1). The finding that the amino acid 
sequences of the IgH and IgL CDR3 regions of these hybridomas 
were practically identical (Tables S1 and S2 in Supplementary 
Material) also supports this conclusion. Thus, at least in mouse 
1 and 3, the ANA production seems to be dominated by a single 
B cell clone.
IgG ANA from B6 × bm12 Mice 
Undergoing a Chronic Graft-versus-Host 
Reaction
We then asked whether the restricted IgG ANA B cell repertoire 
in aging B6 mice, which do not show obvious signs of disease, was 
similarly restricted in B6 × bm12 mice undergoing a chronic graft-
versus-host reaction and, thus, developing an SLE-like disease. 
Hybridomas were independently generated from spleen cells of 
five mice with the highest ANA titers. These fusions resulted in 34 
hybridomas with IgG ANA activity (Table 2). A total of 23 ANAs 
(68%) reacted to histones but again, none reacted to the other 
nuclear antigens (Figure 1B). IgG constant region usage analysis 
revealed a distribution rather similar to that in aged mice with 18 
IgG2a, 13 IgG2b, and only 3 IgG1, the latter all from mouse 5. Thus, 
as in aging B6 mice, in B6 × bm12 mice undergoing a cGVHD, 
the IgG ANA formation appears to be Th1 cell driven. Again, all 
ANAs contained a kappa light chain.
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TABLE 2 | Characteristics of ANA-reactive mAbs derived from graft-versus-host 
disease (GVHD) mice.a,b
Mouse 
number
Hybridoma 
number
IgG 
isotype
Ig-heavy chain 
v-region
Ig-light chain 
v-region
GVHD # 1 1.12.1A IgG2b Vh8-8 D2-14 J4 Vk4-74 Jk2
1.28.1 IgG2a Vh1-26 D1-1 J1 Vk4-74 Jk2
1.308.1 IgG2a Vh1-55 D2-4 J3 Vk3-4 Jk1
1.356.1 IgG2a Vh1-55 D2-4 J3 Vk3-4 Jk1
1.741.1 IgG2a Vh1-55 D2-4 J3 Vk3-4 Jk1
1.802.1 IgG2b Vh1-26 D1-1 J1 Vk4-63 Jk5
GVHD # 2 2.24.0 IgG2a Vh1-52 D1-1 J1 Vk14-111 Jk5
2.53.8 IgG2b Vh14-2 D2-2 J2 Vk14-111 Jk1
2.58.2 IgG2b Vh14-2 D2-2 J2 Vk14-111 Jk1
2.70.8 IgG2a Vh14-4 D1-1 J3 Vk3-10 Jk1
2.80.9 IgG2a Vh14-4 D1-1 J3 Vk3-12 Jk1
2.152.9 IgG2a Vh1-52 D1-1 J1 Vk3-10 Jk1
2.300.2 IgG2b Vh1-55 D2-1 J2 Vk3-10 Jk5
2.344.3 IgG2a Vh1-52 D1-1 J1 Vk14-111 Jk5
2.374.1 IgG2a Vh1-26 D1-1 J1 Vk3-7 Jk1
2.382.2 IgG2a Vh14-4 D2-1 J3 Vk3-10 Jk1
2.388.2 IgG2a Vh1-31 D2-4 J4 Vk3-10 Jk2
2.394.1 IgG2a Vh14-4 D1-1 J3 Vk3-10 Jk1
GVHD # 3 3.55.1 IgG2a Vh1-26 D1-1 J3 Vk4-74 Jk2
3.69.1 IgG2b Vh1-26 D1-1 J3 Vk4-74 Jk2
3.71.1 IgG2a Vh1-26 D2-5 J1 Vk4-74 Jk2
3.77.1 IgG2a Vh1-26 D1-1 J3 Vk4-74 Jk2
3.152.1 IgG2b Vh1-26 D1-1 J3 Vk4-74 Jk2
GVHD # 4 63.3.1 IgG2b Vh1-55 D2-4 J2 Vk4-74 Jk2
165.2.1 IgG2a Vh8-12 D2-2 J1 Vk15-103 Jk5
GVHD # 5 14.11.A IgG2b Vh1-50 D1-1 J2 Vk1-117 Jk2
381.11.A IgG2b Vh1-54 J4 Vk14-111 Jk2
685.9.A IgG2b Vh1-59 D2-5 J3 Vk17-127 Jk5
724.3.A IgG1 Vh1-26 D1-1 J3 Vk4-91 Jk4
738.8.A IgG1 Vh1-26 D1-1 J3 Vk3-7 Jk1
762.5.A IgG2a Vh5-17 D1-2 J4 Vk?
810.4.A IgG1 Vh1-52 D2-12 J2 Vk3-10 Jk1
865.12.A IgG2b Vh1-72 D3-3 J2 Vk4-74 Jk5
1011.39.A IgG2b Vh1-53 D1-1 J2 Vk17-127 Jk5
aAll the mAbs converted into germline sequences are boxed in orange.
bAll the mAbs using Vh1-26 are boxed in yellow and those using Vk4-74 in red.
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results are summarized in Tables S1–S4 in Supplementary 
Material.
Since in aging B6 mice the ANA reactivity was dominated 
by mAbs expressing a Vh1-26/Vk4-74 heavy and light chain 
combination, we tested if somatic mutations in the Vh and/or 
the Vk regions of these mAbs were required for their autore-
activity. Therefore, the Vh and Vk regions of six (derived from 
4 individual mice) mAbs of aging B6 and two mAbs of GVHD 
mice using the Vh1-26/Vk4-74 combination were reverted to 
their germline configuration. After expression and purification, 
the ANA titers of these reverted mAbs were directly compared 
to their original, mutated forms. As shown in Figures  2A,B, 
the ANA titers of all mAbs, in which the Vh region had been 
reverted into germline configuration but the Vk regions were still 
somatically mutated, behaved like the original ANAs, continuing 
to recognize the histone antigens. However, all mAbs where the 
Vh was still somatically mutated but the Vk had been reverted to 
germline configuration lost ANA reactivity. Also, as expected, all 
mAbs in which both Vh and Vkappa regions had been reverted 
to germline configuration lost ANA reactivity. Thus, the ANA 
reactivity of the Vh1-26/Vk4-74 mAbs is due to somatic muta-
tions in the Vk4-74 gene.
Due to the finding that somatic mutations within the Vk4-74 
gene determined the ANA reactivity of Vh1-26/Vk4-74 mAbs 
and in order to identify a common motif that could account for 
this autoreactivity, we analyzed the sequence of these Vk4-74 
genes in more detail. This analysis revealed that 20 of 23 Vh1-26/
Vk4-74 mAbs derived from aging B6 mice had a mutation at posi-
tion 30 (IMGT numbering) in their CDR1 region of the Vk4-74 
gene. The germline-encoded serine in these mAbs was mutated 
into a positively charged arginine residue. Introduction of such 
a serine to arginine mutation in non-autoreactive germline ver-
sions of three different mAbs resulted in a complete gain of ANA 
reactivity for all of them (Figure 2C). Thus, antinuclear reactivity 
of these mAbs can be induced by a single base pair substitution 
changing the serine at position 30 in the CDR1 of the Vk4-74 light 
chain into an arginine.
B Cells Expressing a Germline-Encoded 
Immunoglobulin Vh Gene with a 
Negatively Charged CDR2 Region 
Contribute to the ANA-Reactive B Cell 
Repertoire
We also tested if non-Vh1-26/Vk4-74 using mAbs require 
somatic mutations in their Vh and/or Vk regions for ANA reac-
tivity. Therefore, the Vh and Vk region of three mAbs of aging 
B6 mice and six mAbs of the GVHD mice were reverted to their 
germline configuration. The 1.G5.B8 mAb derived from an aging 
B6 mouse (No. 2) used a somatically mutated Vh region and a 
germline-encoded Vk region. Reversion of the Vh region of this 
mAb into germline sequences resulted in a complete abrogation 
of its ANA reactivity (Figure 3A). In contrast, upon reversion, 
the other two mAbs (7.7.3A and 6.15.1A, both from mouse 6) 
kept their ANA reactivity (Figure 3A). Thus, B cells expressing 
a germline-encoded immunoglobulin Vh can also contribute to 
the ANA-reactive B cell repertoire in aging B6 mice.
In aging B6 mice, a dominance of Vh1-26 and Vk4-74 
usage by the IgG ANA producing hybridomas was observed. In 
B6 × bm12-derived hybridomas, the same genes were also found 
to be used, but at a much lower frequency. Thus, ten (29.4%) of 
these ANAs used Vh1-26 and nine (26.5%) used Vk4-74. Six of the 
hybridomas using Vk4-74 used the Vh1-26 heavy chain; however, 
five of these were derived from one mouse (GVHD mouse 3). 
These findings show that the IgG ANA B cell repertoires of aging 
B6 mice and B6 × bm12 mice undergoing a cGVHD are partially 
overlapping. However, the IgG ANA B cell repertoire seems to be 
more diverse in the B6 × bm12 mice than in the aging B6 mice. 
Therefore, the mechanisms underlying the generation of these 
autoreactive B cells might be different in the two model systems.
Somatic Mutations in the Light Chain 
Determine the ANA Reactivity of Vh1-26/
Vk4-74 Using mAbs
Sequence analysis revealed that most mAbs with ANA reactivity 
carried somatic mutations in their Vh and Vk regions. These 
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FIGURE 2 | ANA reactivity of Vh1-26/Vk4-74 using mAbs is caused by mutations in the light chain. ANA titers of different Vh1-26/Vk4-74 mAbs derived from (A) 
aging B6 (Table 1) or (B) young B6 × bm12 mice undergoing a cGvH reaction (Table 2). The histograms depict titers of individual mAbs, either with the original 
SHM, or Vh and/or Vk in germline configuration (GL), or (C) having a single mutation in their Vk CDR1 resulting in a serine to arginine conversion. A titer of one was 
defined as binding at a concentration of 5 µg/ml mAb, followed by 1:2 serial dilution steps and recording the last dilution where binding still was possible. SHM, 
somatic hypermutation; GL, germline; n.b., no binding detectable at 5 µg/ml of mAb.
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From the six GVHD-derived mAbs, one (1.12.1A, mouse 1) 
lost ANA reactivity upon reversion of the Vk but not the Vh gene 
into germline configuration (Figure 3B). The fact that this mAb 
uses the Vk4-74 gene indicates that this Vk gene can also give rise 
to ANA reactivity when paired with a Vh gene other than Vh1-26. 
The other five mAbs kept their ANA reactivity upon reversion of 
their Vh and Vk genes to germline configuration (Figure 3B). 
Thus, B  cells expressing a germline-encoded immunoglobulin 
can also contribute to the ANA-reactive repertoire in mice 
undergoing a cGVHD.
A remarkable observation was that 5 of 7 mAbs (one from 
aging B6 mice and four from GVHD mice), which kept ANA 
reactivity upon complete reversion of their Ig genes into germline 
configuration, had a negatively charged Vh-CDR2 region as 
defined by having at least two more negatively than positively 
charged amino acids in this region (see Table 3). This observa-
tion prompted us to test if these negatively charged amino acids 
are involved in ANA reactivity. Therefore, the negatively charged 
amino acids in the CDR2 regions of these five mAbs were mutated 
into neutral glycine. As shown in Figure 3C, one mAb derived 
from an aging B6 mouse (6.15.1A) and two from a GVHD mouse 
(2.58.2 and 2.394.1), completely lost ANA reactivity upon aspar-
tic acid/glutamic acid conversion into glycine. The ANA titers 
of the other two GVHD-derived mAbs (2.344.3 and 165.2.1) 
diminished by a factor of 2 and 3, respectively (Figure 3C). Thus, 
B  cells expressing a germline-encoded immunoglobulin with 
a negatively charged Vh-CDR2 region contribute to the ANA-
reactive repertoire. At this point, it is noteworthy that 6 of 11 
(54.6%) of the non-Vh1-26 using ANA mAbs from aging B6 mice 
and 14 of 24 (58.3%) from mice undergoing cGVHD indeed carry 
a negatively charged Vh-CDR2 (Table 3).
DISCUSSION
Two Pathways to ANA-Producing B Cells
In the present study, we compared antinuclear autoantibodies 
(ANAs) from aging B6 mice, which do not show signs of disease, 
with those derived from mice undergoing a chronic GVH reac-
tion (GVHD mice) and which develop an SLE-like disease (23). 
In order to study the V-regions of ANAs, we generated B cell 
hybridomas from mice with high ANA titers in their serum. 
Almost all monoclonal ANAs bound to a mixture of histones. As 
expected from previous studies, ANA production was T cell and 
antigen dependent (1–3, 22), since virtually all V-regions of our 
monoclonal ANAs contained somatic mutations. To determine 
whether the ANA-producing B cells were derived from progeni-
tors expressing B cell receptors (BCRs) for nuclear antigens, we 
reverted the mutated V-regions into the corresponding germline 
sequences and tested the resulting antibodies for ANA reactivity. 
Based on such analyses, we found that some ANA-producing 
B cells in both aging B6 mice and GVHD mice must be derived 
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FIGURE 3 | ANA reactivity of non-Vh1-26/Vk4-74 using mAbs is mainly germline encoded. ANA titers of different non-Vh1-26/Vk4-74 mAbs derived from (A) aging 
B6 or (B) young B6 × bm12 mice undergoing a chronic graft-versus-host disease. The histograms depict titers of individual mAbs listed in Table 3 containing 
V-regions, either with the original somatic hypermutations (SHM), or Vh and/or Vk in germline configuration (GL), or (C) containing a Vh CDR2 with conversions of 
aspartic and glutamic acids to glycine. Titers and legends as defined in Figure 2.
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from progenitors expressing germline-encoded genes for BCRs 
specific for nuclear antigens, while several others were derived 
from progenitors expressing BCRs that showed no ANA reactiv-
ity. The vast majority of the latter were derived from progenitors 
using Vh1-26 in combination with Vk4-74. Antibodies with the 
germline sequences of these V-regions had no ANA reactivity. 
It has been shown previously that non-autoreactive B  cells 
can become autoreactive upon acquiring somatic mutations 
in their Vh and/or Vl regions (6, 10, 13, 20). In contrast to the 
findings with Vh1-26/Vk4-74 expressing ANAs, the reversion 
of other Vh and Vk regions of several monoclonal ANAs to 
the corresponding germline sequences did not abolish ANA 
reactivity. The maintenance of ANA reactivity upon reversion 
into germline sequences was observed with 2 of 3 monoclonal 
ANAs from aging B6 mice, and with 5 of 6 monoclonal ANAs 
from GVHD mice. Thus, two pathways can be envisaged for the 
generation of ANA specific antibody forming B cells (Figure 4). 
In pathway one, they are derived from B cells undergoing somatic 
hypermutations in response to a foreign antigen (Figure 4, red 
line); in pathway two, they are derived from B cell progenitors 
expressing ANA-specific receptors that escape tolerance induc-
tion in the bone marrow, possibly by exposure to BCR crosslink-
ing by nuclear antigens (Figure 4, blue line). Indeed, we showed 
previously that anti-dsDNA reactive B  cells escaped tolerance 
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FIGURE 4 | Two distinct pathways generate ANA producing B cells. [(A) red background] B cells with a B-cell receptor (BCR) using a germline-encoded Vh1-26 in 
combination with a germline-encoded Vk4-74 gets stimulated by a non-self (NS) antigen/hapten. Due to somatic hypermutations in the Vk4-74 gene, ANA-reactive 
memory B cells are generated. In aging B6 mice, these memory cells are then activated by nuclear antigens and Th1 cells to produce ANA. In the GVHD mice, 
nuclear antigens and alloreactive T cells activate these memory cells, resulting in ANA formation. [(B) blue background] Immature B cells in the bone marrow with 
germline-encoded BCRs specific for nuclear antigens escape tolerance induction mechanisms through BCR cross-linking by a T cell independent type 2-antigen 
(TI-2) antigens or a signal from alloreactive T cells. In the periphery of aging B6 mice, these cells get stimulated by nuclear antigens and Th1 cells to produce ANAs. 
In the periphery of GVHD mice, nuclear antigens and alloreactive T cells activate these cells to ANA formation.
TABLE 3 | Vh-CDR2 regions of non-Vh1-26 ANA-reactive mAbs of graft-versus-host disease (GVHD) and aging B6 mice.a,b
Mouse number Hybridoma number Vh-region Vh-CDR2 region Mouse number Hybridoma number Vh-region Vh-CDR2 region
GVHD # 1 1.12.1A Vh8-8 I W W D D D Aging B6 # 1 7.F9.F1 Vh1-75 I L P G S G S S
1.308.1 Vh1-55 I Y P G S G S T
1.356.1 Vh1-55 I Y P G S G S T Aging B6 # 2 1.G5.B8 Vh1-39 V N P N Y G T I
1.741.1 Vh1-55 I Y P G S G S T
Aging B6 # 6 3.2.2A Vh1-74 I H P S D S D T
GVHD # 2 2.24.0 Vh1-52 I D P S D G E T Aging B6 # 6 6.15.1A Vh8-12 I Y W D D D K
2.53.8 Vh14-2 I D P E D G E T 7.7.3A Vh1-22 I N P N N G G T
2.58.2 Vh14-2 I D P E D G E S 20.15.1A Vh1-50 I D P S D T F T 
2.70.8 Vh14-4 I D P E N G D T 23.6.1A Vh1-22 I N P N N G D T
2.80.9 Vh14-4 I D P E N G D T 24.18.1A Vh1-22 I N P N N D D T
2.152.9 Vh1-52 I D P S D G E T 25.8.1A Vh3-6 I S C D G S S
2.300.2 Vh1-55 I Y P G S V S T
2.344.3 Vh1-52 I D P S D D E T Aging B6 # 7 3.25A Vh1-50 I D P S D T Y T 
2.382.2 Vh14-4 I D P E N G D T Aging B6 # 7 3.36A Vh1-80 I Y P G D G D T
2.388.2 Vh1-31 I F P Y N G V S
2.394.1 Vh14-4 I D P E N G D T
GVHD # 4 63.3.1 Vh1-55 I Y P G S G S T
165.2.1 Vh8-12 I Y W D D D K
GVHD # 5 14.11.A Vh1-50 I D P S D S Y I
381.11.A Vh1-54 I N P G S G G I
685.9.A Vh1-59 I D P S D S S S
762.5.A Vh5-17 I S R G S G I L
810.4.A Vh1-52 I D P S D S E T
865.12.A Vh1-72 I D P S S G G T
1011.39.A Vh1-53 I N P S N D G T
1011.39.A Vh1-53 I N P S N D G T
Bold font highlights negatively and positively charged amino acids.
aAll mAbs that were converted into germline sequences or in which the negatively charged amino acids in the CDR2 were converted into glycine are marked with orange boxes.
bAll the negatively charged amino acids in Vh-CDR2 region are marked in yellow and the positively charged amino acids in green.
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induction by the crosslinking of their BCRs by a T cell independ-
ent type 2-antigen (24).
Restricted Diversity of ANA Specific  
B Cells
Inspection of the V-region usage of ANA producing hybridomas 
shows that many ANAs derived from aging mice (21 of 36) 
(Table 1; Figure 4) and few from mice undergoing a cGVHD (6 of 
34) (Table 2; Figure 4) express Vh1-26 in combination with Vk4-
74. Interestingly this Vh/Vk combination is expressed in virtually 
all ANAs from aging mouse 1 (11 of 12), aging mouse 3 (6 of 6), 
and from the GVHD mouse 3 (5 of 5). Inspection of the V-regions 
strongly suggests that these ANAs are generated from single B cell 
clones with the exception of one clone of the GVHD mouse 3, 
which differs in the CDR3 compared to the other four. In other 
mice, ANAs are clearly generated from multiple B cell clones. In 
aging mouse 6, one ANA expresses the Vh1-26/Vk4-74 combina-
tion, one expresses the Vh1-26 with Vk4-61, two express the Vk4-
74 with Vh1-50 and Vh3-6, respectively, and five express different 
Vh/Vk combinations. In GVHD mice, all except one mouse (No. 
3) express ANAs derived from multiple B cell clones. Thus, in 
aging B6 mice, the ANA repertoire tends to be restricted, while 
in GVHD mice, the ANA repertoire tends to be less restricted. 
The more important question to be answered is why ANAs are 
oligoclonal in some mice and polyclonal in others. One reason for 
this restricted repertoire might be that Vh1-26 and Vk4-74 genes 
are overrepresented in the B cell repertoire of B6 mice in general. 
RNA sequence analysis of Vh1 usage by B cells from young and 
aging B6 mice showed that around 10% of these used Vh1-26 
(our unpublished results). Since about 50% of all B cells use a 
Vh1 family member, Vh1-26 is expressed by 5% of them. We did 
not attempt to verify this number in the hybrids generated, by, 
for example, cloning and sequencing the Vh regions of random 
IgM or IgG antibodies not reacting to nuclear antigens. With 
respect to Vk4-74 usage, Aoki-Ota et al. (31) analyzed the kappa 
light chain repertoire in B6 mice. This analysis revealed that B6 
B cells rarely use the Vk4-74 gene. We also have determined the 
Vk usage in developing B6 B cells and found that Vk4-74 was 
used less than 1% in single Vk-rearrangements of preBII cells and 
immature B cells of the bone marrow [unpublished observation, 
(32)]. Thus, the restricted ANA-reactive B cell repertoire does not 
simply appear to reflect a selective usage of the Vh1-26 and the 
Vk4-74 genes by the B6 B cells. Instead, and more interestingly, 
this restricted ANA repertoire may occur through selection by 
and as yet to be defined T cell dependent antigen.
Many years ago, it was shown that haptens such as NP 
(4-hydoxy-3-nitrophenyl)acetyl (33, 34), oxazolone (2-phenyl-
5-oxazolone) (35, 36), and arsonate (p-azophenyl-arsonate) 
(37, 38) could elicit an oligoclonal humoral immune response, 
at least in certain inbred strains of mice. Based on this, one 
might envisage that a hapten-like structure is responsible for the 
restricted ANA-reactive B cell repertoire in aging B6 mice. Thus, 
one could imagine that the frequency of ANA-producing B cells 
that are derived from hapten-induced memory cells in aging mice 
(red pathway in Figure 4) is higher than the frequency of B cell 
progenitors with receptors for nuclear antigens that escape toler-
ance induction in the bone marrow (blue pathway in Figure 4).
Activation of ANA-Producing B Cells
In ANA-producing mice, B  cells expressing nuclear antigen-
specific BCRs must be activated by nuclear antigens and helper 
T  cells. In GVHD mice, the alloreactive T  cells act as helper 
T cells. In their initial report on the “allogeneic effect,” Katz et al. 
reported a drastic enhancement of IgG responses as a result of 
a GVH reaction (39). Later, Osborne and Katz showed that a 
simple non-immunogenic hapten–polypeptide conjugate might 
elicit a vigorous primary IgG response as a consequence of the 
allogeneic effect (40). Likewise, Hamilton and Miller reported 
that otherwise tolerogenic hapten-conjugated syngeneic mouse 
erythrocytes would elicit a strong primary antibody response as 
a result of a GVH reaction (41). It is possible that this type of gen-
eral B cell help by alloreactive T cells contributes to the tendency 
of the ANA response in cGVHD mice to be more diverse.
In aging mice, the specificity and origin of the T helper cells 
that are required for ANA production is not known. Based on 
the IgG class of the ANAs produced in these mice, it is con-
ceivable that the helper cells involved in the ANA response are 
Th1 cells (30).
Conclusions Regarding the Structure of 
Anti-Histone Antibodies
Almost 30 years ago, Weigert and coworkers showed that arginine 
residues in CDR regions play a crucial role for the specificity of 
anti-dsDNA autoantibodies (10, 11). In the present study, we find 
an important role of arginine in the Vk-region of certain ANAs. 
Site-directed mutagenesis revealed that somatic mutations in 
the Vk4-74 light chains of the Vh1-26/Vk4-74 mAbs determine 
ANA reactivity, since conversion into their germline sequence 
completely abolished ANA reactivity. Interestingly, and highly 
significant, 20 of 23 Vh1-26/Vk4-74-expressing ANAs derived 
from aging B6 mice had a serine to arginine mutation at posi-
tion 30 in the CDR1 region of the Vk4-74 gene. In 1 of these 23 
mAbs, this change to arginine was the only mutation present in 
the entire Vk4-74 gene. The finding that one of these (17A9E6) 
mAb loses ANA-binding activity upon conversion of this arginine 
into serine strongly indicates the importance of this mutation for 
ANA reactivity. Furthermore, the introduction of single serine to 
arginine mutations in the germline configuration of three different 
mAbs conferred their antinuclear reactivity. This proves that this 
single mutation can convert an ANA-negative mAb into a positive 
one and clearly shows how easily Vh1-26/Vk4-74 using mAbs may 
become autoantibodies. The ANA-reactive B cell repertoire has 
also been analyzed in B6 mice congenic for a SLE susceptibility 
locus. Also this analysis revealed a rather frequent usage of Vk4-74 
light chains. Thus, Liang et al. (12) found that 9 of 30 ANA pro-
ducing hybridomas used Vk4-74 light chain (herein called ai4). 
Moreover, it was shown that 3 of these 9 had a serine to arginine 
mutation at position 30 in the CDR1. In a report by Guo et al. (13), 
9 of 33 ANA-producing hybridomas used a Vk4-74 light chain 
(herein also called ai4). At least 5 of these 9 had a serine to arginine 
mutation at position 30 in the CDR1, like we report herein.
However, since 5 of 6 Vh1-26/Vk4-74 using mAbs derived 
from the GVHD mice did not have this serine to arginine muta-
tion, other mutations in the Vk4-74 gene can be involved in ANA 
reactivity.
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Yet, another interesting finding reported here is that a high 
percentage of ANA-reactive mAbs not using the Vh1-26 gene, 
especially in the repertoire derived from GVHD mice, possess 
a germline-encoded negatively charged Vh CDR2 region. Thus, 
14 of the total 34 monoclonal ANAs (41.2%) derived from the 
GVHD mice and 6 of 36 (16.7%) derived from the aging B6 mice 
have such a CDR2 region. Within the total Vh gene repertoire 
of B6 mice, 11.5% possess such a negatively charged CDR2 
(42). Thus, our findings suggest that B cells with such a charged 
CDR2 might be positively selected into the ANA-reactive B cell 
repertoire, especially in GVHD mice. The finding that mutations 
of these negatively charged amino acids into glycine can result 
in a complete loss of ANA binding supports this hypothesis 
and, moreover, indicates the potential importance of this region 
in ANA reactivity. However, additional structural effects of the 
amino acid change to glycine cannot be excluded, especially since 
glycine is known to be a helix breaker.
It is noteworthy that despite high ANA serum titers, aging 
B6 mice do not show the typical lesions that are observed in 
multiple organs of SLE patients, whereas the GVHD mice do 
show this. Therefore, one could envisage that the ANA reper-
toire difference between aging B6 and GVHD mice is playing 
a role in the pathogenesis of the SLE-like disease observed in 
GVHD mice.
Overall, the findings described in the present study highlight 
various new characteristics of ANA-reactive B cell repertoires and 
argue for similar mechanisms of ANA generation in SLE patients. 
This might improve our understanding of the pathogenesis of 
this disease, thereby opening new concepts and therapies for its 
control.
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TABLES S1 AND S2 | Nucleotide sequences and their translation into amino 
acids of Vh- and Vk-regions of all hybridomas described herein, which were 
derived from aging B6 mice.
TABLES S3 AND S4 | Nucleotide sequences and their translation into amino 
acids of Vh- and Vk-regions of all hybridomas described herein, which were 
derived from young B6 × bm12 mice undergoing a GvH reaction.
TABLE S5 | Sequences of primers used for cDNA synthesis of total mRNA 
obtained from ANA-reactive hybridomas. The sequences of primers used for 
sequencing of Vh- and Vk-regions of the obtained cDNA are also shown.
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